O	Tablets
O	,
O	Injection
O	,
O	and
O	Oral
O	Solution
O	One
O	study
O	in
O	six
O	subjects
O	demonstrated
O	that
O	the
O	combination
O	of
B-drug	furosemide
O	and
B-drug	acetylsalicylic
I-drug	acid
O	temporarily
O	reduced
O	creatinine
O	clearance
O	in
O	patients
O	with
O	chronic
O	renal
O	insufficiency
O	.

O	Because
O	the
O	potential
O	interaction
O	of
B-drug	efavirenz
O	with
O	oral
B-group	contraceptives
O	has
O	not
O	been
O	fully
O	characterized
O	,
O	a
O	reliable
O	method
O	of
O	barrier
O	contraception
O	should
O	be
O	used
O	in
O	addition
O	to
O	oral
B-group	contraceptives
O	.

O	and
O	exert
O	direct
O	effects
O	on
O	the
O	mechanisms
O	of
O	insulin
O	resistance
O	.

O	Furthermore
O	,
O	whenever
O	one
O	of
O	these
O	drugs
O	is
O	withdrawn
O	from
O	co-therapy
O	,
O	an
O	increased
O	dose
O	of
B-group	tricyclic
I-group	antidepressant
I-group	agent
O	may
O	be
O	required
O	.

O	use
O	of
O	a
B-group	nonhormonal
I-group	contraceptive
I-group	product
O	is
O	recommended
O	.

O	Transfer
O	from
O	the
O	intestinal
O	lumen
O	to
O	the
O	mucosal
O	cells
O	at
O	low
B-drug_n	As
I-drug_n	(
I-drug_n	V
I-drug_n	)
O	concentration
O	(
O	0.1
O	mM
O	)
O	is
O	rapid
O	,
O	while
O	transfer
O	from
O	the
O	mucosal
O	cells
O	to
O	the
O	body
O	occurs
O	more
O	slowly
O	.

O	Increased
B-drug	metoprolol
O	plasma
O	levels
O	have
O	been
O	associated
O	with
O	decreased
O	cardioselectivity
O	.

B-group	Bacteriostatic
I-group	Antibiotics
O	:
B-drug	Chloramphenicol
O	,
B-drug	erythromycins
O	,
B-group	sulfonamides
O	,
O	or
B-group	tetracyclines
O	may
O	interfere
O	with
O	the
O	bactericidal
O	effect
O	of
B-group	penicillins
O	.

O	It
O	is
O	possible
O	that
O	the
O	cardiovascular
O	action
O	of
O	other
B-group	calcium
I-group	channel
I-group	blockers
O	could
O	be
O	enhanced
O	by
O	the
O	addition
O	of
B-brand	Nimotop
O	.

O	Free
O	T4
O	and
O	T3
O	concentrations
O	are
O	unaltered
O	.

O	uterine
O	fibroids
O	;

O	Co-administration
O	of
B-drug	tacrolimus
O	and
B-drug	bosentan
O	resulted
O	in
O	markedly
O	increased
O	plasma
O	concentrations
O	of
B-drug	bosentan
O	in
O	animals
O	.

B-drug	sucralfate
O	or
O	divalent
O	or
O	trivalent
O	cations
O	such
O	as
B-drug	iron
O	;

B-drug_n	Indocyanine
I-drug_n	green
O	as
O	an
O	index
O	of
O	hepatic
O	drug
O	extraction
O	has
O	been
O	tested
O	and
O	no
O	significant
O	effects
O	have
O	been
O	found
O	.

O	Tumors
O	of
O	more
O	malignant
O	phenotype
O	were
O	demonstrated
O	only
O	in
O	genetically
O	predisposed
O	mice
O	(
O	C57BL/6N
O	X
O	C3H/HeN
O	F1
O	)
O	that
O	received
O	one
O	dose
O	of
O	carcinogen
O	.

O	use
B-drug	potassium
O	supplements
O	if
O	necessary
O	.

O	It
O	is
O	recommended
O	that
O	plasma
B-drug	lithium
O	levels
O	be
O	monitored
O	when
B-drug	ketoprofen
O	is
O	coadministered
O	with
B-drug	lithium
O	.

B-brand	Tagamet
O	,
O	apparently
O	through
O	an
O	effect
O	on
O	certain
O	microsomal
O	enzyme
O	systems
O	,
O	has
O	been
O	reported
O	to
O	reduce
O	the
O	hepatic
O	metabolism
O	of
B-group	warfarin-type
I-group	anticoagulants
O	,
B-drug	phenytoin
O	,
B-drug	propranolol
O	,
B-drug	nifedipine
O	,
B-drug	chlordiazepoxide
O	,
B-drug	diazepam
O	,
O	certain
B-group	tricyclic
I-group	antidepressants
O	,
B-drug	lidocaine
O	,
B-drug	theophylline
O	and
B-drug	metronidazole
O	,
O	thereby
O	delaying
O	elimination
O	and
O	increasing
O	blood
O	levels
O	of
O	these
O	drugs
O	.

O	Drug/Laboratory
O	Test
O	Interactions
O	A
O	false-positive
O	reaction
O	for
O	ketones
O	in
O	the
O	urine
O	may
O	occur
O	with
O	tests
O	using
B-drug	nitroprusside
O	but
O	not
O	with
O	those
O	using
B-drug	nitroferricyanide
O	.

O	Because
O	of
O	the
O	potential
O	for
O	adverse
O	reactions
O	from
O	the
O	drugs
O	in
O	nursing
O	infants
O	,
O	a
O	decision
O	must
O	be
O	made
O	whether
O	to
O	discontinue
O	nursing
O	or
O	discontinue
B-brand	PEGASYS
O	and
B-brand	COPEGUS
O	treatment
O	.

O	Several
O	classes
O	of
O	cardiovascular
O	drugs
O	are
O	also
O	discussed
O	in
O	relationship
O	to
O	their
O	differential
O	effects
O	on
O	the
O	management
O	and
O	progression
O	of
O	renal
O	disease
O	.

O	Exercise
O	that
O	produces
O	cardiopulmonary
O	stimulation
O	is
O	a
O	helpful
O	means
O	of
O	reducing
O	drug
O	hunger
O	and
O	anxiety
O	during
O	recovery
O	therapy
O	.

O	There
O	has
O	been
O	little
O	experience
O	with
O	the
O	coadministration
O	of
B-brand	TAMBOCOR
O	and
O	either
B-drug	disopyramide
O	or
B-drug	verapamil
O	.

O	The
O	administration
O	of
B-drug	cefdinir
O	may
O	result
O	in
O	a
O	false-positive
O	reaction
O	for
O	glucose
O	in
O	urine
O	using
O	Clinitest
O	,
O	Benedict
O	s
O	solution
O	,
O	or
O	Fehlings
O	solution
O	.

O	Anaesthesia
O	and
O	the
O	epileptic
O	pateint
O	.

O	.

O	therefore
O	,
B-drug	nelfinavir
O	should
O	be
O	administered
O	(
O	with
O	food
O	)
O	one
O	hour
O	after
O	or
O	more
O	than
O	two
O	hours
O	before
B-drug	didanosine
O	.

O	Dose
O	reduction
O	of
B-drug	rifabutin
O	to
O	half
O	the
O	standard
O	dose
O	and
O	a
O	dose
O	increase
O	of
B-brand	CRIXIVAN
O	to
O	1000
O	mg
O	(
O	three
O	333-mg
O	capsules
O	)
O	every
O	8
O	hours
O	are
O	recommended
O	when
B-drug	rifabutin
O	and
B-brand	CRIXIVAN
O	are
O	coadministered
O	.

B-drug	Succinylcholine
O	may
O	cause
O	a
O	sudden
O	extrusion
O	of
O	potassium
O	from
O	muscle
O	cells
O	,
O	and
O	may
O	thereby
O	cause
O	arrhythmias
O	in
O	digitalized
O	patients
O	.

B-drug	dextrothyroxine
O	;

O	Cardiac
O	effects
O	of
B-drug	dopamine
O	are
O	antagonized
O	by
B-group	beta-adrenergic
I-group	blocking
I-group	agents
O	,
O	such
O	as
B-drug	propranolol
O	and
B-drug	metoprolol
O	.

O	The
O	principal
O	drugs
O	given
O	(
O	number
O	of
O	patients
O	in
O	parentheses
O	)
O	were
O	:
B-group	cardiac
I-group	glycosides
O	(
O	115
O	)
O	,
B-group	sedatives
O	and
B-group	hypnotics
O	(
O	103
O	)
O	,
B-group	coronary
I-group	vasodilators
O	(
O	52
O	)
O	,
O	oral
B-group	hypoglycemics
O	(
O	45
O	)
O	,
O	cough
O	and
O	cold
O	preparations
O	(
O	45
O	)
O	,
B-group	NSAIDs
O	(
O	38
O	)
O	,
B-group	antihyperlipidemics
O	(
O	29
O	)
O	,
B-group	antigout
I-group	drugs
O	(
O	24
O	)
O	,
O	oral
B-group	contraceptives
O	(
O	18
O	)
O	,
B-group	bronchodilators
O	(
O	13
O	)
O	,
B-drug	insulin
O	(
O	10
O	)
O	,
O	and
B-group	beta
I-group	blockers
O	(
O	10
O	)
O	.

B-drug	Phenobarbital
O	:
O	Estimates
O	of
O	steady-state
O	pharmacokinetic
O	parameters
O	for
B-drug	phenobarbital
O	or
B-drug	gabapentin
O	(
O	300
O	mg
O	TID
O	;

O	It
O	is
O	concluded
O	that
B-drug	chloral
I-drug	hydrate
O	and
B-drug	methaqualone
O	may
O	be
O	administered
O	safely
O	without
O	additional
O	caution
O	in
O	prothrombin
O	test
O	monitoring
O	during
O	oral
B-group	anticoagulant
O	therapy
O	.

O	Based
O	on
O	anecdotal
O	reports
O	,
O	there
O	may
O	be
O	an
O	interaction
O	between
B-drug	buprenorphine
O	and
B-group	benzodiazepines
O	.

O	Unlike
O	nucleolin/C23
O	,
O	down-regulation
O	of
O	nucleophosmin/B23
O	was
O	thus
O	not
O	proliferation-dependent
O	but
O	caspase-3-
O	and
O	apoptosis-dependent
O	.

B-drug_n	Buforin
I-drug_n	II
O	showed
O	moderate
O	activity
O	,
O	which
O	increased
O	with
O	increasing
O	concentration
O	to
O	55.7
O	%
O	suppression
O	of
O	growth
O	at
O	20
O	microM
O	.

O	To
O	avoid
O	this
O	interaction
O	,
B-drug	delavirdine
O	or
B-drug	indinavir
O	should
O	be
O	given
O	1
O	hour
O	prior
O	to
O	dosing
O	with
B-brand	VIDEX
O	.

O	Drug
O	interactions
O	with
B-drug	clomiphene
I-drug	citrate
O	tablets
O	USP
O	have
O	not
O	been
O	documented
O	.

O	Drug
O	Name

O	In
O	the
O	general
O	population
O	,
B-drug	sildenafil
O	is
O	considered
O	to
O	have
O	an
O	acceptable
O	tolerability
O	profile
O	;

O	The
O	incidence
O	of
O	cancer
O	increases
O	progressively
O	with
O	age
O	.

O	Absorption
O	of
B-drug	tetracycline
O	is
O	impaired
O	by
B-drug	bismuth
I-drug	subsalicylate
O	.

O	increased
O	factors
O	II
O	,
O	VII
O	antigen
O	,
O	VIII
O	antigen
O	,
O	VIII
O	coagulant
O	activity
O	,
O	IX
O	,
O	X
O	,
O	XII
O	,
O	VII-X
O	complex
O	,
O	II-VII-X
O	complex
O	,
O	and
O	beta-thromboglobulin
O	;

O	If
B-drug	labetalol
I-drug	HCl
O	is
O	used
O	with
B-drug	nitroglycerin
O	in
O	patients
O	with
O	angina
O	pectoris
O	,
O	additional
O	antihypertensive
O	effects
O	may
O	occur
O	.

B-drug	Oxcarbazepine
O	can
O	inhibit
O	CYP2C19
O	and
O	induce
O	CYP3A4/5
O	with
O	potentially
O	important
O	effects
O	on
O	plasma
O	concentrations
O	of
O	other
O	drugs
O	.

O	Thus
O	,
O	results
O	of
O	the
O	DST
O	should
O	be
O	interpreted
O	with
O	caution
O	in
O	these
O	patients
O	.

B-group	Broad-Spectrum
I-group	Antibiotics-Broad-spectrum
I-group	antibiotics
O	may
O	sterilize
O	the
O	bowel
O	and
O	decrease
O	the
B-group	vitamin
I-group	K
O	contribution
O	to
O	the
O	body
O	by
O	the
O	intestinal
O	microflora
O	.

O	The
O	effect
O	of
B-brand	TORADOL
O	on
B-drug	methotrexate
O	clearance
O	has
O	not
O	been
O	studied
O	.

O	Exaggerated
O	hypertensive
O	responses
O	have
O	been
O	reported
O	from
O	the
O	combined
O	use
O	of
B-group	beta-adrenergic
I-group	antagonists
O	and
B-group	alpha-adrenergic
I-group	stimulants
O	,
O	including
O	those
O	contained
O	in
O	proprietary
O	cold
O	remedies
O	and
O	vasoconstrictive
O	nasal
O	drops
O	.

B-brand	TAMBOCOR
O	has
O	been
O	administered
O	to
O	patients
O	receiving
B-group	digitalis
I-group	preparations
O	or
B-group	beta-adrenergic
I-group	blocking
I-group	agents
O	without
O	adverse
O	effects
O	.

O	Pharmacological
O	treatment
O	of
O	depression
O	:
O	the
O	role
O	of
B-drug	paroxetine
O	.

O	Anticoagulant
O	inhibition
O	was
O	observed
O	during
O	the
O	administration
O	of
B-drug	phenobarbital
O	,
B-drug	secobarbital
O	and
B-drug	glutethimide
O	;

O	Hypertensive
O	crises
O	have
O	resulted
O	when
B-group	sympathomimetic
I-group	amines
O	have
O	been
O	used
O	concomitantly
O	within14
O	days
O	following
O	use
O	of
B-group	monoamine
I-group	oxidase
I-group	inhibitors
O	.

O	Systemic
O	exposure
O	is
O	limited
O	,
O	as
B-drug	fluvastatin
O	is
O	subject
O	to
O	first-pass
O	metabolism
O	,
O	and
O	the
O	plasma
O	half-life
O	of
O	the
O	drug
O	is
O	approximately
O	30
O	minutes
O	.

O	In
O	these
O	subjects
O	(
O	R=
O	B
O	)
O	,
O	the
O	clearance
O	of
B-drug	diazepam
O	was
O	reduced
O	by
O	65
O	%
O	and
O	that
O	of
B-drug_n	N-desmethyldiazepam
O	to
O	a
O	level
O	that
O	was
O	too
O	low
O	to
O	measure
O	over
O	the
O	course
O	of
O	the
O	2
O	week
O	long
O	study
O	.

O	an
O	interval
O	of
O	at
O	least
O	4
O	hours
O	between
O	intake
O	of
O	these
O	agents
O	and
B-drug	chloroquine
O	should
O	be
O	observed
O	.

O	Following
O	the
O	administration
O	of
B-brand	INAPSINE
O	,
O	the
O	dose
O	of
O	other
B-group	CNS
I-group	depressant
I-group	drugs
O	should
O	be
O	reduced
O	.

B-brand	PROLEUKIN
O	may
O	affect
O	central
O	nervous
O	function
O	.

O	In
O	another
O	study
O	with
O	intravenous
O	administration
O	of
B-drug	midazolam
O	,
B-drug	Aprepitant
O	was
O	given
O	as
O	125
O	mg
O	on
O	Day
O	1
O	and
O	80
O	mg/day
O	on
O	Days
O	2
O	and
O	3
O	,
O	and
B-drug	midazolam
O	2
O	mg
O	IV
O	was
O	given
O	prior
O	to
O	the
O	administration
O	of
O	the
O	3-day
O	regimen
O	of
B-drug	Aprepitant
O	and
O	on
O	Days
O	4
O	,
O	8
O	,
O	and
O	15
O	.

O	The
O	impact
O	of
O	the
O	combined
O	chemotherapy
O	plus
O	HAART
O	treatment
O	on
O	patient
O	survival
O	needs
O	urgently
O	to
O	be
O	evaluated
O	in
O	prospective
O	studies
O	.

O	In
O	clinical
O	studies
O	,
B-drug	caspofungin
O	did
O	not
O	induce
O	the
O	CYP3A4
O	metabolism
O	of
O	other
O	drugs
O	.

B-drug	Physostigmine
O	pretreatment
O	augmented
O	the
O	depressant
O	effect
O	of
B-drug	alcohol
O	on
O	the
O	early
O	components
O	P1
O	and
O	N1
O	,
O	while
O	attenuating
B-drug	alcohol
O	's
O	influence
O	on
O	components
O	P2
O	and
O	P3
O	.

O	Concomitant
O	use
O	with
B-group	iron
O	supplements
O	may
O	result
O	in
O	the
O	reduced
O	absorption
O	of
B-drug	iron
O	.

O	Skin
O	tests
O	:
B-group	Corticosteroids
O	may
O	suppress
O	reactions
O	to
O	skin
O	tests
O	.

O	If
B-drug	digitalis
O	treatment
O	is
O	continued
O	,
O	serum
O	levels
O	should
O	be
O	closely
O	monitored
O	and
O	patients
O	observed
O	for
O	clinical
O	evidence
O	of
O	toxicity
O	.

B-drug	Dexamethasone
O	is
O	a
O	moderate
O	inducer
O	of
O	CYP
O	3A4
O	.

O	Caution
O	should
O	be
O	exercised
O	when
O	the
O	following
O	drugs
O	are
O	administered
O	concomitantly
O	with
B-brand	LODOSYN
O	(
B-drug	Carbidopa
O	)
O	given
O	with
B-drug	levodopa
O	or
B-drug	carbidopa-levodopa
O	combination
O	products
O	.

O	In
O	patients
O	,
O	the
O	concomitant
O	administration
O	of
B-drug	digoxin
O	with
B-drug	dofetilide
O	was
O	associated
O	with
O	a
O	higher
O	occurrence
O	of
O	torsade
O	de
O	pointes
O	.

B-drug	Chlorthalidone
O	and
O	related
O	drugs
O	may
O	decrease
O	arterial
O	responsiveness
O	to
B-drug	norepinephrine
O	.

B-group	Anticholinergic
I-group	drugs
O	in
O	the
O	presence
O	of
O	increased
O	intraocular
O	pressure
O	may
O	be
O	hazardous
O	when
O	taken
O	concurrently
O	with
O	agents
O	such
O	as
O	corti
O	costeroids..

O	Although
O	there
O	may
O	be
O	decreased
B-drug	zalcitabine
O	activity
O	because
O	of
O	lessened
O	active
O	metabolite
O	formation
O	,
O	the
O	clinical
O	relevance
O	of
O	these
O	in
O	vitro
O	results
O	are
O	not
O	known
O	.

B-drug	Phenytoin/Phenobarbital
O	:
O	The
O	coadministration
O	of
B-drug	phenytoin
O	or
B-drug	phenobarbital
O	will
O	not
O	affect
O	plasma
O	concentrations
O	of
B-group	vitamin
I-group	D
O	,
O	but
O	may
O	reduce
O	endogenous
O	plasma
O	levels
O	of
B-drug	calcitriol/ergocalcitriol
O	by
O	accelerating
O	metabolism
O	.

O	Because
O	the
O	incidence
O	of
O	infections
O	and
O	certain
O	malignancies
O	is
O	higher
O	in
O	the
O	elderly
O	population
O	,
O	in
O	general
O	,
O	caution
O	should
O	be
O	used
O	in
O	treating
O	the
O	elderly
O	.

O	An
O	increase
O	of
O	63
O	%
O	in
O	the
O	mean
O	AUC
O	and
O	increases
O	of
O	50
O	%
O	and
O	4
O	%
O	,
O	respectively
O	,
O	in
O	the
O	mean
O	T
O	max
O	and
O	mean
O	C
O	max
O	were
O	noted
O	in
O	1
O	study
O	of
O	6
O	individuals
O	.

O	-
B-group	Anticoagulants
O	(
B-group	blood
O	thinners
O	)
O	or

O	The
O	use
O	of
B-drug	erythromycin
O	in
O	patients
O	concurrently
O	taking
O	drugs
O	metabolized
O	by
O	the
O	cytochrome
O	P450
O	system
O	may
O	be
O	associated
O	with
O	elevations
O	in
O	serum
O	levels
O	of
O	these
O	other
O	drugs
O	.

O	Results
O	demonstrate
O	that
B-drug	oxcarbazepine
O	and
O	its
O	pharmacologically
O	active
O	10-monohydroxy
O	metabolite
O	(
B-drug_n	MHD
O	)
O	have
O	little
O	or
O	no
O	capacity
O	to
O	function
O	as
O	inhibitors
O	for
O	most
O	of
O	the
O	human
O	cytochrome
O	P450
O	enzymes
O	evaluated
O	(
O	CYP1A2
O	,
O	CYP2A6
O	,
O	CYP2C9
O	,
O	CYP2D6
O	,
O	CYP2E1
O	,
O	CYP4A9
O	and
O	CYP4A11
O	)
O	with
O	the
O	exception
O	of
O	CYP2C19
O	and
O	CYP3A4/5
O	.

O	The
O	use
O	of
B-drug	codeine
O	may
O	result
O	in
O	additive
O	CNS
O	depressant
O	effects
O	when
O	coadministered
O	with
B-drug	alcohol
O	,
B-group	antihistamines
O	,
B-group	psychotropics
O	or
O	other
O	drugs
O	that
O	produce
O	CNS
O	depression
O	.

O	Concomitant
O	administration
O	of
B-brand	Targretin
O	capsules
O	and
B-drug	gemfibrozil
O	resulted
O	in
O	substantial
O	increases
O	in
O	plasma
O	concentrations
O	of
B-drug	bexarotene
O	,
O	probably
O	at
O	least
O	partially
O	related
O	to
O	cytochrome
O	P450
O	3A4
O	inhibition
O	by
B-drug	gemfibrozil
O	.

O	It
O	is
O	recommended
O	that
O	GABA-positive
O	drugs
O	be
O	included
O	into
O	a
O	complex
O	of
O	treatment
O	measures
O	for
O	edema
O	.

O	The
O	effects
O	of
O	coadministered
O	drugs
O	and
B-drug	ethanol
O	on
O	the
O	binding
O	of
O	therapeutic
O	drugs
O	to
O	human
O	serum
O	in
O	vitro
O	was
O	investigated
O	.

O	Oral
B-group	Contraceptives
O	:
O	May
O	be
O	less
O	effective
O	and
O	increased
O	breakthrough
O	bleeding
O	may
O	occur
O	.

B-drug	rifampin
O	;

O	Specific
O	drug
O	interaction
O	studies
O	have
O	not
O	been
O	conducted
O	with
B-brand	ENBREL
O	.

O	However
O	,
O	patients
O	on
B-drug	digoxin
O	may
O	show
O	elevations
O	of
B-drug	digoxin
O	concentrations
O	after
O	initiation
O	of
O	therapy
O	with
B-brand	FLOLAN
O	,
O	which
O	may
O	be
O	clinically
O	significant
O	in
O	patients
O	prone
O	to
B-drug	digoxin
O	toxicity
O	.

O	A
O	number
O	of
O	substances
O	affect
O	glucose
O	metabolism
O	and
O	may
O	require
B-drug	insulin
O	dose
O	adjustment
O	and
O	particularly
O	close
O	monitoring
O	.

O	While
O	no
O	clinical
O	studies
O	have
O	been
O	conducted
O	to
O	evaluate
O	the
O	effect
O	of
B-drug	grepafloxacin
O	on
O	the
O	metabolism
O	of
O	C.P.A
O	.

O	Alternatives
O	to
B-drug	clarithromycin
O	,
O	such
O	as
B-drug	azithromycin
O	,
O	should
O	be
O	considered
O	.

O	Drugs
O	that
O	raise
O	the
O	gastrointestinal
O	pH
O	may
O	lead
O	to
O	an
O	earlier
O	release
O	of
B-drug	duloxetine
O	.

I-drug	indinavir
O	concentration
B-drug	rifabutin
O	concentration

B-group	Coumarin
I-group	Anticoagulants
O	Altered
O	coagulation
O	parameters
O	and/or
O	bleeding
O	have
O	been
O	reported
O	in
O	patients
O	taking
B-drug	capecitabine
O	concomitantly
O	with
B-group	coumarin-derivative
I-group	anticoagulants
O	such
O	as
B-drug	warfarin
O	and
B-drug	phenprocoumon
O	.

B-drug	Fluconazole
O	,
O	and
O	the
B-group	5-HT3
I-group	antiemetics
B-drug	ondansetron
O	(
B-brand	Zofran
O	)
O	and
B-drug	granisetron
O	(
B-brand	Kytril
O	)
O	have
O	all
O	been
O	used
O	with
B-brand	BUSULFEX
O	.

O	Though
O	individual
B-drug	theophylline
O	levels
O	fluctuated
O	,
O	there
O	were
O	no
O	clinically
O	significant
O	symptoms
O	of
O	drug
O	inter-action
O	.

O	Furthermore
O	,
O	whenever
O	one
O	of
O	these
O	other
O	drugs
O	is
O	withdrawn
O	from
O	co-therapy
O	,
O	an
O	increased
O	dose
O	of
B-group	tricyclic
I-group	antidepressant
O	may
O	be
O	required
O	.

O	Serum
O	potassium
O	levels
O	should
O	be
O	monitored
O	and
O	deficiencies
O	corrected
O	.

O	These
O	effects
O	were
O	not
O	observed
O	when
B-drug	Vardenafil
O	20
O	mg
O	was
O	taken
O	24
O	hours
O	before
O	the
B-drug	NTG
O	.

O	Caution
O	should
O	be
O	exercised
O	when
B-brand	INDOCIN
O	and
B-group	anticoagulants
O	are
O	administered
O	concomitantly
O	.

O	Administration
O	of
B-group	quinolones
O	with
B-group	antacids
O	containing
B-drug	aluminum
O	,
B-drug	magnesium
O	,
O	or
B-drug	calcium
O	,
O	with
B-drug	sucralfate
O	,
O	with
O	metal
O	cations
O	such
O	as
B-drug	iron
O	,
O	or
O	with
B-group	multivitamins
O	containing
B-drug	iron
O	or
B-drug	zinc
O	,
O	or
O	with
O	formulations
O	containing
O	divalent
O	and
O	trivalent
O	cations
O	such
O	as
B-brand	VIDEX
O	(
B-drug	didanosine
O	)
O	chewable/buffered
O	tablets
O	or
O	the
O	pediatric
O	powder
O	for
O	oral
O	solution
O	,
O	may
O	substantially
O	interfere
O	with
O	the
O	absorption
O	of
B-group	quinolones
O	,
O	resulting
O	in
O	systemic
O	concentrations
O	considerably
O	lower
O	than
O	desired
O	.

O	Steady-state
O	serum
O	concentrations
O	of
B-group	tricyclic
I-group	antidepressants
O	are
O	reported
O	to
O	fluctuate
O	significantly
O	when
B-drug	cimetidine
O	is
O	either
O	added
O	or
O	deleted
O	from
O	the
O	drug
O	regimen
O	.

O	Concurrent
O	therapy
O	with
B-drug	bumetanide
O	is
O	thus
O	not
O	recommended
O	.

O	Drug
O	Laboratory
O	Test
O	Interactions
O	:
O	Prolongation
O	of
O	the
O	template
O	bleeding
O	time
O	has
O	been
O	reported
O	during
O	continuous
O	intravenous
O	infusion
O	of
B-brand	AMICAR
O	at
O	dosages
O	exceeding
O	24
O	g/day
O	.

B-drug	Diazepam
O	:
O	The
O	co-administration
O	of
B-drug	Fluvoxamine
O	Tablets
O	and
B-drug	diazepam
O	is
O	generally
O	not
O	advisable
O	.

B-group	Anti-HIV
I-group	Protease
I-group	Inhibitors

O	Although
B-drug	verapamil
O	administered
O	at
O	either
O	dose
O	had
O	little
O	or
O	no
O	effect
O	on
O	the
O	enhancement
O	of
O	intestinal
O	carcinogenesis
O	by
B-drug_n	bombesin
O	or
O	on
O	the
O	location
O	,
O	histologic
O	type
O	,
O	depth
O	of
O	involvement
O	,
O	labeling
O	index
O	,
O	apoptotic
O	index
O	or
O	tumor
O	vascularity
O	of
O	intestinal
O	cancers
O	,
O	it
O	significantly
O	decreased
O	the
O	incidence
O	of
O	cancer
O	metastasis
O	.

O	The
O	following
O	are
O	examples
O	of
O	drugs
O	known
O	to
O	inhibit
O	the
O	metabolism
O	of
O	other
O	related
B-group	benzodiazepines
O	,
O	presumably
O	through
O	inhibition
O	of
O	CYP3A
O	:
B-drug	nefazodone
O	,
B-drug	fluvoxamine
O	,
B-drug	cimetidine
O	,
B-drug	diltiazem
O	,
B-drug	isoniazide
O	,
O	and
O	some
B-group	macrolide
I-group	antibiotics
O	.

O	There
O	have
O	been
O	no
O	formal
O	drug-interaction
O	studies
O	performed
O	with
B-brand	Mylotarg
O	.

B-group	Vasoconstrictors
O	:
B-brand	D.H.E
I-brand	.
I-brand	45
O	(
B-drug	dihydroergotamine
I-drug	mesylate
O	)
O	Injection
O	,
O	USP
O	should
O	not
O	be
O	used
O	with
B-group	peripheral
I-group	vasoconstrictors
O	because
O	the
O	combination
O	may
O	cause
O	synergistic
O	elevation
O	of
O	blood
O	pressure
O	.

B-drug	Valproate
O	:
O	A
O	recent
O	case
O	study
O	has
O	shown
O	a
O	possible
O	increase
O	in
O	the
O	plasma
O	level
O	of
B-drug	valproate
O	when
O	co
O	administered
O	with
B-drug	isoniazid
O	.

O	This
O	did
O	not
O	result
O	in
O	any
O	statistically
O	or
O	clinically
O	relevant
O	changes
O	in
O	the
O	pharmacokinetic
O	parameters
O	of
O	either
B-drug	caffeine
O	or
O	its
O	major
O	metabolite
O	,
B-drug_n	paraxanthine
O	.

O	Leukopenia
O	was
O	similar
O	between
O	the
O	two
O	groups
O	,
O	but
O	colony
O	stimulating
O	factor
O	support
O	was
O	significantly
O	greater
O	in
O	the
O	CHOP-HAART
O	group
O	than
O	in
O	the
O	control
O	group
O	(
O	92
O	%
O	vs.
O	66
O	%
O	,
O	respectively
O	;
O	P
O	=
O	0.03
O	)
O	.

O	The
O	possibility
O	of
O	hypotensive
O	effects
O	with
B-brand	PRINIVIL
O	can
O	be
O	minimized
O	by
O	either
O	discontinuing
O	the
B-group	diuretic
O	or
O	increasing
O	the
O	salt
O	intake
O	prior
O	to
O	initiation
O	of
O	treatment
O	with
B-brand	PRINIVIL
O	.

O	When
O	other
B-group	antiplatelet
I-group	agents
O	or
B-group	anticoagulants
O	are
O	used
O	concomitantly
O	,
O	there
O	is
O	the
O	potential
O	for
B-brand	FLOLAN
O	to
O	increase
O	the
O	risk
O	of
O	bleeding
O	.

O	Taking
O	a
B-group	rauwolfia
I-group	alkaloid
O	while
O	you
O	are
O	taking
O	or
O	within
O	2
O	weeks
O	of
O	taking
B-group	MAO
I-group	inhibitors
O	may
O	increase
O	the
O	risk
O	of
O	central
O	nervous
O	system
O	depression
O	or
O	may
O	cause
O	a
O	severe
O	high
O	blood
O	pressure
O	reaction
O	.

O	No
O	autoinduction
O	has
O	been
O	observed
O	with
B-brand	Trileptal
O	.

O	Latent
O	diabetes
O	mellitus
O	may
O	become
O	manifest
O	during
B-drug	chlorthalidone
O	administration
O	.

O	Repeated
O	oral
O	administration
O	of
B-drug_n	coumaphos
O	in
O	sheep
O	:
O	interactions
O	of
B-drug_n	coumaphos
O	with
B-drug	bishydroxycoumarin
O	,
B-drug_n	trichlorfon
O	,
O	and
B-drug	phenobarbital
I-drug	sodium
O	.

O	surgery
O	;

O	In
O	another
O	drug
O	interaction
O	study
O	,
O	co-administration
O	of
O	orally
O	inhaled
B-drug	ciclesonide
O	and
O	oral
B-drug	ketoconazole
O	,
O	a
O	potent
O	inhibitor
O	of
O	cytochrome
O	P450
O	3A4
O	,
O	increased
O	the
O	exposure
O	(
O	AUC
O	)
O	of
B-drug	des-ciclesonide
O	by
O	approximately
O	3.6-fold
O	at
O	steady
O	state
O	,
O	while
O	levels
O	of
B-drug	ciclesonide
O	remained
O	unchanged
O	.

I-drug	rifabutin
O	concentration

O	The
O	percentage
O	of
O	neurons
O	hyperpolarized
O	by
B-group	mu-
O	,
O	delta
O	(
O	1
O	)
O	-
O	,
O	and
B-group	kappa-selective
I-group	opioids
O	was
O	significantly
O	reduced
O	when
O	1
O	%
O	but
O	not
O	<

B-group	antacids
O	after
O	meals
O	.

O	Coadministration
O	of
B-drug	rifampin
O	with
B-drug	diltiazem
O	lowered
O	the
B-drug	diltiazem
O	plasma
O	concentrations
O	to
O	undetectable
O	levels
O	.

O	Laboratory
O	Tests
O	:
O	The
O	combination
O	of
B-drug	Amprenavir
O	and
O	low-dose
B-drug	ritonavir
O	has
O	been
O	associated
O	with
O	elevations
O	of
O	cholesterol
O	and
O	triglycerides
O	,
O	SGOT
O	(
O	AST
O	)
O	,
O	and
O	SGPT
O	(
O	ALT
O	)
O	in
O	some
O	patients
O	.

O	The
O	elimination
O	half
O	life
O	of
B-drug	midazolam
O	and
B-drug	triazolam
O	also
O	increased
O	(
O	1.5-2.5
O	fold
O	)
O	during
O	coadministration
O	with
B-drug	diltiazem
O	.

O	These
O	effects
O	have
O	been
O	attributed
O	to
O	inhibition
O	of
O	renal
O	prostaglandin
O	synthesis
O	by
O	the
B-group	NSAID
O	.

O	If
O	possible
O	,
B-group	anticholinesterase
I-group	agents
O	should
O	be
O	withdrawn
O	at
O	least
O	24
O	hours
O	before
O	initiating
B-group	corticosteroid
O	therapy
O	.

O	Potential
O	for
O	Interaction
O	with
B-group	Monoamine
I-group	Oxidase
I-group	Inhibitors

O	Therefore
O	,
O	the
O	combination
O	of
B-drug	ketoprofen
O	and
B-drug	probenecid
O	is
O	not
O	recommended
O	.

B-drug	Eprosartan
O	doses
O	of
O	up
O	to
O	300
O	mg
O	b.i.d
O	.
O	have
O	been
O	safely
O	used
O	concomitantly
O	with
O	sustained-release
B-group	calcium
I-group	channel
I-group	blockers
O	(
O	sustained-release
B-drug	nifedipine
O	)
O	with
O	no
O	clinically
O	significant
O	adverse
O	interactions
O	.

O	there
O	was
O	no
O	effect
O	on
O	the
O	3
O	major
O	metabolites
O	(
B-drug_n	5-DFUR
O	,
B-drug_n	5-FU
O	and
B-drug_n	FBAL
O	)
O	.

O	Concomitant
O	use
O	of
B-brand	ELLENCE
O	with
O	other
O	cardioactive
O	compounds
O	that
O	could
O	cause
O	heart
O	failure
O	(
O	e.g.
O	,
B-group	calcium
I-group	channel
I-group	blockers
O	)
O	,
O	requires
O	close
O	monitoring
O	of
O	cardiac
O	function
O	throughout
O	treatment
O	.

O	Clearance
O	of
B-drug_n	hydrodolasetron
O	decreased
O	by
O	about
O	27
O	%
O	when
B-drug	dolasetron
I-drug	mesylate
O	was
O	administered
O	intravenously
O	concomitantly
O	with
B-drug	atenolol
O	.

O	The
O	blockade
O	of
O	the
O	spinal
O	endorphinergic
O	system
O	by
O	intrathecal
B-drug	naloxone
O	on
O	the
O	production
O	of
O	tail-flick
O	inhibition
O	induced
O	by
O	intraventricular
B-drug_n	beta-endorphin
O	and
B-drug	morphine
O	was
O	then
O	studied
O	.

O	The
O	time
O	to
O	onset
O	of
O	maximum
O	block
O	following
B-brand	NIMBEX
O	is
O	approximately
O	2
O	minutes
O	faster
O	with
O	prior
O	administration
O	of
B-drug	succinylcholine
O	.

O	There
O	is
O	no
O	significant
O	change
O	in
O	platelet
O	count
O	,
O	prothrombin
O	time
O	,
O	partial
O	thromboplastin
O	time
O	,
O	or
O	thrombin
O	time
O	.

O	Serum
O	transaminase
O	levels
O	should
O	be
O	obtained
O	before
O	starting
O	treatment
O	with
B-brand	Plenaxis
O	and
O	periodically
O	during
O	treatment
O	.

B-drug	Benzthiazide
O	may
O	interact
O	with
B-drug	alcohol
O	,
B-group	blood
O	thinners
O	,
B-group	decongestant
I-group	drugs
O	(
O	allergy
O	,
O	cold
O	,
O	and
O	sinus
O	medicines
O	)
O	,
O	diabetic
O	drugs
O	,
B-drug	lithium
O	,
B-drug	norepinephrine
O	,
B-group	NSAIDs
O	like
B-brand	Aleve
O	or
B-drug	Ibuprofen
O	,
O	and
O	high
O	blood
O	pressure
O	medications
O	.

O	Concomitant
O	use
O	of
O	prostaglandin
O	synthase
O	inhibiting
O	drugs
O	,
O	eg
O	,
B-drug	indomethacin
O	,
O	may
O	decrease
O	the
O	hypotensive
O	effects
O	of
B-group	beta
I-group	blockers
O	.

O	Therefore
O	when
B-group	central
I-group	nervous
I-group	system
I-group	depressants
O	are
O	administered
O	concomitantly
O	with
B-drug	hydroxyzine
O	their
O	dosage
O	should
O	be
O	reduced
O	.

O	-
O	The
O	persistence
O	of
O	clinical
O	and
O	laboratory
O	evidence
O	of
O	hypothyroidism
O	in
O	spite
O	of
O	adequate
O	dosage
O	replacement
O	indicates
O	either
O	poor
O	patient
O	compliance
O	,
O	poor
O	absorption
O	,
O	excessive
O	fecal
O	loss
O	,
O	or
O	inactivity
O	of
O	the
O	preparation
O	.

O	.

B-drug	Diclofenac
O	:
O	Administration
O	of
O	morning
O	and
O	lunch
O	doses
O	of
B-brand	Starlix
O	120
O	mg
O	in
O	combination
O	with
O	a
O	single
O	75-mg
O	dose
O	of
B-drug	diclofenac
O	in
O	healthy
O	volunteers
O	resulted
O	in
O	no
O	significant
O	changes
O	to
O	the
O	pharmacokinetics
O	of
O	either
O	agent
O	.

B-drug	Loratadine
O	(
O	10
O	mg
O	once
O	daily
O	)
O	has
O	been
O	coadministered
O	with
O	therapeutic
O	doses
O	of
B-drug	erythromycin
O	,
B-drug	cimetidine
O	,
O	and
B-drug	ketoconazole
O	in
O	controlled
O	clinical
O	pharmacology
O	studies
O	in
O	adult
O	volunteers
O	.

O	No
O	data
O	on
O	the
O	level
O	of
O	circulating
O	catecholamines
O	after
B-brand	ALPHAGAN
I-brand	P
O	administration
O	are
O	available
O	.

B-drug	Amitriptyline
O	in
O	combination
O	with
B-drug	clonidine
O	enhances
O	the
O	manifestation
O	of
O	corneal
O	lesions
O	in
O	rats
O	Epidural
O	Injection
B-drug	Clonidine
O	may
O	potentiate
O	the
O	CNS-depressive
O	effect
O	of
B-drug	alcohol
O	,
B-group	barbiturates
O	or
O	other
B-group	sedating
I-group	drugs
O	.

O	Other
O	substances
O	,
O	including
O	herbal
O	preparations
O	:
O	St.
O	John
O	s
O	Wort
O	(
O	Hypericum
O	perforatum
O	)
O	induces
O	CYP3A4
O	.

O	In
O	normal
O	volunteers
O	receiving
B-drug	indomethacin
O	,
O	the
O	administration
O	of
B-drug	diflunisal
O	decreased
O	the
O	renal
O	clearance
O	and
O	significantly
O	increased
O	the
O	plasma
O	levels
O	of
B-drug	indomethacin
O	.

B-drug	Valproate
O	:
B-brand	Felbatol
O	causes
O	an
O	increase
O	in
O	steady-state
B-drug	valproate
O	concentrations
O	.

O	APRD00513_IN
O	,
O	txt

O	These
O	agents
O	should
O	not
O	be
O	taken
O	within
O	the
O	two
O	hour
O	period
O	before
O	or
O	within
O	the
O	two-hour
O	period
O	after
B-drug	nalidixic
I-drug	acid
O	administration
O	.

O	Intrathecal
O	injection
O	of
B-drug	naloxone
O	at
O	doses
O	of
O	0.4
O	to
O	40
O	micrograms
O	caused
O	a
O	dose-related
O	blockade
O	of
O	the
O	inhibition
O	of
O	the
O	tail-flick
O	response
O	induced
O	by
O	intraventricular
O	injection
O	of
B-drug_n	beta-endorphin
O	,
O	and
O	a
O	high
O	dose
O	of
B-drug	naloxone
O	(
O	40
O	micrograms
O	)
O	completely
O	blocked
O	the
O	tail-flick
O	inhibition
O	induced
O	by
O	intraventricular
B-drug_n	beta-endorphin
O	(
O	16
O	micrograms
O	)
O	.

O	In
O	one
O	survey
O	,
O	2.3
O	%
O	of
O	patients
O	taking
B-drug	labetalol
I-drug	HCl
O	in
O	combination
O	with
B-group	tricyclic
I-group	antidepressants
O	experienced
O	tremor
O	,
O	as
O	compared
O	to
O	0.7
O	%
O	reported
O	to
O	occur
O	with
B-drug	labetalol
I-drug	HCl
O	alone
O	.

O	When
B-group	sympathomimetic
I-group	drugs
O	are
O	given
O	to
O	patients
O	receiving
B-group	monoamine
I-group	oxidase
I-group	inhibitors
O	,
O	hypertensive
O	reactions
O	,
O	including
O	hypertensive
O	crises
O	,
O	may
O	occur
O	.

B-group	Resins
O	:
O	Since
B-group	bile
I-group	acid
I-group	sequestrants
O	may
O	bind
O	other
O	drugs
O	given
O	concurrently
O	,
O	patients
O	should
O	take
B-brand	TRICOR
O	at
O	least
O	1
O	hour
O	before
O	or
O	4-6
O	hours
O	after
O	a
B-group	bile
I-group	acid
I-group	binding
I-group	resin
O	to
O	avoid
O	impeding
O	its
O	absorption
O	.

O	No
O	drug
O	interaction
O	studies
O	have
O	been
O	performed
O	.

O	In
O	common
O	with
O	other
B-group	broad-spectrum
I-group	antibiotics
O	,
B-brand	AUGMENTIN
I-brand	XR
O	may
O	reduce
O	the
O	efficacy
O	of
O	oral
B-group	contraceptives

B-group	Antimycobacterial
I-group	Agents

B-drug	Valdecoxib
O	steady
O	state
O	plasma
O	concentrations
O	(
O	40
O	mg
O	BID
O	)
O	were
O	not
O	affected
O	significantly
O	with
O	multiple
O	doses
O	of
B-drug	omeprazole
O	(
O	40
O	mg
O	QD
O	)
O	.

I-drug	lopinavir
O	concentration

O	3
O	.

B-drug	Warfarin
O	and
B-group	Anticoagulants
O	:
O	Increased
O	prothrombin
O	time
O	,
O	with
O	or
O	without
O	clinical
O	bleeding
O	,
O	has
O	been
O	reported
O	when
B-drug	cefixime
O	is
O	administered
O	concomitantly
O	.

O	Drugs
O	that
O	Lower
O	Seizure
O	Threshold
O	:
O	Concurrent
O	administration
O	of
B-brand	WELLBUTRIN
O	and
O	agents
O	(
O	e.g.
O	,
B-group	antipsychotics
O	,
O	other
B-group	antidepressants
O	,
B-drug	theophylline
O	,
O	systemic
B-group	steroids
O	,
O	etc
O	.
O	)
O	that
O	lower
O	seizure
O	threshold
O	should
O	be
O	undertaken
O	only
O	with
O	extreme
O	caution
O	.

O	Drug
O	Name

O	A
O	single
O	0.5
O	mg
O	oral
O	dose
O	of
B-drug	digoxin
O	elixir
O	was
O	administered
O	on
O	the
O	7th
O	day
O	of
O	each
O	11-day
O	period
O	.

B-drug	HCTZ
O	50
O	mg
O	QD
O	or
B-drug	HCTZ/triamterene
O	50/100
O	mg
O	QD
O	was
O	co-administered
O	with
B-brand	TIKOSYN
O	(
O	500
O	mcg
O	BID
O	)
O	for
O	5
O	days
O	(
O	following
O	2
O	days
O	of
B-group	diuretic
O	use
O	at
O	half
O	dose
O	)
O	.

O	Results
O	from
O	existing
O	clinical
O	trials
O	suggest
O	no
O	significant
O	interactions
O	between
B-brand	COPAXONE
O	and
O	other
O	therapies
O	commonly
O	used
O	in
O	MS
O	patients
O	,
O	including
O	the
O	concurrent
O	use
O	of
B-group	corticosteroids
O	for
O	up
O	to
O	28
O	days
O	.

B-group	Antacids
O	may
O	interfere
O	with
O	the
O	absorption
O	of
B-brand	LEVSIN
O	.

O	The
B-drug	zidovudine
O	study
O	dosed
O	subjects
O	with
O	1200
O	mg/day
O	of
B-drug	azithromycin
O	(
O	n
O	=
O	7
O	)
O	(
O	later
O	changed
O	to
O	600
O	mg/day
O	[
O	n
O	=
O	5
O	]
O	)
O	for
O	Days
O	8
O	to
O	21
O	of
O	a
O	21-day
O	course
O	of
O	100
O	mg
O	,
O	five
O	times/day
O	of
B-drug	zidovudine
O	.

B-drug	Sulindac
O	:
O	The
O	concomitant
O	administration
O	of
B-drug	diflunisal
O	and
B-drug	sulindac
O	in
O	normal
O	volunteers
O	resulted
O	in
O	lowering
O	of
O	the
O	plasma
O	levels
O	of
O	the
O	active
O	sulindac
O	sulfide
O	metabolite
O	by
O	approximately
O	one-third
O	.

O	Thus
O	,
O	concomitant
O	administration
O	of
B-drug	enoxacin
O	and
B-drug	bismuth
I-drug	subsalicylate
O	should
O	be
O	avoided
O	.

B-brand	CRIXIVAN
O	may
O	not
O	be
O	effective
O	due
O	to
O	decreased
B-drug	indinavir
O	concentrations
O	in
O	patients
O	taking
O	these
O	agents
O	concomitantly
O	.

B-drug	Nifedipine
O	:
B-drug	Vardenafil
O	20
O	mg
O	,
O	when
O	co-administered
O	with
O	slow-release
B-drug	nifedipine
O	30
O	mg
O	or
O	60
O	mg
O	once
O	daily
O	,
O	did
O	not
O	affect
O	the
O	relative
O	bioavailability
O	(
O	AUC
O	)
O	or
O	maximum
O	concentration
O	(
O	Cmax
O	)
O	of
B-drug	nifedipine
O	,
O	a
O	drug
O	that
O	is
O	metabolized
O	via
O	CYP3A4
O	.

B-drug	Isoflurane
O	,
B-drug	enflurane
O	,
O	and
B-drug	halothane
O	decrease
O	the
O	ED50
O	of
B-brand	NUROMAX
O	by
O	30
O	%
O	to
O	45
O	%
O	.

O	Since
O	photic
O	evoked
O	potential
O	components
O	are
O	representations
O	of
O	neural
O	pathways
O	which
O	are
O	activated
O	during
O	photic
O	stimulation
O	,
O	study
O	of
O	the
O	effects
O	of
B-drug	alcohol
O	on
O	these
O	components
O	may
O	help
O	to
O	trace
O	pathways
O	which
O	are
O	affected
O	by
B-drug	alcohol
O	.

O	While
O	all
O	the
B-group	selective
I-group	serotonin
I-group	reuptake
I-group	inhibitors
O	(
B-group	SSRIs
O	)
O	,
O	e.g.
O	,
B-drug	fluoxetine
O	,
O	seriraline
O	,
O	and
B-drug	paroxetine
O	,
O	inhibit
O	P450
O	2D6
O	,
O	they
O	may
O	vary
O	in
O	the
O	extent
O	of
O	inhibition
O	.

O	In
O	this
O	study
O	,
O	we
O	investigated
O	the
O	mechanism
O	(
O	s
O	)
O	of
B-drug_n	resveratrol-induced
O	vasorelaxation
O	in
O	resistance
O	mesenteric
O	arteries
O	from
O	male
O	lean
O	and
O	dietary-induced
O	obese
O	rats
O	.

O	Coadministration
O	of
B-brand	VIDEX
O	with
O	drugs
O	that
O	are
O	known
O	to
O	cause
O	pancreatitis
O	may
O	increase
O	the
O	risk
O	of
O	this
O	toxicity
O	(
O	see
O	WARNINGS
O	)
O	and
O	should
O	be
O	done
O	with
O	extreme
O	caution
O	,
O	only
O	if
O	other
O	alternatives
O	are
O	not
O	available
O	,
O	and
O	only
O	if
O	clearly
O	indicated
O	.

O	When
O	such
O	drugs
O	are
O	withdrawn
O	from
O	a
O	patient
O	receiving
B-drug	glipizide
O	,
O	the
O	patient
O	should
O	be
O	observed
O	closely
O	for
O	hypoglycemia
O	.

O	The
O	in
O	vitro
O	interaction
O	between
B-drug	nevirapine
O	and
O	the
B-group	antithrombotic
I-group	agent
B-drug	warfarin
O	is
O	complex
O	.

O	In
O	addition
O	,
O	neuromuscular
O	blocking
O	action
O	is
O	enhanced
O	by
O	general
B-group	anesthetics
O	,
O	local
B-group	anesthetics
O	like
B-drug	lidocaine
O	,
B-drug	procaine
O	,
B-group	beta-blockers
O	,
B-drug	metaclopramide
O	,
B-drug	lithium
I-drug	carbonate
O	,
O	and
B-drug	terbutaline
O	.

O	The
O	optimal
O	dose
O	of
B-drug	indinavir
O	,
O	when
O	given
O	in
O	combination
O	with
B-drug	efavirenz
O	,
O	is
O	not
O	known
O	.

O	Example
O	inducers
O	include
B-drug	aminoglutethimide
O	,
B-drug	carbamazepine
O	,
B-drug	nafcillin
O	,
B-drug	nevirapine
O	,
B-drug	phenobarbital
O	,
B-drug	phenytoin
O	,
O	and
B-group	rifamycins
O	.

B-drug	Cobalt
O	excretion
O	was
O	enhanced
O	by
O	supplementary
B-drug	cobalt
O	;

O	This
O	effect
O	is
O	small
O	with
O	occasional
O	doses
O	of
B-group	antacids
O	,
O	but
O	may
O	be
O	clinically
O	significant
O	when
B-group	antacids
O	are
O	used
O	on
O	a
O	continuous
O	schedule
O	.

O	Toxicologic
O	and
O	toxicokinetic
O	studies
O	in
O	rats
O	did
O	not
O	demonstrate
O	any
O	alterations
O	in
O	the
O	clearance
O	or
O	toxicologic
O	profile
O	of
O	either
B-drug	methotrexate
O	or
B-brand	Kineret
O	when
O	the
O	two
O	agents
O	were
O	administered
O	together
O	.

O	Whether
O	this
O	interaction
O	also
O	occurs
O	with
O	the
O	intravenous
O	,
O	topical
O	,
O	or
O	vaginal
O	preparations
O	of
B-drug	miconazole
O	is
O	not
O	known
O	.

O	Concomitant
O	administration
O	of
B-drug	Aprepitant
O	with
O	strong
O	CYP3A4
O	inhibitors
O	should
O	be
O	approached
O	cautiously
O	.

O	Dosage
O	adjustment
O	may
O	be
O	warranted
O	when
B-drug	levobupivacaine
O	is
O	concurrently
O	administered
O	with
O	CYP3A4
O	inhibitors
O	and
O	CYP1A2
O	inhibitors
O	as
O	systemic
B-drug	levobupivacaine
O	levels
O	may
O	rise
O	resulting
O	in
O	toxicity
O	.

O	Microdosed
O	minipill
B-drug	progestin
O	preparations
O	are
O	not
O	recommended
O	for
O	use
O	with
B-drug	Soriatane
O	.

O	An
O	in
O	vivo
O	interaction
O	study
O	in
O	humans
O	demonstrated
O	that
O	a
O	single
O	1mg
O	dose
O	of
B-drug	anagrelide
O	administered
O	concomitantly
O	with
O	a
O	single
O	900
O	mg
O	dose
O	of
B-brand	aspirin
O	was
O	generally
O	well
O	tolerated
O	.

O	N=50
O	)
O	Cmax
O	and
O	AUC
O	values
O	in
O	a
O	dose-dependent
O	manner
O	relative
O	to
O	administration
O	of
B-drug	hydrocodone
O	alone
O	;

B-brand	INDOCIN
O	can
O	reduce
O	the
O	antihypertensive
O	effects
O	of
B-drug	captopril
O	and
B-drug	losartan
O	.

O	The
O	general
O	public
O	feels
O	that
B-drug	cocaine
O	is
O	not
O	particularly
O	dangerous
O	because
O	it
O	does
O	not
O	produce
O	a
O	well
O	defined
O	physical
O	dependency
O	and
O	abstinence
O	syndrome
O	.

O	It
O	should
O	also
O	be
O	avoided
O	in
O	patients
O	with
O	blood
O	,
O	liver
O	or
O	kidney
O	diseases
O	,
O	recent
O	radiation
O	treatment
O	,
O	or
O	uncontrolled
O	diabetes
O	.

O	A
O	decrease
O	of
O	the
O	dosage
O	may
O	be
O	necessary
O	when
O	patient
O	becomes
O	euthyroid
O	.

B-group	dihydropyridine
I-group	calcium
I-group	channel
I-group	blockers
O	concentration

O	The
O	clinical
O	relevance
O	of
O	the
O	potential
O	effect
O	of
B-drug	grepafloxacin
O	on
O	the
O	metabolism
O	of
O	C.P.A
O	.
O	substrates
O	is
O	not
O	known
O	.

O	Acute
B-drug	hydrocortisone
O	administration
O	does
O	not
O	affect
O	subjective
O	responses
O	to
B-drug	d-amphetamine
O	in
O	humans
O	.

B-drug	Acetaminophen
O	:
O	May
O	increase
O	plasma
O	concentration
O	of
B-group	synthetic
I-group	estrogens
O	,
O	possibly
O	by
O	inhibiting
O	conjugation
O	.

O	Concomitant
O	Crohn
O	s
O	disease
O	medications
O	were
B-group	antibiotics
O	,
B-group	antivirals
O	,
B-group	corticosteroids
O	,
B-drug	6-MP/AZA
O	and
O	aminosalicylates
O	.

O	Serum
O	concentrations
O	of
O	drugs
O	metabolized
O	by
O	the
O	cytochrome
O	P450
O	system
O	should
O	be
O	monitored
O	closely
O	in
O	patients
O	concurrently
O	receiving
B-drug	erythromycin
O	.

O	Interaction
O	between
B-drug	oxytocin
O	and
O	antidiuretic
O	hormone
O	and
O	its
O	effect
O	on
O	the
O	milk
O	secretion
O	by
O	alveoli
O	of
O	the
O	mammary
O	gland
O	of
O	lactating
O	rats
O	.

O	The
O	following
O	eight
O	target
O	drug/added
O	drug
O	combinations
O	were
O	studied
O	:
B-drug	acetaminophen/phenobarbital
O	.

O	The
B-group	antifungal
I-group	drug
O	,
B-drug	miconazole
I-drug	nitrate
O	,
O	inhibits
O	the
O	growth
O	of
O	several
O	species
O	of
O	Candida
O	.

O	No
O	dosage
O	adjustment
O	is
O	required
O	for
B-drug	Fluvoxamine
O	Tablets
O	.

B-drug	Fluoroquinolones
O	,
B-drug	macrolide
I-drug	antibiotics
O	,
O	and
O	azoles
O	are
O	known
O	to
O	cause
O	QTc
O	prolongation
O	.

O	Concomitant
O	use
O	with
O	other
B-drug	calcium-containing
O	medicines
O	(
O	including
B-group	antacids
O	)
O	may
O	cause
O	too
O	much
B-drug	calcium
O	in
O	the
O	blood
O	or
O	urine
O	,
O	which
O	may
O	increase
O	the
O	chance
O	of
O	side
O	effects
O	.

O	These
O	individuals
O	may
O	develop
O	higher
O	than
O	expected
O	plasma
O	concentrations
O	of
B-drug	clozapine
O	when
O	given
O	usual
O	doses
O	.

O	Other
O	reported
O	interactions
O	with
B-drug	amiodarone
O	:
B-drug	Fentanyl
O	(
B-drug	CYP3A4
O	substrate
O	)
O	in
O	combination
O	with
B-drug	amiodarone
O	may
O	cause
O	hypotension
O	,
O	bradycardia
O	,
O	and
O	decreased
O	cardiac
O	output
O	.

O	Finally
O	,
O	it
O	is
O	notable
O	that
O	xanthine-derived
O	adenosine
O	antagonists
O	tested
O	here
O	commonly
O	showed
O	anxiogenic
O	effects
O	in
O	the
O	light/dark
O	test
O	in
O	mice
O	.

B-drug	Theophylline
O	:
O	The
O	pharmacokinetics
O	of
B-drug	theophylline
O	(
B-drug	aminophylline
O	5.8
O	mg/kg
O	infused
O	over
O	20
O	minutes
O	)
O	were
O	unchanged
O	following
O	a
O	single
O	oral
O	dose
O	of
B-drug	albendazole
O	(
O	400
O	mg
O	)
O	in
O	6
O	healthy
O	subjects
O	.

O	Drug/Laboratory
O	Tests
O	Interactions
O	Because
O	false
O	positive
O	readings
O	were
O	reported
O	with
O	the
O	Ames
O	N-Multistix
O	SG
O	dipstick
O	test
O	for
O	urinary
O	protein
O	when
B-drug	gabapentin
O	was
O	added
O	to
O	other
B-group	antiepileptic
I-group	drugs
O	,
O	the
O	more
O	specific
O	sulfosalicylic
O	acid
O	precipitation
O	procedure
O	is
O	recommended
O	to
O	determine
O	the
O	presence
O	of
O	urine
O	protein

O	Thus
O	,
O	certain
O	factors
O	,
O	such
O	as
O	reinforcing
O	drug
O	effects
O	,
O	conditioning
O	processes
O	,
O	automatic
O	behavior
O	,
O	and
O	stress
O	,
O	may
O	influence
O	the
O	development
O	of
O	dependence
O	on
O	both
O	drugs
O	.

O	.

O	This
O	risk
O	is
O	present
O	whether
O	the
O	drugs
O	are
O	administered
O	as
O	oral
O	,
O	parenteral
O	,
O	or
O	topical
O	formulations
O	.

O	Successful
O	prophylaxis
O	of
O	manic-depressive
O	disorder
O	requires
O	more
O	than
O	the
O	prescription
O	of
B-drug	lithium
I-drug	carbonate
O	.

O	Dependent
O	measures
O	included
O	self-reported
O	mood
O	and
O	subjective
O	effects
O	(
O	Addiction
O	Research
O	Center
O	inventory
O	,
O	the
O	profile
O	of
O	mood
O	states
O	,
O	and
O	a
O	series
O	of
O	visual
O	analogue
O	scales
O	)
O	,
O	vital
O	signs
O	,
O	salivary
O	cortisol
O	,
O	and
O	psychomotor
O	performance
O	.

O	When
O	these
O	products
O	are
O	administered
O	concomitantly
O	,
O	prothrombin
O	or
O	other
O	suitable
O	coagulation
O	tests
O	should
O	be
O	monitored
O	closely
O	.

O	No
O	formal
O	drug
O	interaction
O	studies
O	have
O	been
O	conducted
O	with
B-brand	Cyanokit
O	.

B-drug	vitamin
I-drug	C
O	;

B-drug	Meclofenamate
I-drug	sodium
O	does
O	not
O	affect
O	serum
B-group	salicylate
O	levels
O	.

O	The
O	use
O	of
B-group	NSAIDs
O	in
O	patients
O	who
O	are
O	receiving
B-group	ACE
I-group	inhibitors
O	may
O	potentiate
O	renal
O	disease
O	states
O	.

O	Therapeutic
O	drug
O	monitoring
O	can
O	avoid
O	iatrogenic
O	alterations
O	caused
O	by
B-drug	99mTc-methylene
I-drug	diphosphonate
O	(
O	MDP
O	)
B-drug	-gentamicin
O	interaction
O	.

O	Consequently
O	,
O	prothrombin
O	time
O	should
O	be
O	reassessed
O	periodically
O	in
O	patients
O	receiving
O	both
O	drugs
O	.

B-drug	Rifampin
O	has
O	been
O	reported
O	to
O	increase
O	the
B-drug	warfarin
O	requirements
O	in
O	human
O	subjects
O	ingesting
O	these
O	agents
O	simultaneously
O	.

O	This
O	appears
O	to
O	be
O	the
O	only
O	clinically
O	relevant
O	interaction
O	of
O	this
O	kind
O	with
B-drug	Mefloquine
O	,
O	although
O	theoretically
O	,
O	coadministration
O	of
O	other
O	drugs
O	known
O	to
O	alter
O	cardiac
O	conduction
O	(
O	eg
O	,
B-drug	anti-arrhythmic
O	or
B-group	beta-adrenergic
I-group	blocking
I-group	agents
O	,
B-group	calcium
I-group	channel
I-group	blockers
O	,
B-group	antihistamines
O	or
B-group	H1-blocking
I-group	agents
O	,
B-group	tricyclic
I-group	antidepressants
O	and
B-group	phenothiazines
O	)
O	might
O	also
O	contribute
O	to
O	a
O	prolongation
O	of
O	the
O	QTc
O	interval
O	.

O	The
O	effect
O	was
O	present
O	for
O	at
O	least
O	7
O	days
O	after
O	the
O	last
O	dose
O	of
B-drug	bupropion
O	.

B-group	Barbiturates
O	,
B-drug	carbamazepine
O	,
O	and
B-drug	phenytoin
O	decrease
O	the
O	half-life
O	of
B-drug	doxycycline
O	.

O	If
B-drug	nifedipine
O	therapy
O	is
O	initiated
O	in
O	a
O	patient
O	currently
O	receiving
B-drug	cimetidine
O	,
O	cautious
O	titration
O	is
O	advised
O	.

O	During
O	concomitant
O	therapy
O	of
B-brand	Ponstel
O	with
B-drug	furosemide
O	,
O	the
O	patient
O	should
O	be
O	observed
O	closely
O	for
O	signs
O	of
O	renal
O	failure
O	,
O	as
O	well
O	as
O	to
O	assure
O	diuretic
O	efficacy
O	.

O	However
O	,
O	appropriate
O	monitoring
O	of
O	blood
O	glucose
O	should
O	be
O	performed
O	when
O	initiating
B-brand	EXTRANEAL
O	in
O	diabetic
O	patients
O	and
B-drug	insulin
O	dosage
O	should
O	be
O	adjusted
O	if
O	needed
O	.

O	Depending
O	on
O	the
O	fraction
O	of
O	drug
O	metabolized
O	by
O	P450
O	2D6
O	,
O	the
O	increase
O	in
O	plasma
O	concentration
O	may
O	be
O	small
O	,
O	or
O	quite
O	large
O	(
O	8-fold
O	increase
O	in
O	plasma
O	AUC
O	of
O	the
B-group	TCA
O	)
O	.

O	An
O	alternative
O	non-CYP3A4
O	substrate
B-group	hypnotic
I-group	agent
O	may
O	be
O	considered
O	in
O	patients
O	taking
O	CYP3A4
O	inducers
O	such
O	as
B-drug	rifampin
O	,
B-drug	phenytoin
O	,
B-drug	carbamazepine
O	,
O	and
B-drug	phenobarbital
O	.

B-group	Antidiabetic
I-group	Agents
O	:
O	Disturbances
O	of
O	blood
O	glucose
O	,
O	including
O	hyperglycemia
O	and
O	hypoglycemia
O	,
O	have
O	been
O	reported
O	in
O	patients
O	treated
O	concomitantly
O	with
B-group	quinolones
O	and
O	an
B-group	antidiabetic
I-group	agent
O	.

O	The
O	purpose
O	of
O	this
O	study
O	was
O	to
O	evaluate
O	the
O	effect
O	of
B-drug_n	sodium
I-drug_n	carboxymethylcellulose
O	(
B-drug_n	NaCMC
O	)
O	and
B-drug_n	carboxymethylcellulose-cysteine
O	(
B-drug_n	CMC-Cys
O	)
O	conjugates
O	on
O	the
O	intestinal
O	permeation
O	of
B-drug	sodium
I-drug	fluorescein
O	(
B-drug	NaFlu
O	)
O	and
O	model
O	peptide
O	drugs
O	,
B-drug	bacitracin
O	and
B-drug	insulin
O	.

B-group	Uricosuric
I-group	Agents
O	:
B-brand	Aspirin
O	may
O	decrease
O	the
O	effects
O	of
B-drug	probenecid
O	,
B-drug	sulfinpyrazone
O	,
O	and
B-drug	phenylbutazone
O	.

O	The
O	effects
O	of
B-drug	fulvestrant
O	on
O	the
O	fertility
O	of
O	female
O	rats
O	appear
O	to
O	be
O	consistent
O	with
O	its
O	anti-estrogenic
O	activity
O	.

O	The
O	availability
O	of
O	potent
B-group	non-nucleoside
I-group	reverse
I-group	transcriptase
I-group	inhibitor
O	(
B-group	NNRTI
O	)
O	-based
O	regimens
O	for
B-group	antiretroviral
O	therapy
O	and
O	concerns
O	regarding
B-group	protease
I-group	inhibitor
O	(
B-group	PI
O	)
O	-related
O	metabolic
O	disturbances
O	have
O	led
O	to
O	significant
O	shifts
O	in
O	treatment
O	practices
O	in
O	HIV
O	infection
O	.

O	-
B-group	Antidiabetic
I-group	drugs
O	:
O	(
O	Oral
O	agents
O	and
B-drug	insulin
O	)
O	Dosage
O	adjustment
O	of
O	the
B-group	antidiabetic
I-group	drug
O	may
O	be
O	required

B-drug	Ketoconazole
O	:
B-drug	Ketoconazole
O	has
O	been
O	reported
O	to
O	decrease
O	the
O	metabolism
O	of
O	certain
B-group	corticosteroids
O	by
O	up
O	to
O	60
O	%
O	,
O	leading
O	to
O	increased
O	risk
O	of
B-group	corticosteroid
O	side
O	effects
O	.

O	a
O	See
O	Tables
O	1
O	and
O	2
O	.

B-group	NSAIDs
O	should
O	be
O	used
O	with
O	caution
O	in
O	patients
O	taking
B-drug	cyclosporine
O	,
O	and
O	renal
O	function
O	should
O	be
O	carefully
O	monitored
O	.

O	Electrophilic
O	agents
O	--
O	a
O	class
O	of
O	chemicals
O	that
O	includes
O	most
O	genotoxic
O	compounds
O	--
O	can
O	be
O	inactivated
O	by
O	reaction
O	with
O	glutathione
O	or
O	other
O	SH-bearing
O	molecules
O	.

B-drug	Theophylline
O	:
O	In
O	three
O	pharmacokinetic
O	studies
O	including
O	46
O	normal
O	,
O	healthy
O	subjects
O	,
B-drug	theophylline
O	clearance
O	and
O	concentration
O	were
O	not
O	significantly
O	altered
O	by
O	the
O	addition
O	of
B-drug	lomefloxacin
O	.

O	Concurrent
O	therapy
O	with
B-brand	ORENCIA
O	and
B-group	TNF
I-group	antagonists
O	is
O	not
O	recommended
O	.

B-drug	Cimetidine
O	:
B-drug	Cimetidine
O	can
O	inhibit
O	the
O	metabolism
O	of
B-drug	chloroquine
O	,
O	increasing
O	its
O	plasma
O	level
O	.

O	the
O	time
O	to
O	reach
O	maximum
O	concentration
O	was
O	delayed
O	approximately
O	30
O	minutes
O	.

O	It
O	is
O	also
O	shown
O	that
O	after
O	14
O	days
O	of
O	daily
O	administration
O	of
B-drug	chlordiazepoxide
O	,
O	withdrawal
O	of
O	the
O	drug
O	not
O	only
O	re-results
O	in
O	almost
O	complete
O	loss
O	of
O	bar-press
O	response
O	in
O	the
O	E-strain
O	subjects
O	but
O	also
O	results
O	in
O	a
O	temporary
O	decrease
O	in
O	the
O	acquired
O	behavioral
O	response
O	of
O	the
O	stable
O	A-strain
O	subjects
O	.

O	This
O	interaction
O	should
O	be
O	given
O	consideration
O	in
O	patients
O	taking
B-brand	CELEBREX
O	concomitantly
O	with
B-group	ACE-inhibitors
O	.

B-drug	Lithium
O	:
B-drug	Lithium
O	toxicity
O	has
O	been
O	reported
O	in
O	patients
O	receiving
B-drug	lithium
O	concomitantly
O	with
O	drugs
O	which
O	cause
O	elimination
O	of
O	sodium
O	,
O	including
B-group	ACE
I-group	inhibitors
O	.

O	Reciprocal
O	interactions
O	may
O	occur
O	with
O	concomitant
O	use
O	of
B-brand	Antizol
O	and
O	drugs
O	that
O	increase
O	or
O	inhibit
O	the
O	cytochrome
O	P450
O	system
O	(
O	e.g.
O	,
B-drug	phenytoin
O	,
B-drug	carbamazepine
O	,
B-drug	cimetidine
O	,
B-drug	ketoconazole
O	)
O	,
O	though
O	this
O	has
O	not
O	been
O	studied

B-drug	Ranitidine
O	also
O	has
O	no
O	effect
O	on
B-drug	eprosartan
O	pharmacokinetics
O	.

B-group	multivitamins
O	containing
B-drug	zinc
O	;

O	The
B-group	benzodiazepines
O	are
O	a
O	family
O	of
B-group	anxiolytic
O	and
B-group	hypnotic
I-group	drugs
O	.

B-drug	Warfarin
O	:
O	The
O	effects
O	of
B-drug	aliskiren
O	on
B-drug	warfarin
O	pharmacokinetics
O	have
O	not
O	been
O	evaluated
O	in
O	a
O	well-controlled
O	clinical
O	trial
O	.

B-drug	Phenobarbital
O	:
O	It
O	appears
O	that
B-drug	phenobarbital
O	may
O	reduce
O	plasma
B-drug	felbamate
O	concentrations
O	.

O	False-negative
O	results
O	in
O	the
O	dexamethasone
O	suppression
O	test
O	(
O	DST
O	)
O	in
O	patients
O	being
O	treated
O	with
B-brand	INDOCIN
O	have
O	been
O	reported
O	.

O	The
O	EC50
O	values
O	for
B-drug	isoproterenol
O	,
O	which
O	is
O	not
O	a
O	substrate
O	for
B-drug	norepinephrine
O	uptake-1
O	,
O	were
O	reduced
O	in
O	myocardium
O	in
O	functional
O	classes
O	II
O	to
O	III
O	and
O	IV
O	compared
O	with
O	those
O	in
O	nonfailing
O	myocardium
O	.

B-group	HIV
I-group	Protease
I-group	Inhibitors
O	:
O	The
O	effect
O	of
B-drug	amprenavir
O	on
O	total
O	drug
O	concentrations
O	of
O	other
B-group	HIV
I-group	protease
I-group	inhibitors
O	in
O	subjects
O	receiving
O	both
O	agents
O	was
O	evaluated
O	using
O	comparisons
O	to
O	historical
O	data
O	.

O	A
O	false-positive
O	direct
O	Coombs
O	test
O	has
O	been
O	reported
O	during
O	treatment
O	with
O	other
B-group	cephalosporin
I-group	antibiotics
O	;

O	Another
O	study
O	showed
O	that
B-drug	alosetron
O	had
O	no
O	clinically
O	significant
O	effect
O	on
O	plasma
O	concentrations
O	of
O	the
O	oral
B-group	contraceptive
I-group	agents
B-drug	ethinyl
I-drug	estradiol
O	and
B-drug	levonorgestrel
O	(
O	CYP3A4
O	substrates
O	)
O	.

B-brand	Cytadren
O	accelerates
O	the
O	metabolism
O	of
B-drug	dexamethasone
O	;

O	CONTRAINDICATED
O	due
O	to
O	potential
O	for
O	serious
O	and/or
O	life-threatening
O	reactions
O	such
O	as
O	acute
O	ergot
O	toxicity
O	characterized
O	by
O	peripheral
O	vasospasm
O	and
O	ischemia
O	of
O	the
O	extremities
O	and
O	other
O	tissues
O	.

B-group	Anticholinergics
O	:
O	Concurrent
O	administration
O	of
O	certain
B-group	anticholinergic
I-group	compounds
O	,
O	such
O	as
B-group	belladonna
I-group	alkaloids
O	and
B-drug	dicyclomine
O	,
O	would
O	be
O	expected
O	to
O	compromise
O	the
O	beneficial
O	effects
O	of
B-drug	cisapride
O	.

O	Use
O	of
O	a
B-group	nonhormonal
I-group	contraceptive
I-group	product
O	is
O	recommended
O	.

B-drug	Phenytoin
O	:
B-drug	Isoniazid
O	may
O	increase
O	serum
O	levels
O	of
B-drug	phenytoin
O	.

B-group	Non-nucleoside
I-group	reverse
I-group	transcriptase
I-group	inhibitors
O	(
B-group	NNRTIs
O	)
O	:
B-drug	Nevirapine
O	may
O	decrease
O	plasma
O	levels
O	of
B-group	combination
I-group	hormonal
I-group	contraceptives
O	;

B-brand	PEGASYS
O	contains
B-drug_n	benzyl
I-drug_n	alcohol
O	.

O	because
O	of
O	this
O	,
O	the
O	dosage
O	of
B-drug	flecainide
O	should
O	be
O	adjusted
O	when
O	these
B-drug	drugs
O	are
O	administered
O	concomitantly
O	.

O	The
O	possibility
O	of
O	hypotensive
O	effects
O	with
B-brand	Lotensin
O	can
O	be
O	minimized
O	by
O	either
O	discontinuing
O	the
B-group	diuretic
O	or
O	increasing
O	the
O	salt
O	intake
O	prior
O	to
O	initiation
O	of
O	treatment
O	with
B-brand	Lotensin
O	.

O	these
O	drugs
O	were
O	not
O	tested
O	to
O	determine
O	the
O	effect
O	of
O	administration
O	one
O	hour
O	before
B-drug	colestipol
I-drug	hydrochloride
O	.

O	Patients
O	receiving
B-group	beta-adrenergic
I-group	blocking
I-group	agents
O	along
O	with
O	either
O	oral
O	or
O	intravenous
B-group	calcium
I-group	antagonists
O	should
O	be
O	monitored
O	for
O	possible
O	atrioventricular
O	conduction
O	disturbances
O	,
O	left
O	ventricular
O	failure
O	and
O	hypotension
O	.

B-drug	Nitrofurantoin
O	interferes
O	with
O	the
O	therapeutic
O	action
O	of
B-drug	nalidixic
I-drug	acid
O	.

O	In
O	vitro
O	,
O	at
O	total
O	drug
O	concentrations
O	27-fold
O	higher
O	than
O	peak
O	plasma
O	concentrations
O	observed
O	with
O	the
O	1-mg
O	dosage
O	,
B-drug	alosetron
O	inhibited
O	CYP
O	enzymes
O	1A2
O	(
O	60
O	%
O	)
O	and
O	2E1
O	(
O	50
O	%
O	)
O	.

O	Activity
O	of
B-drug_n	buforin
I-drug_n	II
O	alone
O	and
O	in
O	combination
O	with
B-drug	azithromycin
O	and
B-drug	minocycline
O	against
O	Cryptosporidium
O	parvum
O	in
O	cell
O	culture
O	.

O	In
O	patients
O	using
B-group	cardiac
I-group	glycosides
O	(
B-drug	digoxin
O	and
O	others
O	)
O	,
O	plasma
O	levels
O	of
O	calcium
O	,
O	potassium
O	and
O	magnesium
O	must
O	be
O	carefully
O	monitored
O	.

O	This
O	study
O	indicates
O	that
O	:
O	(
O	a
O	)
O	the
O	maximal
O	effects
O	of
B-drug_n	resveratrol
O	on
O	resistance
O	arteries
O	from
O	lean
O	and
O	dietary-obese
O	rats
O	are
O	not
O	effected
O	by
O	endothelial
O	dysfunction
O	,
O	and
O	(
O	b
O	)
O	the
O	effects
O	of
B-drug_n	resveratrol
O	in
O	lean
O	animals
O	(
O	where
O	endothelial
O	function
O	is
O	not
O	impaired
O	)
O	,
O	but
O	not
O	in
O	dietary-obese
O	rats
O	,
O	are
O	mediated
O	via
O	NO
O	.

O	In
O	period
O	B
O	,
O	the
O	volunteers
O	were
O	randomly
O	assigned
O	to
O	one
O	of
O	two
O	groups
O	.

O	However
O	,
O	there
O	are
O	several
O	instances
O	in
O	the
O	animal
O	literature
O	showing
O	that
O	hippocampal
O	lesions
O	actually
O	produced
O	enhanced
O	learning
O	and
O	memory
O	function
O	.

O	This
O	secretory
O	diarrhea
O	model
O	is
O	suitable
O	for
O	evaluating
O	the
O	antidiarrheal
O	activity
O	of
O	drugs
O	.

O	In
O	addition
O	,
O	there
O	have
O	been
O	cases
O	reported
O	in
O	which
O	concomitant
O	use
O	of
B-drug	amphotericin
I-drug	B
O	and
B-drug	hydrocortisone
O	was
O	followed
O	by
O	cardiac
O	enlargement
O	and
O	congestive
O	heart
O	failure
O	.

B-drug	Cyclosporine
O	:
O	Increased
O	activity
O	of
O	both
B-drug	cyclosporine
O	and
B-group	corticosteroids
O	may
O	occur
O	when
O	the
O	two
O	are
O	used
O	concurrently
O	.

B-drug	Phenytoin/Phenobarbital
O	:
O	The
O	coadministration
O	of
B-drug	phenytoin
O	or
B-drug	phenobarbital
O	will
O	not
O	affect
O	plasma
O	concentrations
O	of
B-group	vitamin
I-group	D
O	,
O	but
O	may
O	reduce
O	endogenous
O	plasma
O	levels
O	of
B-drug	calcitriol/ergocalcitriol
O	by
O	accelerating
O	metabolism
O	.

O	Clinical
O	studies
O	in
O	healthy
O	volunteers
O	show
O	that
O	the
O	pharmacokinetics
O	of
B-brand	CANCIDAS
O	are
O	not
O	altered
O	by
B-drug	itraconazole
O	,
B-drug	amphotericin
I-drug	B
O	,
B-drug	mycophenolate
O	,
B-drug	nelfinavir
O	,
O	or
B-drug	tacrolimus
O	.

O	The
O	implications
O	of
O	these
O	results
O	are
O	discussed
O	,
O	especially
O	with
O	respect
O	to
O	observations
O	which
O	indicate
O	that
O	homocysteine
O	may
O	be
O	a
O	precipitating
O	factor
O	in
O	the
O	development
O	of
O	thrombosis
O	.

B-drug	Calcium
O	Supplements
O	:
O	Uncontrolled
O	intake
O	of
O	additional
B-drug	calcium-containing
O	preparations
O	should
O	be
O	avoided
O	.

O	Available
O	data
O	are
O	neither
O	sufficient
O	to
O	rule
O	out
O	possible
O	increases
O	in
O	serum
B-drug	digoxin
O	with
O	concomitant
O	treatment
O	in
O	some
O	patients
O	,
O	nor
O	other
O	possible
O	interactions
O	,
O	particularly
O	in
O	patients
O	with
O	cardiac
O	conduction
O	abnormalities
O	(
O	Also
O	see
O	WARNINGS
O	Congestive
O	Heart
O	Failure
O	)
O	.

O	6
O	.

O	In
O	clinical
O	studies
B-drug	propofol
O	had
O	no
O	effect
O	on
O	the
O	duration
O	of
O	action
O	or
O	dosing
O	requirements
O	for
B-brand	NIMBEX
O	.

O	The
O	pharmacodynamic
O	consequences
O	of
O	concomitant
O	use
O	of
B-drug	losartan
O	and
O	inhibitors
O	of
O	P450
O	2C9
O	have
O	not
O	been
O	examined
O	.

O	this
O	was
O	seen
O	in
O	studies
O	with
B-drug	estazolam
O	.

O	In
O	some
O	cases
O	the
O	onset
O	of
O	the
O	injection
O	site
O	reaction
O	either
O	occurred
O	during
O	a
O	prolonged
O	infusion
O	or
O	was
O	delayed
O	by
O	a
O	week
O	to
O	ten
O	days
O	.

O	Free
O	T3
O	resin
O	uptake
O	is
O	decreased
O	,
O	reflecting
O	the
O	elevated
O	TBG
O	;

B-group	Anticonvulsants
O	:
O	In
O	a
O	pharmacokinetic
O	study
O	,
O	maximum
O	plasma
O	concentrations
O	of
B-drug	felodipine
O	were
O	considerably
O	lower
O	in
O	epileptic
O	patients
O	on
O	long-term
B-group	anticonvulsant
O	therapy
O	(
O	eg
O	,
B-drug	phenytoin
O	,
B-drug	carbamazepine
O	,
O	or
B-drug	phenobarbital
O	)
O	than
O	in
O	healthy
O	volunteers
O	.

O	The
O	injection
O	should
O	be
O	made
O	immediately
O	after
O	mixing
O	.

O	Patients
O	using
O	cardiovascular
O	drugs
O	concurrently
O	with
B-brand	IOPIDINE
O	0.5
O	%
O	Ophthalmic
O	Solution
O	should
O	have
O	pulse
O	and
O	blood
O	pressures
O	frequently
O	monitored
O	.

O	Because
O	of
O	the
O	potential
O	for
B-brand	ARAVA
O	levels
O	to
O	continue
O	to
O	increase
O	with
O	multiple
O	dosing
O	,
O	caution
O	should
O	be
O	used
O	if
O	patients
O	are
O	to
O	be
O	receiving
O	both
B-brand	ARAVA
O	and
B-drug	rifampin
O	.

O	Frequent
O	vital
O	sign
O	monitoring
O	,
O	particularly
O	during
O	the
O	first
O	hour
O	of
B-brand	TAXOL
O	infusion
O	,
O	is
O	recommended
O	.

B-group	tricyclic
I-group	antidepressants
O	(
O	such
O	as
B-drug	amitriptyline
O	)
O	;

O	Numerous
O	drug
O	interactions
O	are
O	possible
O	with
O	some
B-group	anticonvulsant
I-group	agents
O	,
O	such
O	as
B-drug	phenobarbitone
O	and
B-drug	phenytoin
O	,
O	which
O	affect
O	hepatic
O	microsomal
O	enzyme
O	systems
O	.

O	Therefore
O	,
B-drug	cyclosporine
O	serum
O	levels
O	should
O	be
O	monitored
O	and
O	appropriate
B-drug	cyclosporine
O	dosage
O	adjustments
O	made
O	when
O	these
O	drugs
O	are
O	used
O	concomitantly
O	.

B-drug	Amprenavir
O	decreased
O	the
O	results
O	of
O	the
O	ERMBT
O	by
O	83
O	%
O	.

O	There
O	was
O	no
O	effect
O	on
O	the
O	pharmacokinetics
O	of
O	representative
O	drugs
O	metabolized
O	by
O	CYP
O	2C9
O	,
O	CYP
O	2C19
O	,
O	CYP
O	2D6
O	or
O	CYP
O	3A4
O	.

B-group	Systemic
I-group	Corticosteroids
O	:
B-group	Systemic
I-group	corticosteroids
O	are
O	known
O	to
O	cause
O	osteoporosis
O	.

O	The
O	influence
O	of
B-drug	midazolam
O	and
B-drug	diazepam
O	on
O	antinociceptive
O	effect
O	of
B-drug	morphine
O	(
O	10
O	mg/kg
O	)
O	,
B-drug	metamizol
O	(
O	500
O	mg/kg
O	)
O	and
B-drug	indomethacin
O	(
O	10
O	mg/kg
O	)
O	was
O	investigated
O	in
O	a
O	mouse
O	model
O	using
O	the
O	tail-flick
O	and
O	hot-plate
O	tests
O	.

O	Drug/Laboratory
O	Test
O	Interactions
O	:
O	There
O	have
O	been
O	no
O	chemical
O	or
O	laboratory
O	test
O	interactions
O	with
B-drug	ceftibuten
O	noted
O	to
O	date
O	.

O	incomplete
O	data
O	for
B-drug	efavirenz
O	.

O	Preliminary
O	clinical
O	data
O	suggest
O	that
O	the
O	incidence
O	of
O	nephrolithiasis
O	is
O	higher
O	in
O	patients
O	receiving
B-drug	indinavir
O	in
O	combination
O	with
B-drug	ritonavir
O	than
O	those
O	receiving
B-brand	CRIXIVAN
O	800
O	mg
O	q8h
O	.

B-drug	Propranolol
O	:
O	In
O	normal
O	volunteers
O	,
O	there
O	was
O	no
O	clinically
O	significant
O	pharmacokinetic
O	or
O	pharmacodynamic
O	interaction
O	with
O	concomitant
O	administration
O	of
O	single
O	doses
O	of
B-drug	lovastatin
O	and
B-drug	propranolol
O	.

O	cases
O	,
O	occurred
O	between
O	the
O	5th
O	and
O	the
O	11th
O	day
O	of
O	treatment
O	.

B-drug	Arginine
O	,
O	in
O	the
O	presence
O	of
B-drug	glucose
O	and
B-drug	theophylline
O	,
O	caused
O	excessive
O	glucagon
O	release
O	but
O	nearly
O	normal
O	insulin
O	release
O	in
O	the
O	diabetics
O	.

O	A
O	routine
O	dosage
O	adjustment
O	of
B-drug	zaleplon
O	is
O	not
O	considered
O	necessary
O	.

B-drug	Sirolimus
O	:
O	mammalian
O	target
O	of
B-drug	rapamycin
O	inhibitor
O	to
O	prevent
O	kidney
O	rejection
O	.

O	Serum
B-drug	theophylline
O	concentrations
O	increase
O	when
B-drug	grepafloxacin
O	is
O	initiated
O	in
O	a
O	patient
O	maintained
O	on
B-drug	theophylline
O	.

B-drug	Amprenavir
O	is
O	an
O	inhibitor
O	of
O	cytochrome
O	P450
O	C.P.A
O	.
O	metabolism
O	and
O	therefore
O	should
O	not
O	be
O	administered
O	concurrently
O	with
O	medications
O	with
O	narrow
O	therapeutic
O	windows
O	that
O	are
O	substrates
O	of
O	CYP3A4
O	.

B-drug	Colestipol
O	:
O	Plasma
O	concentrations
O	of
B-drug	atorvastatin
O	decreased
O	approximately
O	25
O	%
O	when
B-drug	colestipol
O	and
B-drug	atorvastatin
O	were
O	coadministered
O	.

O	Although
O	the
O	clinical
O	significance
O	is
O	not
O	known
O	,
O	it
O	is
O	not
O	recommended
O	that
B-drug	cefditoren
I-drug	pivoxil
O	be
O	taken
O	concomitantly
O	with
B-group	antacids
O	.

B-drug	Maprotiline
O	:
O	Risk
O	of
O	cardiac
O	arrhythmias
O	may
O	increase
O	.

O	Effects
O	of
B-drug	Aliskiren
O	on
O	Other
O	Drugs
B-drug	Aliskiren
O	does
O	not
O	inhibit
O	the
O	CYP450
O	isoenzymes
O	(
O	CYP1A2
O	,
O	2C8
O	,
O	2C9
O	,
O	2C19
O	,
O	2D6
O	,
O	2E1
O	,
O	and
O	CYP
O	3A
O	)
O	or
O	induce
O	CYP
O	3A4
O	.

O	Clinical
O	interaction
O	studies
O	with
B-drug	cimetidine
O	and
B-drug	warfarin
O	indicated
O	that
O	the
O	coadministration
O	of
B-brand	Femara
O	with
O	these
O	drugs
O	does
O	not
O	result
O	in
O	clinically-
O	significant
O	drug
O	interactions
O	.

O	This
O	may
O	lead
O	to
O	reduced
O	clearance
O	of
B-drug	caffeine
O	and
O	a
O	prolongation
O	of
O	its
O	serum
O	half-life
O	.

B-drug	Ganciclovir
O	:
O	The
O	pharmacokinetics
O	of
B-drug	foscarnet
O	and
B-drug	ganciclovir
O	were
O	not
O	altered
O	in
O	13
O	patients
O	receiving
O	either
O	concomitant
O	therapy
O	or
O	daily
O	alternating
O	therapy
O	for
O	maintenance
O	of
O	CMV
O	disease
O	.

O	Drug/Laboratory
O	Tests
O	Interactions
O	No
O	clinically
O	relevant
O	changes
O	in
O	the
O	results
O	of
O	clinical
O	laboratory
O	tests
O	have
O	been
O	observed
O	.

O	Pretreatment
O	with
B-drug	atropine
O	likewise
O	further
O	reduced
O	the
O	amplitudes
O	of
O	components
O	P1
O	and
O	N1
O	,
O	and
O	produced
O	a
O	similar
O	effect
O	on
O	component
O	N3
O	.

B-drug	naproxen
O	;

O	Pharmacodynamic-related
O	Interactions
O	:
O	The
O	mechanism
O	of
B-drug	Clozapine
O	induced
O	agranulocytosis
O	is
O	unknown
O	;

O	Consequently
O	,
O	the
O	effect
O	of
B-drug	iron
O	on
O	the
O	retention
O	of
B-drug	cobalt
O	was
O	lower
O	than
O	on
O	absorption
O	.

B-drug	Dextromethorphan
O	is
O	a
O	substrate
O	for
O	both
B-drug	CYP2D6
O	and
B-drug	CYP3A4
O	.

O	The
O	AUC
O	and
O	Cmax
O	of
B-drug	metoprolol
O	,
O	however
O	,
O	were
O	increased
O	approximately
O	31
O	and
O	38
O	%
O	,
O	respectively
O	.

O	Patients
O	receiving
B-group	antihistamines
O	should
O	be
O	advised
O	against
O	the
O	concurrent
O	use
O	of
O	other
B-group	CNS
I-group	depressant
I-group	drugs
O	.

O	Fourteen
O	days
O	later
O	,
O	all
O	animals
O	were
O	challenged
O	with
O	a
O	single
O	hypnotic
O	dose
O	of
B-drug	ethanol
O	(
O	3.5
O	g/kg
O	IP
O	)
O	.

B-drug	Quinidine
O	at
O	648
O	mg
O	bid
O	decreased
O	the
O	bioavailability
O	(
O	AUC
O	)
O	of
B-drug	nisoldipine
O	by
O	26
O	%
O	,
O	but
O	not
O	the
O	peak
O	concentration
O	.

B-group	Dopamine
I-group	D2
I-group	receptor
I-group	antagonists
O	(
O	e.g.
O	,
B-group	phenothiazines
O	,
B-group	butyrophenones
O	,
B-drug	risperidone
O	)
O	and
B-drug	isoniazid
O	may
O	reduce
O	the
O	therapeutic
O	effects
O	of
B-drug	levodopa
O	.

O	or
O	=0.2
O	%
O	biocytin
O	was
O	included
O	in
O	the
O	recording
O	pipette
O	,
O	compared
O	with
O	neurons
O	recorded
O	without
O	biocytin
O	.

O	Whenever
O	increased
O	thioether
O	excretion
O	is
O	observed
O	,
O	it
O	is
O	likely
O	to
O	be
O	due
O	to
O	exposure
O	to
O	one
O	or
O	more
O	suspect
O	compounds
O	.

O	Two
O	studies
O	were
O	conducted
O	in
O	HIV-infected
O	subjects
O	to
O	assess
O	the
O	potential
O	for
B-drug	azithromycin
O	to
O	interact
O	with
B-drug	zidovudine
O	and
B-drug	dideoxyinosine
O	.

O	Comparative
O	analysis
O	of
O	the
O	effects
O	of
O	stimulation
O	and
O	inhibition
O	of
O	cholino-
O	and
O	adrenoreceptors
O	on
O	this
O	inhibitory
O	action
O	of
B-drug_n	angiotensins
O	suggested
O	the
O	mediation
O	of
B-drug_n	angiotensin
O	influence
O	through
O	the
O	modulation
O	of
O	cholinergic
O	reactions
O	of
O	parietal
O	cells
O	in
O	the
O	stomach
O	.

B-drug	Cimetidine
O	reduces
O	the
O	clearance
O	of
B-brand	ALFENTA
O	.

O	Drugs
O	that
O	cause
O	significant
O	sustained
O	elevation
O	in
O	gastric
O	pH
O	(
B-group	histamine
I-group	H2-receptor
I-group	antagonists
O	such
O	as
B-drug	ranitidine
O	or
B-drug	cimetidine
O	)
O	may
O	reduce
O	plasma
O	concentrations
O	of
B-brand	IRESSA
O	and
O	therefore
O	potentially
O	may
O	reduce
O	efficacy
O	.

O	Therefore
O	,
B-drug	linezolid
O	has
O	the
O	potential
O	for
O	interaction
O	with
B-group	adrenergic
O	and
B-group	serotonergic
I-group	agents
O	.

B-drug_n	Phencyclidine
O	(
B-drug_n	PCP
O	)
O	produces
O	psychotomimetic
O	effects
O	in
O	humans
O	that
O	resemble
O	schizophrenia
O	symptoms
O	.

B-drug	Simvastatin
O	and
O	Other
B-group	Statins
O	:
O	Co-administration
O	of
B-drug	bosentan
O	decreased
O	the
O	plasma
O	concentrations
O	of
B-drug	simvastatin
O	(
O	a
O	CYP3A4
O	substrate
O	)
O	,
O	and
O	its
O	active
O	-hydroxy
O	acid
O	metabolite
O	,
O	by
O	approximately
O	50
O	%
O	.

O	After
O	prolonged
O	administration
O	of
B-group	neuroleptics
O	the
O	displacing
O	effect
O	of
B-drug_n	cerulein
O	,
O	an
O	analog
O	of
O	cholecystokinin
O	octapeptide
O	,
O	was
O	replaced
O	by
O	the
O	stimulant
O	action
O	on
B-drug_n	3H-spiroperidol
O	binding
O	.

O	therefore
O	,
O	administration
O	of
B-brand	EQUETROTM
O	to
O	a
O	patient
O	taking
O	another
O	drug
O	that
O	is
O	highly
O	protein
O	bound
O	should
O	not
O	cause
O	increased
O	free
O	concentrations
O	of
O	the
O	other
O	drug
O	.

O	Medication
O	such
O	as
B-group	digitalis
O	may
O	also
O	influence
O	serum
O	electrolytes
O	.

B-group	Antidiabetic
I-group	drug
O	requirements
O	(
O	i.e.
O	,
B-drug	insulin
O	)
O	may
O	be
O	altered
O	.

O	Drug/Laboratory
O	Test
O	Interactions
O	As
O	a
O	result
O	of
O	the
O	presence
O	of
B-drug	nitrofurantoin
O	,
O	a
O	false-positive
O	reaction
O	for
O	glucose
O	in
O	the
O	urine
O	may
O	occur
O	.

B-group	Urinary
I-group	acidifying
I-group	agents
O	(
B-drug	ammonium
I-drug	chloride
O	,
B-drug	sodium
I-drug	acid
I-drug	phosphate
O	,
O	etc
O	.
O	)
O	increase
O	the
O	concentration
O	of
O	the
O	ionized
O	species
O	of
O	the
B-drug	amphetamine
O	molecule
O	,
O	thereby
O	increasing
O	urinary
O	excretion
O	.

O	Responses
O	to
B-drug	arginine
O	of
O	the
O	perfused
O	pancreas
O	of
O	the
O	genetically
O	diabetic
O	Chinese
O	hamster
O	.

O	A
O	two-way
O	interaction
O	between
O	the
B-group	hydantoin
I-group	antiepileptic
O	,
B-drug	phenytoin
O	,
O	and
O	the
B-group	coumarin
O	anticoagulants
O	has
O	been
O	suggested
O	.

B-drug	Amprenavir
O	plus
B-drug	rifampin
O	was
O	well
O	tolerated
O	.

O	Therefore
O	,
O	if
O	concomitant
O	use
O	of
O	these
O	agents
O	is
O	indicated
O	because
O	of
O	demonstrated
O	hypokalemia
O	,
O	they
O	should
O	be
O	used
O	with
O	caution
O	and
O	with
O	frequent
O	monitoring
O	of
O	serum
O	potassium
O	.

B-drug	Lithium
O	:
O	Increased
O	serum
B-drug	lithium
O	levels
O	and
O	symptoms
O	of
B-drug	lithium
O	toxicity
O	have
O	been
O	reported
O	in
O	patients
O	receiving
O	concomitant
B-drug	lithium
O	and
B-group	ACE
I-group	inhibitor
O	therapy
O	.

O	Patients
O	who
O	have
O	developed
O	severe
O	hypersensitivity
O	reactions
O	should
O	not
O	be
O	rechallenged
O	with
B-brand	TAXOL
O	.

O	and
O	,
O	rarely
O	,
O	enuresis
O	,
O	urinary
O	retention
O	,
O	dysuria
O	,
O	impotence
O	,
O	inability
O	to
O	ejaculate
O	,
O	nocturia
O	,
O	hematuria
O	.

O	A
O	single
O	dose
O	of
O	liquid
B-group	antacid
O	did
O	not
O	affect
O	the
O	C
O	max
O	or
O	AUC
O	of
B-drug	ceftibuten
O	;

O	An
O	evaluation
O	of
O	prothrombin
O	time
O	and
O	an
O	adjustment
O	of
B-group	anticoagulant
O	dosage
O	are
O	recommended

O	For
O	this
O	reason
O	,
O	the
O	dose
O	of
O	the
B-drug	anticoagulant
O	should
O	be
O	reduced
O	by
O	30
O	-
O	50
O	%
O	at
O	the
O	start
O	of
O	treatment
O	with
B-brand	Bezalip
O	or
B-brand	Bezalip
O	retard
O	and
O	then
O	titrated
O	according
O	to
O	the
O	blood
O	clotting
O	parameters

B-drug	ibuprofen
O	;

O	The
O	appropriate
O	dose
O	for
B-drug	nelfinavir
O	incombination
O	with
B-drug	nevirapine
O	,
O	with
O	respectto
O	safety
O	and
O	efficacy
O	,
O	has
O	not
O	been
O	established
O	.

O	Concomitant
O	administration
O	of
B-drug	fenofibrate
O	(
O	equivalent
O	to
O	145mg
B-brand	TRICOR
O	)
O	with
B-drug	pravastatin
O	(
O	40
O	mg
O	)
O	once
O	daily
O	for
O	10
O	days
O	has
O	been
O	shown
O	to
O	increase
O	the
O	mean
O	Cmax
O	and
O	AUC
O	values
O	for
B-drug	pravastatin
O	by
O	36
O	%
O	(
O	range
O	from
O	69
O	%
O	decrease
O	to
O	321
O	%
O	increase
O	)
O	and
O	28
O	%
O	(
O	range
O	from
O	54
O	%
O	decrease
O	to
O	128
O	%
O	increase
O	)
O	,
O	respectively
O	,
O	and
O	for
O	3
O	-hydroxy-iso-pravastatin
O	by
O	55
O	%
O	(
O	range
O	from
O	32
O	%
O	decrease
O	to
O	314
O	%
O	increase
O	)
O	and
O	39
O	%
O	(
O	range
O	from
O	24
O	%
O	decrease
O	to
O	261
O	%
O	increase
O	)
O	,
O	respectively
O	in
O	23
O	healthy
O	adults
O	.

O	Data
O	from
O	several
O	studies
O	,
O	ie
O	,
O	TIMI-II
O	,
O	ISIS-2
O	,
O	currently
O	do
O	not
O	suggest
O	any
O	clinical
O	interaction
O	between
B-brand	aspirin
O	and
B-group	beta
I-group	blockers
O	in
O	the
O	acute
O	myocardial
O	infarction
O	setting
O	.

B-drug	chlordiazepoxide
O	;

O	Treatment
O	with
O	daily
O	doses
O	of
O	2
O	mg
O	of
B-drug_n	coumaphos/kg
O	for
O	6
O	days
O	did
O	not
O	modify
O	the
O	anticholinesterase
O	effect
O	of
O	a
O	2nd
O	series
O	of
O	treatments
O	given
O	6
O	weeks
O	later
O	.

O	Effects
O	of
B-drug	Vardenafil
O	on
O	other
O	drugs

B-drug	Doxorubicin
O	:
B-drug	Doxorubicin
O	caused
O	a
O	decrease
O	in
B-drug	zalcitabine
O	phosphorylation
O	(
O	50
O	%
O	inhibition
O	of
O	total
O	phosphate
O	formation
O	)
O	in
O	U937/Molt
O	4
O	cells
O	.

O	it
O	is
O	possible
O	that
O	larger
B-drug	theophylline
O	doses
O	could
O	have
O	a
O	greater
O	effect
O	.

O	Progestin-only
O	oral
O	contraception
O	:
O	a
O	comprehensive
O	review
O	.

O	Although
O	the
O	magnitude
O	of
O	changes
O	in
B-drug	diazepam
O	plasma
O	exposure
O	when
O	coadministered
O	with
B-drug	valdecoxib
O	were
O	not
O	sufficient
O	to
O	warrant
O	dosage
O	adjustments
O	,
O	patients
O	may
O	experience
O	enhanced
O	sedative
O	side
O	effects
O	caused
O	by
O	increased
O	exposure
O	of
B-drug	diazepam
O	under
O	this
O	circumstance
O	.

O	cardiovascular
O	effects
O	can
O	be
O	potentiated
O	.

O	However
O	,
O	interactions
O	may
O	be
O	expected
O	,
O	and
B-brand	UROXATRAL
O	should
O	NOT
O	be
O	used
O	in
O	combination
O	with
O	other
B-group	alpha-blockers
O	.

O	The
O	addition
O	of
O	540
O	mg/kg/day
O	of
B-drug	cromolyn
I-drug	sodium
O	(
O	approximately
O	340
O	times
O	the
O	maximum
O	recommended
O	daily
O	inhalation
O	dose
O	in
O	adults
O	on
O	a
O	mg/m2
O	basis
O	)
O	to
O	2.7
O	mg/kg/day
O	of
B-drug	isoproterenol
O	(
O	approximately
O	7
O	times
O	the
O	maximum
O	recommended
O	daily
O	inhalation
O	dose
O	in
O	adults
O	on
O	a
O	mg/m2
O	basis
O	)
O	appears
O	to
O	have
O	increased
O	the
O	incidence
O	of
O	both
O	resorptions
O	and
O	malformations
O	.

O	Agents
O	with
O	Decreased
O	Levels
O	in
O	the
O	Presence
O	of
B-drug	Carbamazepine
O	due
O	to
O	Induction
O	of
O	Cytochrome
O	P450
O	Enzymes
B-drug	Carbamazepine
O	is
O	known
O	to
O	induce
O	CYP1A2
O	and
O	CYP3A4
O	.

O	Drug/Laboratory
O	Test
O	Interactions
O	As
O	with
O	other
B-drug	penicillins
O	,
O	the
O	administration
O	of
B-brand	PIPRACIL
O	may
O	result
O	in
O	a
O	false-positive
O	reaction
O	for
O	glucose
O	in
O	the
O	urine
O	using
O	a
O	copper-reduction
O	method
O	.

O	The
O	total
O	drug
O	exposure
O	for
O	the
O	plasma
O	was
O	approximately
O	twofold
O	at
O	the
O	higher
B-drug	cisplatin
O	dose
O	.

O	The
O	patient
O	should
O	be
O	informed
O	that
O	the
O	response
O	to
B-drug	alcohol
O	may
O	be
O	exaggerated
O	.

O	Drug
O	Interaction
O	with
B-drug	Fluoxetine
O	:
O	A
O	multiple-dose
O	study
O	was
O	conducted
O	to
O	assess
O	the
O	effect
O	of
B-drug	fluoxetine
O	20
O	mg
O	BID
O	on
O	the
O	pharmacokinetics
O	of
B-drug	estazolam
O	2
O	mg
O	QHS
O	after
O	seven
O	days
O	.

O	Reductions
O	in
O	serum
O	endogenous
O	vitamin
O	D
O	concentrations
O	have
O	been
O	observed
O	following
O	the
O	administration
O	of
O	300
O	mg/day
O	to
O	1200
O	mg/day
B-drug	ketoconazole
O	for
O	a
O	week
O	to
O	healthy
O	men
O	.

O	+45
O	%
O	+39
O	%
O	+43
O	%
O	+72
O	%

B-brand	Geocillin
O	(
B-drug	carbenicillin
I-drug	indanyl
I-drug	sodium
O	)
O	blood
O	levels
O	may
O	be
O	increased
O	and
O	prolonged
O	by
O	concurrent
O	administration
O	of
B-drug	probenecid
O	.

O	It
O	may
O	increase
O	excretion
O	of
B-group	barbiturates
O	,
B-drug	lithium
O	,
O	and
B-drug	ASA
O	and
O	may
O	also
O	increase
O	the
O	toxicity
O	of
B-group	salicylates
O	.

O	Do
O	not
O	mix
B-brand	TORADOL
O	and
B-drug	morphine
O	in
O	the
O	same
O	syringe
O	.

O	The
O	steady-state
O	Cmin
O	increased
O	to
O	21
O	5
O	micrograms/mL
O	when
O	1200
O	mg/day
O	of
B-drug	felbamate
O	was
O	coadministered
O	.

B-drug	Isoflurane
O	or
B-drug	enflurane
O	administered
O	with
B-drug	nitrous
I-drug	oxide/oxygen
O	to
O	achieve
O	1.25
O	MAC
O	[
O	Minimum
O	Alveolar
O	Concentration
O	]
O	may
O	prolong
O	the
O	clinically
O	effective
O	duration
O	of
O	action
O	of
O	initial
O	and
O	maintenance
O	doses
O	of
B-brand	NIMBEX
O	and
O	decrease
O	the
O	required
O	infusion
O	rate
O	of
B-brand	NIMBEX
O	.

O	It
O	is
O	,
O	therefore
O	,
O	advisable
O	to
O	monitor
B-drug	digoxin
O	concentrations
O	in
O	patients
O	receiving
B-drug	ketoconazole
O	.

O	-
B-group	Vitamin
I-group	K
O	(
O	e.g.
O	,
B-brand	AquaMEPHYTON
O	,
B-brand	Synkayvite
O	)
O	Use
O	of
B-drug	sulfapyridine
O	with
O	these
O	medicines
O	may
O	increase
O	the
O	chance
O	of
O	side
O	effects
O	affecting
O	the
O	blood

O	No
O	information
O	provided

O	Patients
O	receiving
O	the
O	two
O	drugs
O	concomitantly
O	should
O	be
O	carefully
O	monitored
O	.

O	Notably
O	,
O	systemic
O	exposure
O	(
O	AUC0-12
O	)
O	of
B-drug_n	dapsone
I-drug_n	hydroxylamine
O	(
B-drug_n	DHA
O	)
O	was
O	more
O	than
O	doubled
O	in
O	the
O	presence
O	of
B-drug	TMP/SMX
O	.

O	If
O	the
O	two
O	drugs
O	are
O	coadministered
O	,
O	the
B-group	beta
I-group	blocker
O	should
O	be
O	withdrawn
O	several
O	days
O	before
O	the
O	gradual
O	withdrawal
O	of
B-drug	clonidine
O	.

O	Therefore
O	concomitant
O	administration
O	of
B-drug	ketoconazole
O	tablets
O	with
B-drug	cisapride
O	is
O	contraindicated
O	.

O	benign
O	breast
O	disease
O	;

B-drug	Colchicine
O	is
O	inhibited
O	by
B-group	acidifying
I-group	agents
O	.

O	Co-administration
O	with
B-drug	efavirenz
O	or
B-drug	fluconazole
O	had
O	a
O	modest
O	effect
O	on
O	the
O	pharmacokinetics
O	of
B-drug	azithromycin
O	.

O	Oral
B-group	Hypoglycemic
I-group	Agents
O	:
O	In
O	pharmacokinetic
O	studies
O	of
B-brand	MEVACOR
O	in
O	hypercholesterolemic
O	noninsulin
O	dependent
O	diabetic
O	patients
O	,
O	there
O	was
O	no
O	drug
O	interaction
O	with
B-drug	glipizide
O	or
O	with
B-drug	chlorpropamide

O	Comparison
O	of
B-drug	cisplatin
O	pharmacokinetics
O	in
O	patients
O	treated
O	with
O	202.5
O	mg/m2
O	plus
B-drug	thiosulfate
O	to
O	those
O	in
O	patients
O	treated
O	with
O	100
O	mg/m2
O	without
B-drug	thiosulfate
O	indicated
O	that
O	there
O	were
O	no
O	changes
O	in
O	the
O	elimination
O	rate
O	constant
O	,
O	volume
O	of
O	distribution
O	,
O	or
O	total
O	body
O	clearance
O	of
B-drug	cisplatin
O	.

O	Dosage
O	adjustment
O	may
O	be
O	required
O	if
B-drug	cyclosporine
O	,
B-drug	tacrolimus
O	,
O	or
B-drug	methylprednisolone
O	are
O	given
O	concomitantly
O	with
B-brand	NIZORAL
O	Tablets
O	.

O	No
O	depressant
O	effect
O	on
O	blood
O	levels
O	in
O	humans
O	was
O	noted
O	when
B-drug	colestipol
I-drug	hydrochloride
O	was
O	administered
O	with
O	any
O	of
O	the
O	following
O	drugs
O	:
B-brand	aspirin
O	,
B-brand	clindamycin
O	,
B-drug	clofibrate
O	,
B-drug	methyldopa
O	,
B-drug	nicotinic
I-drug	acid
O	(
B-drug	niacin
O	)
O	,
B-drug	tolbutamide
O	,
B-drug	phenytoin
O	or
B-drug	warfarin
O	.

O	-
B-drug	phenytoin
O	(
B-brand	Dilantin
O	)
O	;

O	Withdrawal
O	from
B-drug	cocaine
O	dependence
O	usually
O	involves
O	depression
O	,
O	anxiety
O	and
O	lethargy
O	.

O	Therapeutic
O	drug
O	monitoring
O	(
O	TDM
O	)
O	of
B-drug	gentamicin
O	therapy
O	,
O	and
O	bone
O	scintigraphy
O	employing
B-drug	99mTc-MDP
O	as
O	the
B-group	radiopharmaceutical
O	was
O	carried
O	out
O	in
O	22
O	patients
O	.

O	Refer
O	to
O	the
O	package
O	insert
O	for
B-drug	lithium
O	preparations
O	before
O	use
O	of
O	such
O	preparations
O	with
B-drug	chlorothiazide

O	Drug
O	Interaction
O	with
B-drug	Erythromycin
O	and
B-drug	Ketoconazole
I-drug	Fexofenadine
O	has
O	been
O	shown
O	to
O	exhibit
O	minimal
O	(
O	ca
O	.
O	5
O	%
O	)
O	metabolism
O	.

O	Because
B-drug	eprosartan
O	is
O	not
O	metabolized
O	by
O	the
O	cytochrome
O	P450
O	system
O	,
O	inhibitors
O	of
O	CYP450
O	enzyme
O	would
O	not
O	be
O	expected
O	to
O	affect
O	its
O	metabolism
O	,
O	and
B-drug	ketoconazole
O	and
B-drug	fluconazole
O	,
O	potent
O	inhibitors
O	of
O	CYP3A
O	and
O	2C9
O	,
O	respectively
O	,
O	have
O	been
O	shown
O	to
O	have
O	no
O	effect
O	on
B-drug	eprosartan
O	pharmacokinetics
O	.

O	The
O	concomitant
O	intake
O	of
B-drug	alcohol
O	and
B-drug	Acamprosate
O	does
O	not
O	affect
O	the
O	pharmacokinetics
O	of
O	either
B-drug	alcohol
O	or
B-drug	acamprosate
O	.

O	The
O	following
O	specific
O	interactions
O	have
O	been
O	reported
O	:
O	Itraconazole
O	Co-administration
O	of
O	another
O	extended
O	release
O	formulation
O	of
B-drug	felodipine
O	with
B-drug	itraconazole
O	resulted
O	in
O	approximately
O	8-fold
O	increase
O	in
O	the
O	AUC
O	,
O	more
O	than
O	6-
O	fold
O	increase
O	in
O	the
O	Cmax
O	,
O	and
O	2-fold
O	prolongation
O	in
O	the
O	half-
O	life
O	of
B-drug	felodipine
O	.

B-drug	Erythromycin
O	has
O	been
O	reported
O	to
O	significantly
O	alter
O	the
O	metabolism
O	of
O	nonsedating
B-group	antihistamines
B-drug	terfenadine
O	and
B-drug	astemizole
O	when
O	taken
O	concomitantly
O	.

O	Mixtures
O	of
O	cadmium
O	and
B-drug	zinc
O	had
O	a
O	synergistic
O	effect
O	compared
O	with
O	single
O	metal
O	toxicity
O	but
O	only
O	at
O	50000
O	microg/l
O	.

B-brand	ALLEGRA
O	should
O	not
O	be
O	taken
O	closely
O	in
O	time
O	with
B-drug	aluminum
O	and
B-drug	magnesium
O	containing
B-group	antacids
O	.

O	No
O	interaction
O	was
O	noted
O	with
O	the
B-group	MAO-B
I-group	inhibitor
B-drug	selegiline
O	in
O	two
O	multiple-dose
O	interaction
O	studies
O	when
B-drug	entacapone
O	was
O	coadministered
O	with
O	a
B-drug	levodopa/dopa
B-group	decarboxylase
I-group	inhibitor
O	(
O	n=29
O	)
O	.

O	There
O	is
O	the
O	risk
O	of
O	convulsions
O	occurring
O	in
O	susceptible
O	patients
O	following
O	the
O	use
O	of
O	the
O	new
B-group	anaesthetic
I-group	agents
O	which
O	are
O	capable
O	of
O	inducing
O	CNS
O	excitability
O	.

O	RESULTS
O	:
B-drug	Hydrocortisone
O	elevated
O	salivary
O	cortisol
O	levels
O	,
O	produced
O	modest
O	dysphoria
O	,
O	and
O	reduced
O	subjects
O	'
O	reports
O	of
O	wanting
O	more
O	drug
O	.

I-drug	Clarithromycin
O	14OH-
O	clarithromycin

O	Caution
O	should
O	be
O	exercised
O	during
O	the
O	administration
O	of
B-drug	adrenaline
O	to
O	patients
O	anaesthetised
O	with
B-brand	FLUOTHANE
O	as
O	arrhythmias
O	may
O	be
O	precipitated
O	.

B-drug	Probenecid
O	:
O	The
O	oral
O	combination
O	of
B-drug	probenecid
O	before
O	intramuscular
O	injection
O	of
B-brand	PIPRACIL
O	produces
O	an
O	increase
O	in
B-drug	piperacillin
O	peak
O	serum
O	level
O	of
O	about
O	30
O	%
O	.

O	A
O	review
O	.

O	The
O	effects
O	of
O	medicinal
O	products
O	with
O	similar
O	properties
O	such
O	as
O	inotropes
B-drug	milrinone
O	,
B-drug	enoximone
O	,
B-drug	amrinone
O	,
B-drug_n	olprinone
O	and
B-drug	cilostazol
O	may
O	be
O	exacerbated
O	by
B-drug	anagrelide
O	.

O	Our
O	data
O	suggest
O	that
B-drug_n	TAM
O	significantly
O	potentiates
O	the
O	reduction
O	in
O	cell
O	number
O	induced
O	by
B-drug	1,25
I-drug	(
I-drug	OH
I-drug	)
I-drug	2D3
O	alone
O	.

O	Determinants
O	downstream
O	of
O	cleavable
O	complex
O	formation
O	that
O	affect
O	the
O	sensitivity
O	of
O	tumor
O	versus
O	normal
O	cells
O	to
O	topo
O	drugs
O	in
O	particular
O	and
O	DNA-damaging
O	agents
O	in
O	general
O	are
O	little
O	known
O	.

B-drug	ethchlorvynol
O	;

O	Injection
O	of
B-drug	estradiol
O	5
O	min
O	before
O	a
O	nonlethal
O	dose
O	of
B-drug_n	endotoxin
O	changed
O	the
O	serum
O	sex
O	steroid
O	hormone
O	response
O	of
O	male
O	rats
O	to
B-drug_n	endotoxin
O	.

O	Additive
O	depressant
O	effect
O	when
O	used
O	with
O	general
B-group	anesthetics
O	,
B-group	sedatives
O	,
B-group	antianxiety
I-group	drugs
O	,
B-group	hypnotics
O	,
B-drug	alcohol
O	,
O	and
O	other
B-group	opiate
I-group	analgesics
O	.

O	Antagonism
O	has
O	been
O	demonstrated
O	between
B-drug	clindamycin
O	and
B-drug	erythromycin
O	in
O	vitro
O	.

O	It
O	may
O	also
O	interact
O	with
B-drug	amantadine
O	or
O	other
B-group	anticholinergic
I-group	drugs
O	or
B-group	MAOIs
O	,
O	which
O	may
O	intensify
O	the
O	anticholinergic
O	action
O	.

O	Oral
B-group	Anticoagulants
O	:
O	In
O	some
O	normal
O	volunteers
O	,
O	the
O	concomitant
O	administration
O	of
B-drug	diflunisal
O	and
B-drug	warfarin
O	,
B-drug	acenocoumarol
O	,
O	or
B-drug	phenprocoumon
O	resulted
O	in
O	prolongation
O	of
O	prothrombin
O	time
O	.

I-drug	Rifabutin
O	and
O	its
O	metabolite
O	concentrationswere
O	moderately
O	increased
O	.

O	The
O	concomitant
O	use
O	of
B-drug	sodium
I-drug	cephalothin
O	and
B-brand	Coly-Mycin
I-brand	M
O	Parenteral
O	should
O	be
O	avoided
O	.

O	for
O	some
O	strains
O	combinations
O	were
O	synergistic
O	.

O	The
O	absorption
O	of
B-drug	tetracycline
O	,
B-drug	furosemide
O	,
B-drug	penicillin
I-drug	G
O	,
B-drug	hydrochlorothiazide
O	,
O	and
B-drug	gemfibrozil
O	was
O	significantly
O	decreased
O	when
O	given
O	simultaneously
O	with
B-drug	colestipol
I-drug	hydrochloride
O	;

O	The
O	results
O	indicate
O	that
O	a
O	spinal
B-drug	naloxone-sensitive
O	endorphinergic
O	system
O	is
O	involved
O	in
O	the
O	production
O	of
B-drug_n	beta-endorphin
O	but
O	not
B-drug	morphine-induced
O	tail-flick
O	inhibition
O	,
O	and
O	suggest
O	that
O	intraventricular
B-drug_n	beta-endorphin
O	and
B-drug	morphine
O	elicit
O	their
O	pharmacological
O	actions
O	via
O	the
O	activation
O	of
O	different
O	descending
O	pain
O	inhibitory
O	systems
O	;

O	Effects
O	of
O	Other
O	Drugs
O	on
B-drug	Aliskiren
O	Based
O	on
O	in-vitro
O	studies
O	,
B-drug	aliskiren
O	is
O	metabolized
O	by
O	CYP
O	3A4
O	.

O	Combined
O	treatment
O	with
B-drug	1,25
I-drug	(
I-drug	OH
I-drug	)
I-drug	2D3
O	and
B-drug_n	TAM
O	enhances
O	the
O	degree
O	of
O	apoptosis
O	assessed
O	using
O	morphological
O	markers
O	that
O	identify
O	chromatin
O	and
O	nuclear
O	matrix
O	protein
O	condensation
O	.

O	At
O	0.3
O	mg/kg
O	,
O	the
O	diarrhea-inducing
O	effects
O	of
B-drug_n	dmPGE2
O	were
O	more
O	pronounced
O	in
O	cecectomized
O	than
O	in
O	control
O	rats
O	.

O	Tissue
O	culture
O	and
O	animal
O	studies
O	indicate
O	that
B-brand	ELSPAR
O	can
O	diminish
O	or
O	abolish
O	the
O	effect
O	of
B-drug	methotrexate
O	on
O	malignant
O	cells.14
O	This
O	effect
O	on
B-drug	methotrexate
O	activity
O	persists
O	as
O	long
O	as
O	plasma
O	asparagine
O	levels
O	are
O	suppressed
O	.

O	Therefore
O	,
O	the
O	use
O	of
O	genetic
O	data
O	in
O	these
O	instances
O	has
O	to
O	be
O	regulated
O	.

O	-
B-drug	Quinine
O	(
O	e.g.
O	,
B-brand	Quinamm
O	)
O	or

O	Drug-drug
O	interactions
O	have
O	not
O	been
O	observed
O	between
B-drug	Argatroban
O	and
B-drug	digoxin
O	or
B-drug	erythromycin
O	.

B-drug	Probenecid
O	depresses
O	tubular
O	secretion
O	of
O	certain
O	weak
O	acids
O	such
O	as
B-drug	PAH
O	.

O	Particular
O	caution
O	should
O	be
O	observed
O	with
B-group	digitalis
I-group	preparations
O	since
O	there
O	are
O	conflicting
O	results
O	for
O	the
O	effect
O	of
B-drug	colestipol
I-drug	hydrochloride
O	on
O	the
O	availability
O	of
B-drug	digoxin
O	and
B-drug	digitoxin
O	.

O	While
O	taking
B-group	beta
I-group	blockers
O	,
O	patients
O	with
O	a
O	history
O	of
O	severe
O	anaphylactic
O	reaction
O	to
O	a
O	variety
O	of
O	allergens
O	may
O	be
O	more
O	reactive
O	to
O	repeated
O	challenge
O	,
O	either
O	accidental
O	,
O	diagnostic
O	,
O	or
O	therapeutic
O	.

B-drug	Rifampin
O	:
O	When
O	a
O	single
O	375-mg
O	dose
O	of
B-drug	Aprepitant
O	was
O	administered
O	on
O	Day9
O	of
O	a
O	14-day
O	regimen
O	of
O	600
O	mg/day
O	of
B-drug	rifampin
O	,
O	a
O	strong
O	CYP3A4
O	inducer
O	,
O	the
O	AUC
O	of
B-drug	aprepitant
O	decreased
O	approximately
O	11-fold
O	and
O	the
O	mean
O	terminal
O	half-life
O	decreased
O	approximately
O	3-fold
O	.

O	For
O	patients
O	receiving
B-group	monoamine
I-group	oxidase
I-group	inhibitors
O	,
O	see
O	CONTRAINDICATIONS
O	.

O	If
O	used
O	concomitantly
O	,
O	closely
O	monitor
O	serum
O	electrolytes
O	and
O	cardiac
O	function
O	.

O	Interactions
O	with
O	the
O	drugs
O	listed
O	below
O	have
O	not
O	been
O	reported
O	in
O	clinical
O	trials
O	with
B-drug	azithromycin
O	;

B-drug	Propranolol
O	attenuated
O	the
O	heart
O	rate
O	increase
O	following
O	administration
O	of
O	immediate
O	release
B-drug	nisoldipine
O	.

B-drug	Ethinyl
I-drug	estradiol

B-brand	ELLENCE
O	when
O	used
O	in
O	combination
O	with
O	other
O	cytotoxic
O	drugs
O	may
O	show
O	on-treatment
O	additive
O	toxicity
O	,
O	especially
O	hematologic
O	and
O	gastrointestinal
O	effects
O	.

O	poor
O	metabolizers
O	of
B-drug	debrisoquin
O	:
O	Interactions
O	of
B-drug	carvedilol
O	with
O	strong
O	inhibitors
O	of
O	CYP2D6
O	(
O	such
O	as
B-drug	quinidine
O	,
B-drug	fluoxetine
O	,
B-drug	paroxetine
O	,
O	and
B-drug	propafenone
O	)
O	have
O	not
O	been
O	studied
O	,
O	but
O	these
O	drugs
O	would
O	be
O	expected
O	to
O	increase
O	blood
O	levels
O	of
O	the
O	R
O	(
O	+
O	)
O	enantiomer
O	of
B-drug	carvedilol
O	.

O	-
B-drug	Indomethacin
O	:
B-drug	Indomethacin
O	blunts
O	the
O	increases
O	in
O	urine
O	volume
O	and
O	sodium
O	excretion
O	seen
O	during
B-drug	bumetanide
O	treatment
O	and
O	inhibits
O	the
B-drug	bumetanide-induced
O	increase
O	in
O	plasma
O	renin
O	activity
O	.

O	anaphylaxis

O	It
O	has
O	been
O	reported
O	that
O	results
O	of
O	studies
O	in
O	animals
O	indicate
O	that
B-drug	dopamine-induced
O	ventricular
O	arrhythmias
O	during
O	anesthesia
O	can
O	be
O	reversed
O	by
B-drug	propranolol
O	.

B-group	Calcium
I-group	Channel
I-group	Blockers
O	:
O	Isolated
O	cases
O	of
O	conduction
O	disturbance
O	(
O	rarely
O	with
O	hemodynamic
O	compromise
O	)
O	have
O	been
O	observed
O	when
B-brand	COREG
O	is
O	co-administered
O	with
B-drug	diltiazem
O	.

B-drug	Verapamil
O	:
O	Coadministration
O	of
B-drug	almotriptan
O	and
B-drug	verapamil
O	resulted
O	in
O	a
O	24
O	%
O	increase
O	in
O	plasma
O	concentrations
O	of
B-drug	almotriptan
O	.

O	The
O	elevated
O	plasma
B-drug	alprazolam
O	concentrations
O	resulted
O	in
O	decreased
O	psychomotor
O	performance
O	and
O	memory
O	.

O	The
O	potential
O	for
O	binding
O	of
O	these
O	drugs
O	if
O	given
O	concomitantly
O	is
O	present
O	.

O	Intraventricular
O	injection
O	of
B-drug	naloxone
O	at
O	doses
O	of
O	1.2
O	to
O	12
O	micrograms
O	equally
O	antagonized
O	in
O	a
O	dose-dependent
O	manner
O	the
O	tail-flick
O	inhibition
O	induced
O	by
O	intraventricular
B-drug_n	beta-endorphin
O	and
B-drug	morphine
O	.

B-drug	Lamivudine
O	and
B-drug	zalcitabine
O	may
O	inhibit
O	the
O	intracellular
O	phosphorylation
O	of
O	one
O	another
O	.

O	Coadministration
O	of
B-drug	fluoxetine
O	significantly
O	decreased
B-drug	cisapride
O	plasma
O	concentrations
O	.

O	decreased
O	levels
O	of
O	anti-factor
O	Xa
O	and
O	antithrombin
O	III
O	,
O	decreased
O	antithrombin
O	III
O	activity
O	;

O	Some
O	95
O	%
O	of
O	a
O	single
O	dosage
O	of
B-drug	fluvastatin
O	is
O	excreted
O	via
O	the
O	biliary
O	route
O	,
O	with
O	less
O	than
O	2
O	%
O	of
O	this
O	being
O	the
O	parent
O	compound
O	.

O	.

O	higher
O	doses
O	decreased
O	FI
O	and
O	FR
O	responding
O	in
O	both
O	species
O	.

B-drug	ERYTHROMYCIN
O	:
O	In
O	hypercholesterolemic
O	patients
O	,
O	steady-state
B-drug	cerivastatin
O	AUC
O	and
O	Cmax
O	increased
O	approximately
O	50
O	%
O	and
O	24
O	%
O	respectively
O	after
O	10
O	days
O	with
O	co-administration
O	of
B-drug	erythromycin
O	,
O	a
O	known
O	inhibitor
O	of
O	cytochrome
O	P450
O	3A4
O	.

O	As
O	a
O	false-negative
O	result
O	may
O	occur
O	in
O	the
O	ferricyanide
O	test
O	,
O	it
O	is
O	recommended
O	that
O	either
O	the
O	glucose
O	oxidase
O	or
O	hexokinase
O	method
O	be
O	used
O	to
O	determine
O	blood
O	plasma
O	glucose
O	levels
O	in
O	patients
O	receiving
B-drug	cefuroxime
O	.

B-brand	Norpace
O	does
O	not
O	increase
O	serum
B-drug	digoxin
O	levels
O	.

O	Although
O	the
O	interactions
O	observed
O	in
O	these
O	studies
O	do
O	not
O	appear
O	to
O	be
O	of
O	major
O	clinical
O	importance
O	,
B-brand	BREVIBLOC
O	should
O	be
O	titrated
O	with
O	caution
O	in
O	patients
O	being
O	treated
O	concurrently
O	with
B-drug	digoxin
O	,
B-drug	morphine
O	,
B-drug	succinylcholine
O	or
B-drug	warfarin
O	.

O	Carcinogenesis
O	,
O	Mutagenesis
O	,
O	and
O	Fertility

O	[
O	Dose-time
O	effects
O	of
O	competitive
O	displacement
O	of
B-drug	radiopertechnetate
O	by
B-drug_n	sodium
I-drug_n	perchlorate
O	following
O	oral
O	and
O	intravenous
O	administration
O	]
O	The
O	effect
O	of
O	various
O	doses
O	of
B-drug_n	sodium
I-drug_n	perchlorate
O	in
O	several
O	dose
O	fractions
O	on
O	the
O	extent
O	and
O	the
O	time
O	scale
O	of
O	displacement
O	of
B-drug	radiopertechnetate
O	,
O	in
O	dependence
O	on
O	application
O	mode
O	,
O	was
O	studied
O	.

O	oral
B-group	contraceptives
O	;

O	CONCLUSIONS
O	:
O	Single-dose
B-drug	diltiazem
O	coadministration
O	leads
O	to
O	higher
B-drug	sirolimus
O	exposure
O	,
O	presumably
O	by
O	inhibition
O	of
O	the
O	first-pass
O	metabolism
O	of
B-drug	sirolimus
O	.

B-drug	methylphenidate
O	;

B-group	Diuretic
O	:
B-drug	Hydrochlorothiazide
O	,
O	given
O	concomitantly
O	with
B-drug	ketoprofen
O	,
O	produces
O	a
O	reduction
O	in
O	urinary
O	potassium
O	and
O	chloride
O	excretion
O	compared
O	to
B-drug	hydrochlorothiazide
O	alone
O	.

O	Drugs
O	Metabolized
O	by
O	Cytochrome
O	P450
O	Enzymes
O	The
O	drug
O	interaction
O	study
O	evaluating
O	the
O	effect
O	of
B-drug	grepafloxacin
O	on
B-drug	theophylline
O	indicates
O	that
B-drug	grepafloxacin
O	inhibits
B-drug	theophylline
O	metabolism
O	,
O	which
O	is
O	mediated
O	by
O	CYP1A2
O	.

O	When
O	such
O	combined
O	therapy
O	is
O	contemplated
O	,
O	the
O	dose
O	of
O	one
O	or
O	both
O	agents
O	should
O	be
O	reduced
O	.

O	Serum
B-group	digitalis
O	levels
O	may
O	be
O	decreased
O	in
O	hyperthyroidism
O	or
O	when
O	a
O	hypothyroid
O	patient
O	becomes
O	euthyroid
O	.

B-drug	Nafazodone
O	,
B-drug	fluvoxamine
O	,
B-drug	cimetidine
O	(
O	consider
B-brand	Xanax
O	dose
O	reduction
O	)
O	.

O	When
O	the
O	CYP3A4
O	inhibitor
O	is
O	withdrawn
O	from
O	the
O	combination
O	therapy
O	,
B-drug	aripiprazole
O	dose
O	should
O	then
O	be
O	increased
O	.

B-drug	Sildenafil
O	is
O	contraindicated
O	in
O	patients
O	using
B-group	long-acting
I-group	nitrates
O	or
O	who
O	may
O	need
O	to
O	use
B-group	short-acting
I-group	nitrates
O	,
O	because
O	the
O	combination
O	may
O	cause
O	a
O	sharp
O	fall
O	of
O	the
O	blood
O	pressure
O	.

O	In
O	patients
O	with
O	mild
O	to
O	moderate
O	hypertension
O	,
O	administration
O	of
O	25
O	mg
O	daily
O	of
B-brand	VIOXX
O	with
O	the
B-group	ACE
I-group	inhibitor
B-drug	benazepril
O	,
O	10
O	to
O	40
O	mg
O	for
O	4
O	weeks
O	,
O	was
O	associated
O	with
O	an
O	average
O	increase
O	in
O	mean
O	arterial
O	pressure
O	of
O	about
O	3
O	mm
O	Hg
O	compared
O	to
B-group	ACE
I-group	inhibitor
O	alone
O	.

O	The
O	effects
O	seen
O	are
O	poorly
O	understood
O	and
O	depend
O	upon
O	a
O	variety
O	of
O	factors
O	such
O	as
O	dose
O	and
O	type
O	of
B-group	thyroid
I-group	preparations
O	and
O	endocrine
O	status
O	of
O	the
O	patient
O	.

B-drug	Midazolam
O	Synergism

O	Moreover
O	,
O	the
O	acquisition
O	of
O	tasks
O	that
O	are
O	facilitated
O	by
O	hippocampal
O	lesions
O	(
O	or
O	dysfunction
O	)
O	is
O	nevertheless
O	associated
O	,
O	in
O	intact
O	subjects
O	,
O	with
O	specific
O	neurobiological
O	alterations
O	in
O	the
O	hippocampus
O	.

B-drug	Tolazamide
O	:
O	A
O	case
O	of
O	severe
O	hypoglycemia
O	has
O	been
O	reported
O	in
O	a
O	type
O	II
O	diabetic
O	patient
O	maintained
O	on
B-drug	tolazamide
O	(
O	1
O	gm/day
O	)
O	11
O	days
O	after
O	the
O	addition
O	of
B-drug	doxepin
O	(
O	75
O	mg/day
O	)
O	.

O	In
O	situations
O	when
O	concurrent
O	therapy
O	is
O	necessary
O	,
O	careful
O	patient
O	monitoring
O	is
O	essential
O	.

O	Oral
B-group	Anticoagulants
O	Interaction
O	studies
O	with
B-drug	warfarin
O	and
B-drug	acenocoumarol
O	failed
O	to
O	identify
O	any
O	clinically
O	important
O	effects
O	on
O	the
O	serum
O	concentrations
O	or
O	clinical
O	effects
O	of
O	these
B-group	anticoagulants
O	.

O	(
O	Cancer
O	Res.
O	,
O	38
O	:
O	2003-2010
O	,
O	1978
O	)
O	have
O	reported
O	that
O	a
O	single
O	,
O	small
O	pulse
O	of
O	carcinogen
O	can
O	induce
O	early
O	and
O	numerous
O	liver
O	tumors
O	when
O	administered
O	neonatally
O	to
O	mice
O	with
O	a
O	genetic
O	predisposition
O	to
O	hepatotumorigenesis
O	.

O	As
O	with
O	most
O	psychoactive
O	medications
O	,
O	patients
O	should
O	be
O	advised
O	to
O	avoid
B-drug	alcohol
O	while
O	taking
B-brand	ABILIFY

O	This
O	decrease
O	in
O	absorption
O	results
O	in
O	a
O	36
O	%
O	and
O	50
O	%
O	lower
O	AUC
O	for
B-drug	trovafloxacin
O	and
B-drug	ciprofloxacin
O	,
O	respectively
O	,
O	which
O	could
O	cause
O	clinical
O	failures
O	.

O	A
O	pregnancy
O	test
O	must
O	be
O	repeated
O	each
O	month
O	prior
O	to
O	the
O	female
O	patient
O	receiving
O	each
O	prescription

O	The
O	interaction
O	of
B-brand	Exjade
O	with
B-drug	hydroxyurea
O	has
O	not
O	been
O	formally
O	studied
O	.

O	In
O	addition
O	to
O	bleeding
O	associated
O	with
B-drug	heparin
O	and
B-group	vitamin
I-group	K
I-group	antagonists
O	,
O	drugs
O	that
O	alter
O	platelet
O	function
O	(
O	such
O	as
B-drug	acetylsalicylic
I-drug	acid
O	,
B-drug	dipyridamole
O	and
B-drug	Abciximab
O	)
O	may
O	increase
O	the
O	risk
O	of
O	bleeding
O	if
O	administered
O	prior
O	to
O	,
O	during
O	,
O	or
O	after
B-brand	Activase
O	therapy
O	.

O	Although
O	the
O	pressor
O	activity
O	of
B-drug	Desmopressin
O	is
O	very
O	low
O	compared
O	to
O	its
O	antidiuretic
O	activity
O	,
O	large
O	doses
O	of
B-drug	Desmopressin
O	Tablets
O	should
O	be
O	used
O	with
O	other
O	pressor
O	agents
O	only
O	with
O	careful
O	patient
O	monitoring
O	.

O	No
O	formal
O	drug
O	interaction
O	studies
O	with
B-group	anti-neoplastic
I-group	agents
O	have
O	been
O	conducted
O	.

B-drug	Digoxin
O	:
O	Coadministration
O	of
B-drug	digoxin
O	,
O	a
O	P-glycoprotein
O	substrate
O	,
O	with
O	oral
B-drug	conivaptan
O	resulted
O	in
O	a
O	reduction
O	in
O	clearance
O	and
O	an
O	increase
O	in
B-drug	digoxin
O	Cmax
O	and
O	AUC
O	values
O	.

B-group	Cephalosporins-Cephalosporins
O	containing
O	side
O	chains
O	of
O	N-methylthiotetrazole
O	(
B-drug	cefmenoxime
O	,
B-drug	cefoperazone
O	,
B-drug	cefotetan
O	,
B-drug	cefamandole
O	,
B-drug	latamoxef
O	)
O	or
O	methylthiadiazole
O	(
B-drug	cefazolin
O	)
O	can
O	cause
O	vitamin
O	K
O	deficiency
O	and
O	hypoprothrombinemia
O	.

O	May
O	interact
O	with
O	the
O	following
O	:
B-drug	cholestyramine
O	,
B-drug	colestipol
O	(
O	use
O	with
B-group	thiazide
I-group	diuretics
O	may
O	prevent
O	the
B-group	diuretic
O	from
O	working
O	properly
O	;

O	although
O	combinations
O	are
O	sometimes
O	used
O	for
O	therapeutic
O	advantage
O	,
O	when
O	used
O	concurrently
O	,
O	patient
O	should
O	be
O	closely
O	monitored
O	.

O	It
O	is
O	concluded
O	that
B-drug_n	neurotensin
O	modulates
O	in
O	an
O	opposite
O	way
O	the
O	function
O	of
O	the
O	enkephalinergic
O	neurons
O	and
O	the
O	central
O	action
O	of
B-drug_n	tuftsin
O	.

O	Intensive
O	monitoring
O	of
O	renal
O	function
O	is
O	recommended
O	in
O	patients
O	requiring
O	any
O	combination
O	of
O	nephrotoxic
O	medications
O	.

O	Thus
B-drug	cimetidine
O	appeared
O	to
O	alter
O	the
O	renal
O	excretion
O	of
O	both
B-drug	gabapentin
O	and
O	creatinine
O	,
O	an
O	endogenous
O	marker
O	of
O	renal
O	function
O	.

O	May
O	interact
O	with
O	other
O	creams
O	,
O	lotions
O	,
O	or
O	skin
O	medicines
O	when
O	placed
O	on
O	the
O	same
O	areas
O	of
O	your
O	skin
O	that
O	you
O	are
O	using
B-drug_n	bentoquatam
O	.

B-group	Neuroleptic
I-group	Drugs
O	-
B-drug	L-phenylalanine
O	may
O	potentiate
O	the
O	tardive
O	dyskinesia
O	side
O	reactions
O	of
B-group	neuroleptic
I-group	drugs
O	if
O	used
O	concomitantly
O	with
O	them
O	.

B-group	Beta
I-group	blockers
O	may
O	exacerbate
O	the
O	rebound
O	hypertension
O	which
O	can
O	follow
O	the
O	withdrawal
O	of
B-drug	clonidine
O	.

B-group	MAO
I-group	inhibitors
O	prolong
O	and
O	intensify
O	the
O	effects
O	of
B-group	antihistamines
O	.

O	Other
B-group	5-HT1B/1D
I-group	Agonists
O	Concomitant
O	use
O	of
O	other
B-group	5-HT1B/1D
I-group	agonists
O	within
O	24
O	hours
O	of
O	treatment
O	with
B-brand	AXERT
O	is
O	contraindicated
O	.

O	The
O	following
O	agents
O	may
O	increase
O	certain
O	actions
O	or
O	side
O	effects
O	of
B-group	anticholinergic
I-group	drugs
O	.
B-drug	amantadine
B-group	antiarrhythmic
I-group	agents
O	of
O	class
O	(
O	e.g
O	.
B-drug	quinidine
O	)
O	,
B-group	antihistamines
I-group	antipsychotic
I-group	agents
O	(
O	e.g
O	.
B-group	phenothiazines
O	)
O	,
B-group	benzodiazepines
O	.

O	Effect

O	The
O	utilization
O	of
B-drug	digitoxin
O	for
O	such
O	patients
O	may
O	be
O	considered
O	as
O	an
O	alternative
O	.

O	Type
O	2
O	diabetes
O	mellitus
O	is
O	a
O	growing
O	problem
O	not
O	only
O	in
O	the
O	United
O	States
O	but
O	also
O	across
O	the
O	world
O	.

O	No
O	pharmacodynamic
O	effects
O	of
O	either
B-group	histamine
I-group	H2
I-group	receptor
I-group	antagonist
O	were
O	observed
O	.

O	BACKGROUND
O	.

B-group	Neuroleptic
O	:
B-drug	pimozide

O	These
O	results
O	indicate
O	that
O	dosage
O	adjustment
O	of
B-drug	quetiapine
O	may
O	be
O	necessary
O	when
O	the
O	two
O	drugs
O	are
O	given
O	concurrently
O	and
O	that
O	caution
O	may
O	be
O	required
O	when
O	administering
O	other
O	drugs
O	that
O	inhibit
O	or
O	induce
O	cytochromes
O	,
O	particularly
O	P450
O	3A4
O	.

O	Therefore
O	,
O	if
O	concomitant
O	use
O	of
O	these
O	agents
O	is
O	indicated
O	because
O	of
O	demonstrated
O	hypokalemia
O	,
O	they
O	should
O	be
O	used
O	with
O	caution
O	and
O	with
O	frequent
O	monitoring
O	of
O	serum
O	potassium
O	.

B-brand	Aspirin
O	:
B-drug	Ketoprofen
O	does
O	not
O	alter
B-brand	aspirin
O	absorption
O	;

O	Other
O	strong
O	inhibitors
O	of
O	CYP3A4
O	(
O	e.g.
O	,
B-drug	itraconazole
O	,
B-drug	clarithromycin
O	,
B-drug	nefazodone
O	,
B-drug	troleandomycin
O	,
B-drug	ritonavir
O	,
B-drug	nelfinavir
O	)
O	would
O	be
O	expected
O	to
O	behave
O	similarly
O	.

O	Effect
O	of
O	other
O	drugs
O	on
B-drug	Vardenafil

O	No
O	specific
O	drug
O	interaction
O	studies
O	have
O	been
O	conducted
O	.

O	Because
O	of
O	possible
O	clinical
O	significance
O	,
O	the
O	two
O	drugs
O	should
O	not
O	be
O	administered
O	concurrently
O	.

O	These
O	agents
O	may
O	also
O	prolong
O	the
O	clinically
O	effective
O	duration
O	of
O	action
O	by
O	up
O	to
O	25
O	%
O	.

O	Since
O	this
O	could
O	be
O	explained
O	either
O	by
O	enhanced
O	absorption
O	or
O	by
O	an
O	alteration
O	of
O	hepatic
O	metabolism
O	of
B-drug	labetalol
I-drug	HCl
O	,
O	special
O	care
O	should
O	be
O	used
O	in
O	establishing
O	the
O	dose
O	required
O	for
O	blood
O	pressure
O	control
O	in
O	such
O	patients
O	.

B-drug	Rifampin
O	may
O	decrease
O	serum
B-drug	digoxin
O	concentration
O	,
O	especially
O	in
O	patients
O	with
O	renal
O	dysfunction
O	,
O	by
O	increasing
O	the
O	non-renal
O	clearance
O	of
B-drug	digoxin
O	.

O	Drug
O	interaction
O	studies
O	have
O	shown
O	that
B-drug	esomeprazole
O	does
O	not
O	have
O	any
O	clinically
O	significant
O	interactions
O	with
B-drug	phenytoin
O	,
B-drug	warfarin
O	,
B-drug	quinidine
O	,
B-drug	clarithromycin
O	or
B-drug	amoxicillin
O	.

O	In
O	patients
O	receiving
O	concurrent
O	therapy
O	with
B-drug	clonidine
O	,
O	if
O	therapy
O	is
O	to
O	be
O	discontinued
O	,
O	it
O	is
O	suggested
O	that
B-brand	ZEBETA
O	be
O	discontinued
O	for
O	several
O	days
O	before
O	the
O	withdrawal
O	of
B-drug	clonidine
O	.

O	Both
O	groups
O	of
O	agents
O	lower
O	blood
O	levels
O	and
O	efficacy
O	of
B-group	amphetamines
O	.

O	METHODS
O	:
O	Clinical
O	studies
O	,
O	case
O	reports
O	,
O	and
O	commentaries
O	and
O	editorials
O	concerning
B-drug	sildenafil
O	published
O	in
O	the
O	international
O	literature
O	between
O	January
O	1999
O	and
O	August
O	2000
O	were
O	identified
O	through
O	searches
O	of
O	MEDLINE
O	,
O	PREMEDLINE
O	,
O	and
O	International
O	Pharmaceutical
O	Abstracts
O	,
O	using
O	the
O	terms
B-drug	sildenafil
O	,
B-brand	Viagra
O	,
O	and
O	erectile
O	dysfunction
O	.

O	Therefore
O	,
O	if
B-drug	digoxin
O	is
O	administered
O	with
B-brand	VAPRISOL
O	,
O	the
O	clinician
O	should
O	be
O	alert
O	to
O	the
O	possibility
O	of
O	increases
O	in
B-drug	digoxin
O	levels
O	.

O	While
O	no
O	in
O	vivo
O	drug-drug
O	interaction
O	studies
O	were
O	conducted
O	between
B-drug	estazolam
O	and
O	inducers
O	of
O	CYP3A
O	,
O	compounds
O	that
O	are
O	potent
O	CYP3A
O	inducers
O	(
O	such
O	as
B-drug	carbamazepine
O	,
B-drug	phenytoin
O	,
B-drug	rifampin
O	,
O	and
B-group	barbiturates
O	)
O	would
O	be
O	expected
O	to
O	decrease
B-drug	estazolam
O	concentrations
O	.

O	Compounds
O	in
O	these
O	categories
O	result
O	in
O	a
O	decreased
O	efficacy
O	of
B-drug	bromocriptine
I-drug	mesylate
O	:
B-group	phenothiazines
O	,
B-drug	haloperidol
O	,
B-drug	metoclopramide
O	,
B-drug	pimozide
O	.

O	Both
O	the
O	sedative
O	and
O	anticholinergic
O	effects
O	of
O	the
B-group	major
I-group	tranquilizers
O	are
O	also
O	additive
O	to
O	those
O	of
B-drug	desipramine
O	.

O	The
O	intravenous
O	application
O	of
B-drug_n	perchlorate
O	offers
O	advantages
O	in
O	clinical
O	use
O	.

O	therefore
O	,
O	the
O	disposition
O	of
B-drug	eszopiclone
O	is
O	not
O	expected
O	to
O	be
O	sensitive
O	to
O	alterations
O	in
O	protein
O	binding
O	.

O	Three
O	patients
O	met
O	ACR
O	criteria
O	for
O	liver
O	biopsy
O	(
O	1
O	:
O	Roegnik
O	Grade
O	I
O	,
O	2
O	:
O	Roegnik
O	Grade
O	IIIa
O	)
O	.

O	Nervous
O	System
O	:
O	Although
O	the
O	occurrence
O	of
O	peripheral
O	neuropathy
O	is
O	frequent
O	,
O	the
O	development
O	of
O	severe
O	symptomatology
O	is
O	unusual
O	and
O	requires
O	a
O	dose
O	reduction
O	of
O	20
O	%
O	for
O	all
O	subsequentcourses
O	of
B-brand	TAXOL
O	.

O	Effect
O	of
B-drug_n	ginsenosides
O	on
O	voltage-dependent
O	Ca
O	(
O	2+
O	)
O	channel
O	subtypes
O	in
O	bovine
O	chromaffin
O	cells
O	.

B-group	antiarrhythmic
I-group	agents
O	concentration

O	Agents
O	that
O	induce
O	CYP3A4
O	(
O	eg
O	,
B-drug	carbamazepine
O	)
O	could
O	cause
O	an
O	increase
O	in
B-drug	aripiprazole
O	clearance
O	and
O	lower
O	blood
O	levels
O	.

O	Do
O	not
O	take
O	this
O	medicine
O	with
O	thioridizine
O	,
O	or
O	within
O	5
O	weeks
O	of
O	taking
B-drug	fluoxetine
O	.

O	The
O	magnitude
O	of
O	interaction
O	at
O	other
O	doses
O	is
O	not
O	known
O	.

O	However
O	,
O	the
O	peak
O	plasma
O	level
O	of
B-drug	metformin
O	was
O	reduced
O	by
O	approximately
O	20
O	%
O	when
O	taking
B-drug	Acarbose
O	due
O	to
O	a
O	slight
O	delay
O	in
O	the
O	absorption
O	of
B-drug	metformin
O	.

O	However
O	,
O	the
O	concomitant
O	use
O	of
B-drug	Argatroban
O	and
B-drug	warfarin
O	(
O	5-7.5
O	mg
O	initial
O	oral
O	dose
O	followed
O	by
O	2.5-6
O	mg/day
O	orally
O	for
O	6-10
O	days
O	)
O	results
O	in
O	prolongation
O	of
O	the
O	prothrombin
O	time
O	(
O	PT
O	)
O	and
O	International
O	Normalized
O	Ratio
O	(
O	INR
O	)
O	.

O	Little
O	has
O	been
O	studied
O	of
O	the
O	adverse
O	effects
O	of
O	the
O	exposure
O	of
O	the
O	liver
O	to
O	the
O	interaction
O	of
B-drug	ethanol
O	with
O	its
O	congeners
O	and
B-drug_n	acetaldehyde
O	,
O	coexisting
O	in
O	the
O	contents
O	of
O	alcoholic
O	beverages
O	.

O	Other
O	Drugs
O	:
O	In
O	healthy
O	volunteers
O	,
B-drug	amlodipine
O	,
B-drug	phenytoin
O	,
B-drug	glyburide
O	,
B-drug	ranitidine
O	,
B-drug	omeprazole
O	,
B-drug	hormone
O	replacement
O	therapy
O	(
O	a
O	combination
O	of
O	conjugated
B-group	estrogens
O	and
B-drug	medroxyprogesterone
O	)
O	,
B-group	antacid
O	(
O	aluminum
O	and
B-drug	magnesium
O	hydroxides
O	)
O	and
B-drug	theophylline
O	did
O	not
O	affect
O	the
O	pharmacokinetics
O	of
B-brand	TIKOSYN
O	.

B-group	Anticoagulants
O	,
O	oral

O	Although
O	there
O	are
O	no
O	study
O	data
O	to
O	evaluate
O	the
O	possibility
O	,
B-group	nitric
I-group	oxide
I-group	donor
I-group	compounds
O	,
O	including
B-drug	sodium
I-drug	nitroprusside
O	and
B-drug	nitroglycerin
O	,
O	may
O	have
O	an
O	additive
O	effect
O	with
B-brand	INOmax
O	on
O	the
O	risk
O	of
O	developing
O	methemoglobinemia
O	.

B-drug	n-dodecyl
I-drug	gallate
O	showed
O	the
O	most
O	potent
O	inhibition
O	(
O	66
O	%
O	inhibition
O	at
O	10
O	microM
O	)
O	,
O	which
O	was
O	far
O	more
O	potent
O	than
O	that
O	of
O	crude
B-drug	tannic
I-drug	acid
O	.

O	Inhibitors
O	of
O	this
O	isoenzyme
O	(
O	e.g.
O	,
B-group	macrolide
I-group	antibiotics
O	,
B-group	azole
I-group	antifungal
I-group	agents
O	,
B-group	protease
I-group	inhibitors
O	,
B-group	serotonin
I-group	reuptake
I-group	inhibitors
O	,
B-drug	amiodarone
O	,
B-group	cannabinoids
O	,
B-drug	diltiazem
O	,
O	grapefruit
O	juice
O	,
B-drug	nefazadone
O	,
B-drug	norfloxacin
O	,
B-drug	quinine
O	,
B-drug	zafirlukast
O	)
O	should
O	be
O	cautiously
O	coadministered
O	with
B-brand	TIKOSYN
O	as
O	they
O	can
O	potentially
O	increase
B-drug	dofetilide
O	levels
O	.

O	Electroconvulsive
O	Therapy
O	(
O	ECT
O	)
O	-
O	There
O	are
O	no
O	clinical
O	studies
O	of
O	the
O	combined
O	use
O	of
O	ECT
O	and
B-drug	escitalopram
O	.

B-drug	Midazolam
O	:
B-drug	Aprepitant
O	increased
O	the
O	AUC
O	of
B-drug	midazolam
O	,
O	a
O	sensitive
O	CYP3A4
O	substrate
O	,
O	by
O	2.3-fold
O	on
O	Day
O	1
O	and
O	3.3-fold
O	on
O	Day
O	5
O	,
O	when
O	a
O	single
O	oral
O	dose
O	of
B-drug	midazolam
O	2
O	mg
O	was
O	coadministered
O	on
O	Day
O	1
O	and
O	Day
O	5
O	of
O	a
O	regimen
O	of
B-drug	Aprepitant
O	125
O	mg
O	on
O	Day
O	1
O	and
O	80
O	mg/day
O	on
O	Days
O	2
O	through
O	5
O	.

B-group	NNRTI-based
O	regimens
O	may
O	have
O	several
O	advantages
O	over
B-group	PI-based
O	therapy
O	for
O	initial
O	or
O	prolonged
O	therapy
O	,
O	including
O	more
O	convenient
O	administration
O	regimens
O	,
O	lower
O	tablet
O	volume
O	,
O	fewer
O	drug
O	interactions
O	,
O	and
O	central
O	nervous
O	system
O	penetration
O	.

O	The
O	clearance
O	of
B-group	salicylates
O	may
O	be
O	increased
O	with
O	concurrent
O	use
O	of
B-group	corticosteroids
O	.

O	As
O	with
O	all
O	drugs
O	,
O	care
O	should
O	be
O	exercised
O	when
O	treating
O	patients
O	with
O	multiple
O	medications
O	.

O	Caution
O	should
O	be
O	exercised
O	when
O	considering
O	the
O	use
O	of
B-brand	BREVIBLOC
O	and
B-drug	verapamil
O	in
O	patients
O	with
O	depressed
O	myocardial
O	function
O	.

O	For
O	a
O	4-fold
O	range
O	of
B-drug	everolimus
O	doses
O	there
O	were
O	no
O	differential
O	effects
O	on
B-drug	cyclosporine
O	dosing
O	or
O	pharmacokinetics
O	.

O	An
O	increase
O	in
O	serum
B-drug	lithium
O	concentration
O	has
O	been
O	reported
O	during
O	concomitant
O	administration
O	of
B-drug	lithium
O	with
B-brand	ATACAND
O	,
O	so
O	careful
O	monitoring
O	of
O	serum
B-drug	lithium
O	levels
O	is
O	recommended
O	during
O	concomitant
O	use
O	.

O	Neuropathy
O	has
O	occurred
O	more
O	frequently
O	in
O	patients
O	with
O	a
O	history
O	of
O	neuropathy
O	or
O	neurotoxic
O	drug
O	therapy
O	,
O	including
B-drug	stavudine
O	,
O	and
O	these
O	patients
O	may
O	be
O	at
O	increased
O	risk
O	of
O	neuropathy
O	during
B-brand	VIDEX
O	therapy
O	(
O	see
O	ADVERSE
O	REACTIONS
O	)
O	.

O	This
O	interference
O	may
O	result
O	in
O	an
O	apparent
O	factor
O	concentration
O	that
O	is
O	lower
O	than
O	the
O	true
O	concentration
O	.

O	oral
O	clearance
O	was
O	reduced
O	by
O	about
O	50
O	%
O	.

B-group	Antacids
O	containing
B-drug	magnesium
I-drug	trisilicate
O	,
O	when
O	administered
O	concomitantly
O	with
B-drug	nitrofurantoin
O	,
O	reduce
O	both
O	the
O	rate
O	and
O	extent
O	of
O	absorption
O	.

O	An
O	initial
O	dose
O	of
O	5
O	mg
O	should
O	be
O	given
O	to
O	patients
O	who
O	are
O	concomitantly
O	being
O	treated
O	with
B-drug	cimetidine
O	.

O	there
O	was
O	no
O	significant
O	change
O	in
O	prothrombin
O	test
O	results
O	during
O	the
O	trials
O	of
B-drug	chloral
I-drug	hydrate
O	and
B-drug	methaqualone
O	.

O	Patients
O	treated
O	with
O	a
B-group	beta-adrenergic
I-group	receptor
I-group	blocking
I-group	agent
O	plus
O	a
O	catecholamine
O	depletor
O	should
O	therefore
O	be
O	closely
O	observed
O	for
O	evidence
O	of
O	hypotension
O	or
O	marked
O	bradycardia
O	,
O	which
O	may
O	produce
O	vertigo
O	,
O	syncope
O	,
O	or
O	postural
O	hypotension
O	.

B-group	Diuretics
O	:
O	Studies
O	in
O	normal
O	volunteers
O	have
O	shown
O	that
B-drug	flurbiprofen
O	like
O	other
B-group	nonsteroidal
I-group	anti-inflammatory
I-group	drugs
O	,
O	can
O	interfere
O	with
O	the
O	effects
O	of
B-drug	furosemide
O	.

O	Usually
O	,
O	the
O	dosage
O	of
O	the
B-group	anticoagulant
O	should
O	be
O	reduced
O	by
O	one-half
O	(
O	depending
O	on
O	the
O	individual
O	case
O	)
O	to
O	maintain
O	the
O	prothrombin
O	time
O	at
O	the
O	desired
O	level
O	to
O	prevent
O	bleeding
O	complications
O	.

O	This
O	response
O	has
O	been
O	attributed
O	to
O	inhibition
O	of
O	renal
O	prostaglandin
O	synthesis
O	.

O	A
O	1-month
O	washout
O	period
O	was
O	inserted
O	between
O	the
O	treatment
O	periods
O	.

O	The
O	pharmacokinetics
O	of
B-drug	naltrexone
O	and
O	its
O	major
O	metabolite
B-drug_n	6-beta-naltrexol
O	were
O	unaffected
O	following
O	co-administration
O	with
B-drug	Acamprosate
O	.

B-drug	cimetidine
O	;

O	they
O	also
O	suggest
O	that
O	alcoholic
O	beverages
O	are
O	not
O	equivalent
O	in
O	their
O	potential
O	to
O	cause
O	liver
O	damage
O	.

O	Results
O	of
O	preliminary
O	studies
O	in
O	humans
O	and
O	rats
O	suggest
O	that
O	nonabsorbable
B-group	antacids
O	given
O	concurrently
O	with
B-drug	lactulose
O	may
O	inhibit
O	the
O	desired
B-drug	lactulose-induced
O	drop
O	in
O	colonic
O	pH
O	.

B-group	Histamine
I-group	H2
I-group	antagonists
O	:
B-drug	Cimetidine
O	inhibits
O	CYP3A4
O	and
O	can
O	increase
O	serum
B-drug	amiodarone
O	levels
O	.

B-drug	Cyclosporine
O	:
O	Modest
O	increases
O	in
O	mean
O	trough
B-drug	cyclosporine
O	concentrations
O	were
O	observed
O	following
O	initiation
O	of
B-drug	carvedilol
O	treatment
O	in
O	21
O	renal
O	transplant
O	patients
O	suffering
O	from
O	chronic
O	vascular
O	rejection
O	.

O	.

O	These
O	reactions
O	have
O	been
O	observed
O	more
O	frequently
O	with
O	the
O	24-hour
O	infusion
O	than
O	with
O	the
O	3-hour
O	infusion
O	.

O	Altered
O	responsiveness
O	to
B-drug	alcohol
O	after
O	exposure
O	to
O	organic
O	lead
O	.

O	At
O	37
O	degrees
O	C
O	the
O	non-myelinated
O	axons
O	contained
O	28.4
O	plus
O	or
O	minus
O	0.8
O	S.E.M
O	.

O	Drugs
O	that
O	may
O	alter
B-drug	imatinib
O	plasma
O	concentrations
O	Drugs
O	that
O	may
O	increase
B-drug	imatinib
O	plasma
O	concentrations
O	:
O	Caution
O	is
O	recommended
O	when
O	administering
B-brand	Gleevec
O	with
O	inhibitors
O	of
O	the
O	CYP3A4
O	family
O	(
O	e.g.
O	,
B-drug	ketoconazole
O	,
B-drug	itraconazole
O	,
B-drug	erythromycin
O	,
B-drug	clarithromycin
O	)
O	.

B-drug	Indinavir
O	concentrations
O	may
O	be
O	decreased
O	in
O	the
O	presence
O	of
B-drug	nevirapine
O	.

B-brand	Trileptal
O	dose
O	(
O	mg/day
O	)

O	It
O	is
O	recommended
O	that
O	these
O	tests
O	be
O	performed
O	at
O	weekly
O	or
O	biweekly
O	intervals
O	until
O	the
O	lipid
O	response
O	to
B-brand	Accutane
O	is
O	established
O	.

O	Untreated
O	hypothyroidism
O	may
O	interfere
O	with
O	the
O	growth
O	response
O	to
B-drug	somatrem
O	or
B-drug	somatropin
O	.

O	In
O	patients
O	receiving
O	a
O	potent
O	CYP3A4
O	inducer
O	such
O	as
B-drug	rifampicin
O	or
B-drug	phenytoin
O	,
O	a
O	dose
O	increase
O	to
O	500
O	mg
O	daily
O	should
O	be
O	considered
O	in
O	the
O	absence
O	of
O	severe
O	adverse
O	drug
O	reaction
O	,
O	and
O	clinical
O	response
O	and
O	adverse
O	events
O	should
O	be
O	carefully
O	monitored
O	(
O	see
O	CLINICAL
O	PHARMACOLOGY-Pharmacokinetics-Drug-Drug
O	Interactions
O	and
O	DOSAGE
O	AND
O	ADMINISTRATION-Dosage
O	Adjustment
O	sections
O	)
O	.

O	These
O	pharmacokinetic
O	effects
O	did
O	not
O	result
O	in
O	clinically
O	meaningful
O	changes
O	in
O	ECG
O	,
O	heart
O	rate
O	or
O	blood
O	pressure
O	beyond
O	those
O	changes
O	induced
O	by
B-drug	diltiazem
O	alone
O	.

O	Agents
O	that
O	Inhibit
O	Cytochrome
O	P450
O	Isoenzymes
O	and/or
O	Epoxide
O	Hydrolase
B-drug	Carbamazepine
O	is
O	metabolized
O	mainly
O	by
O	cytochrome
O	P450
O	(
O	CYP
O	)
O	3A4
O	to
O	the
O	active
B-drug	carbamazepine
I-drug	10,11-epoxide
O	,
O	which
O	is
O	further
O	metabolized
O	to
O	the
O	trans-diol
O	by
O	epoxide
O	hydrolase
O	.

O	leukopenia

O	Drugs
O	That
O	Alter
O	Renal
O	Excretion
B-drug	Ibuprofen
O	:
B-drug	Ibuprofen
O	is
O	known
O	to
O	affect
O	renal
O	function
O	and
O	,
O	consequently
O	,
O	alter
O	the
O	renal
O	excretion
O	of
O	other
O	drugs
O	.

B-drug_n	Misonidazole
O	also
O	reduced
O	the
O	"
O	early
O	"

O	.

O	There
O	was
O	no
O	evidence
O	of
O	any
O	pharmacokinetic
O	interactions
O	between
B-brand	ERBITUX
O	and
B-drug	irinotecan
O	.

O	Drug-Drug
O	Interactions
B-drug	Cimetidine
O	:
O	Concomitant
O	use
O	of
B-drug	cimetidine
O	is
O	contraindicated
O	.

O	.

O	The
O	possibility
O	of
O	hypotensive
O	effects
O	with
B-drug	captopril
O	can
O	be
O	minimized
O	by
O	either
O	discontinuing
O	the
B-group	diuretic
O	or
O	increasing
O	the
O	salt
O	intake
O	approximately
O	one
O	week
O	prior
O	to
O	initiation
O	of
O	treatment
O	with
B-drug	captopril
O	(
B-drug	captopril
O	tablets
O	,
O	USP
O	)
O	or
O	initiating
O	therapy
O	with
O	small
O	doses
O	(
O	6.25
O	or
O	12.5
O	mg
O	)
O	.

O	Two
O	percent
O	of
O	patients
O	treated
O	concurrently
O	with
B-brand	Kineret
O	and
B-drug	etanercept
O	developed
O	neutropenia
O	(
O	ANC
O	1
O	x
O	109/L
O	)
O	.

B-brand	COPAXONE
O	has
O	not
O	been
O	formally
O	evaluated
O	in
O	combination
O	with
B-drug	Interferon
I-drug	beta
O	.

B-group	Estrogens
O	,
O	including
O	oral
B-group	contraceptives
O	:
B-group	Estrogens
O	may
O	decrease
O	the
O	hepatic
O	metabolism
O	of
O	certain
B-group	corticosteroids
O	,
O	thereby
O	increasing
O	their
O	effect
O	.

O	Potential
O	differences
O	in
B-drug	cyclosporine
O	dosing
O	and
O	pharmacokinetics
O	at
O	different
O	levels
O	of
B-drug	everolimus
O	exposure
O	were
O	assessed
O	in
O	the
O	context
O	of
O	ANOVA
O	.

O	Monitoring
O	of
O	anticoagulation
O	levels
O	is
O	recommended
O	.

O	These
O	data
O	emphasize
O	that
O	apoptosis
O	can
O	be
O	induced
O	in
O	MCF-7
O	cells
O	either
O	by
O	activation
O	of
B-group	vitamin-D-mediated
O	signalling
O	or
O	disruption
O	of
B-group	estrogen-dependent
O	signalling
O	.

B-group	Antithyroid
I-group	agents
O	may
O	decrease
O	thyroidal
O	uptake
O	of
B-drug	sodium
I-drug	iodide
I-drug	I131
O	,
O	a
O	rebound
O	in
O	uptake
O	may
O	occur
O	up
O	to
O	5
O	days
O	after
O	sudden
O	withdrawal
O	of
B-drug	Carbimazole
O	.

B-group	5HT3
I-group	Antagonists
O	:
O	Based
O	on
O	reports
O	of
O	profound
O	hypotension
O	and
O	loss
O	of
O	consciousness
O	when
B-drug	apomorphine
O	was
O	administered
O	with
B-drug	ondansetron
O	,
O	the
O	concomitant
O	use
O	of
B-drug	apomorphine
O	with
O	drugs
O	of
O	the
B-group	5HT3
I-group	antagonist
I-group	class
O	(
O	including
O	,
O	for
O	example
O	,
B-drug	ondansetron
O	,
B-drug	granisetron
O	,
B-drug	dolasetron
O	,
B-drug	palonosetron
O	,
O	and
B-drug	alosetron
O	)
O	is
O	contraindicated
O	.

O	Severe
O	anemia
O	(
O	Grade
O	3-4
O	according
O	to
O	the
O	World
O	Health
O	Organization
O	criteria
O	)
O	was
O	significantly
O	greater
O	in
O	the
O	patients
O	who
O	received
O	CHOP-HAART
O	compared
O	with
O	the
O	patients
O	who
O	received
O	CHOP
O	alone
O	(
O	33
O	%
O	vs.
O	7
O	%
O	,
O	respectively
O	;
O	P
O	=
O	0.001
O	)
O	.

I-drug	atazanavir

B-drug	Magnesium
O	infusions
O	can
O	only
O	be
O	envisaged
O	in
O	intensive
O	care
O	units
O	with
O	careful
O	monitoring
O	of
O	pulse
O	,
O	arterial
O	pressure
O	,
O	deep
O	tendon
O	reflexes
O	,
O	hourly
O	diuresis
O	,
O	electrocardiogram
O	and
O	respiratory
O	recordings
O	.

O	As
B-drug_n	MHD
O	,
O	the
O	predominant
O	plasma
O	substrate
O	,
O	is
O	only
O	a
O	weak
O	inducer
O	of
O	UDP-glucuronyl
O	transferase
O	,
O	it
O	is
O	unlikely
O	to
O	have
O	an
O	effect
O	on
O	drugs
O	that
O	are
O	mainly
O	eliminated
O	by
O	conjugation
O	through
O	UDP-glucuronyl
O	transferase
O	(
O	e.g.
O	,
B-drug	valproic
I-drug	acid
O	,
B-drug	lamotrigine
O	)
O	.

O	Other
O	concomitant
O	therapy
O	Although
O	specific
O	interaction
O	studies
O	were
O	not
O	performed
O	,
B-drug	finasteride
O	doses
O	of
O	1
O	mg
O	or
O	more
O	were
O	concomitantly
O	used
O	in
O	clinical
O	studies
O	with
B-drug	acetaminophen
O	,
B-drug	acetylsalicylic
I-drug	acid
O	,
O	a-blockers
O	,
B-group	analgesics
O	,
B-group	angiotensin-converting
I-group	enzyme
I-group	(
I-group	ACE
I-group	)
I-group	inhibitors
O	,
B-group	anticonvulsants
O	,
B-group	benzodiazepines
O	,
B-group	beta
I-group	blockers
O	,
B-group	calcium-channel
I-group	blockers
O	,
O	cardiac
B-group	nitrates
O	,
B-group	diuretics
O	,
B-group	H2
I-group	antagonists
O	,
B-group	HMG-CoA
I-group	reductase
I-group	inhibitors
O	,
B-group	prostaglandin
I-group	synthetase
I-group	inhibitors
O	(
O	also
O	referred
O	to
O	as
B-group	NSAIDs
O	)
O	,
O	and
B-group	quinolone
I-group	anti-infectives
O	without
O	evidence
O	of
O	clinically
O	significant
O	adverse
O	interactions
O	.

O	however
O	,
O	it
O	is
O	not
O	known
O	if
O	other
B-group	phenothiazines
O	produce
O	a
O	similar
O	response
O	.

O	Inhibition
O	of
O	CYP3A4
O	metabolic
O	reactions
O	was
O	not
O	detected
O	in
O	in
O	vitro
O	experiments
O	.

O	Patients
O	should
O	take
O	other
O	drugs
O	at
O	least
O	one
O	hour
O	before
O	or
O	four
O	hours
O	after
B-brand	COLESTID
O	Tablets
O	to
O	avoid
O	impeding
O	their
O	absorption
O	.

O	Nevertheless
O	,
O	there
O	may
O	be
O	the
O	potential
O	for
O	clinically
O	important
O	alterations
O	of
O	blood
O	levels
O	of
O	coadministered
O	drugs
O	.

O	Injection
O	There
O	is
O	inadequate
O	systematic
O	experience
O	with
O	the
O	use
O	of
B-drug	baclofen
O	injection
O	in
O	combination
O	with
O	other
O	medications
O	to
O	predict
O	specific
O	drug-drug
O	interactions
O	.

O	N=17
O	)
O	were
O	not
O	different
O	and
O	neither
O	were
B-drug	gabapentin
O	pharmacokinetic
O	parameters
O	affected
O	by
B-drug	valproic
I-drug	acid
O	.

O	Other
O	depressasnts
O	such
O	as
B-drug	alcohol
O	,
B-group	barbiturates
O	,
O	and
B-group	MAOIs
O	may
O	enhance
O	CNS
O	depression
O	when
O	administered
O	with
B-drug	ethchlorvynol
O	.

B-drug	Ketoconazole
O	:
O	Concomitant
O	use
O	of
B-drug	ketoconazole
O	is
O	contraindicated
O	.

O	reduced
O	serum
O	folate
O	concentration
O	;

O	One
O	animal
O	in
O	the
O	high
O	dose
O	group
O	developed
O	a
O	B-cell
O	lymphoma
O	that
O	was
O	detected
O	after
O	28
O	weeks
O	of
O	dosing
O	.

B-drug	Clozapine
O	may
O	potentiate
O	the
O	hypotensive
O	effects
O	of
B-group	antihypertensive
I-group	drugs
O	and
O	the
O	anticholinergic
O	effects
O	of
B-drug	atropine-type
O	drugs
O	.

O	Drug
O	Laboratory
O	Test
O	Interactions
O	Interactions
O	between
B-drug	darifenacin
O	and
O	laboratory
O	tests
O	have
O	not
O	been
O	studied
O	.

B-drug	Ketoconazole

O	Increases
O	in
O	serum
O	creatinine
O	have
O	occurred
O	when
B-brand	CEFOTAN
O	was
O	given
O	alone
O	.

O	Therefore
O	,
O	when
B-drug	chlorothiazide
O	and
B-group	non-steroidal
I-group	anti-inflammatory
I-group	agents
O	are
O	used
O	concomitantly
O	,
O	the
O	patient
O	should
O	be
O	observed
O	closely
O	to
O	determine
O	if
O	the
O	desired
O	effect
O	of
O	the
B-group	diuretic
O	is
O	obtained

O	Although
O	the
O	proposed
O	methodology
O	for
O	deriving
O	experimental
O	designs
O	can
O	be
O	applied
O	to
O	any
O	nonlinear
O	regression
O	model
O	,
O	primary
O	focus
O	is
O	given
O	to
O	the
O	additive
O	and
O	nonadditive
O	independent
O	joint
O	action
O	(
O	IJA
O	)
O	models
O	for
O	individual
O	and
O	combined
O	exposures
O	proposed
O	by
O	Barton
O	,
O	Braunberg
O	,
O	and
O	Friedman
O	(
O	1
O	)
O	.

B-drug	diflunisal
O	;

B-drug	Potassium
O	Supplements
O	and
B-group	Potassium-Sparing
I-group	Diuretics
O	:
B-drug	Fosinopril
I-drug	sodium
O	can
O	attenuate
O	potassium
O	loss
O	caused
O	by
B-group	thiazide
I-group	diuretics
O	.

O	a
O	reduction
O	in
O	the
O	usual
B-group	anticoagulant
O	dosage
O	may
O	be
O	required
O	in
O	patients
O	receiving
O	both
O	drugs
O	.

O	Delayed
O	Adverse
O	Reactions
O	to
B-group	Iodinated
I-group	Contrast
I-group	Media
O	:
O	A
O	review
O	of
O	the
O	literature
O	revealed
O	that
O	12.6
O	%
O	(
O	range
O	11-28
O	%
O	)
O	of
O	501
O	patients
O	treated
O	with
O	various
B-drug	interleukin-2
O	containing
O	regimens
O	who
O	were
O	subsequently
O	administered
B-group	radiographic
I-group	iodinated
I-group	contrast
I-group	media
O	experienced
O	acute
O	,
O	atypical
O	adverse
O	reactions
O	.

B-drug	Ketoconazole
O	:
O	When
O	a
O	single
O	125-mg
O	dose
O	of
B-drug	Aprepitant
O	was
O	administered
O	on
O	Day5
O	of
O	a
O	10-day
O	regimen
O	of
O	400
O	mg/day
O	of
B-drug	ketoconazole
O	,
O	a
O	strong
O	CYP3A4
O	inhibitor
O	,
O	the
O	AUC
O	of
B-drug	aprepitant
O	increased
O	approximately
O	5-fold
O	and
O	the
O	mean
O	terminal
O	half-life
O	of
B-drug	aprepitant
O	increased
O	approximately
O	3-fold
O	.

O	At
O	a
O	low
B-drug	cocaine
O	dose
O	and
O	long
O	withdrawal
O	period
O	(
O	10
O	mg/kg
O	,
O	twice
O	a
O	day
O	for
O	5
O	days
O	followed
O	by
O	a
O	14-day
O	withdrawal
O	)
O	,
O	the
O	LST
O	mice
O	showed
O	tolerance
O	development
O	.

O	CONCLUSION
O	:
O	These
O	findings
O	indicate
O	that
B-drug	verapamil
O	inhibits
O	cancer
O	metastasis
O	through
O	actions
O	that
O	do
O	not
O	affect
O	the
O	growth
O	of
O	intestinal
O	cancers
O	.

O	It
O	is
O	recommended
O	that
O	serum
B-drug	lithium
O	levels
O	be
O	monitored
O	frequently
O	if
B-brand	PRINIVIL
O	is
O	administered
O	concomitantly
O	with
B-drug	lithium
O	.

O	Similarly
O	,
O	the
O	effects
O	of
B-drug	phenytoin
O	on
B-drug	phenobarbital
O	,
B-drug	valproic
I-drug	acid
O	and
O	sodium
O	plasma
B-drug	valproate
O	concentrations
O	are
O	unpredictable

O	Potential
O	for
O	Other
O	Drugs
O	to
O	Affect
B-drug	Duloxetine
O	:
O	Both
O	CYP1A2
O	and
O	CYP2D6
O	are
O	responsible
O	for
B-drug	duloxetine
O	metabolism
O	.

O	This
O	medication
O	should
O	not
O	be
O	taken
O	with
B-group	MAO
I-group	inhibitors
O	.

O	Substances
O	that
O	are
O	inducers
O	of
O	CYP3A4
O	activity
O	increase
O	the
O	metabolism
O	of
B-drug	gefitinib
O	and
O	decrease
O	its
O	plasma
O	concentrations
O	.

O	In
O	addition
O	,
O	patients
O	taking
O	drugs
O	that
O	inhibit
O	the
O	cytochrome
O	P450
O	3A4
O	isozyme
O	,
O	which
O	metabolizes
B-drug	sildenafil
O	,
O	may
O	experience
O	increased
O	drug
O	concentrations
O	and
O	possible
O	toxicity
O	from
O	normal
O	doses
O	of
B-drug	sildenafil
O	.

B-group	Alpha-blockers
O	:
O	When
B-drug	Vardenafil
O	10
O	or
O	20
O	mg
O	was
O	given
O	to
O	healthy
O	volunteers
O	either
O	simultaneously
O	or
O	6
O	hours
O	after
O	a
O	10
O	mg
O	dose
O	of
B-drug	terazosin
O	,
O	significant
O	hypotension
O	developed
O	in
O	a
O	substantial
O	number
O	of
O	subjects
O	.

O	Drug
O	Interactions
O	:
B-drug	Flupenthixol
O	may
O	interact
O	with
O	some
O	drugs
O	,
O	like
B-group	Monoamine
I-group	oxidase
I-group	inhibitors
O	(
B-group	MAOI
O	)
O	:
B-group	MAOI
O	could
O	theoretically
O	affect
B-drug	flupenthixol
O	pharmacodynamics
O	-
B-drug_n	Arecoline
O	-
O	Eproxindine
O	-
B-drug	Ethanol
O	:
B-drug	Flupenthixol
O	and
B-drug	Ethanol
O	cause
O	additive
O	CNS
O	depression
O	-
B-group	Tricyclic
I-group	antidepressants
O	:
B-drug	Flupenthixol
O	increases
O	the
O	effect
O	of
B-group	Tricyclic
I-group	antidepressants

O	Hepatic
O	Enzyme
O	Inducers
O	,
O	Inhibitors
O	and
O	Substrates
O	:
O	Drugs
O	which
O	induce
O	cytochrome
O	P450
O	3A4
O	(
O	CYP
O	3A4
O	)
O	enzyme
O	activity
O	(
O	e.g.
O	,
B-group	barbiturates
O	,
B-drug	phenytoin
O	,
B-drug	carbamazepine
O	,
B-drug	rifampin
O	)
O	may
O	enhance
O	the
O	metabolism
O	of
B-group	corticosteroids
O	and
O	require
O	that
O	the
O	dosage
O	of
O	the
B-group	corticosteroid
O	be
O	increased
O	.

O	In
O	addition
O	,
O	the
O	transfusion
O	practices
O	for
O	such
O	patients
O	may
O	need
O	to
O	be
O	modified
O	given
O	the
O	increased
O	risk
O	of
O	bleeding
O	.

O	600-1800

O	See

O	If
O	this
O	is
O	not
O	possible
O	,
O	the
O	starting
O	dose
O	should
O	be
O	reduced
O	.

O	Until
O	data
O	on
O	possible
O	interactions
O	between
B-drug	verapamil
O	and
B-drug	disopyramide
I-drug	phosphate
O	are
O	obtained
O	,
B-drug	disopyramide
O	should
O	not
O	be
O	administered
O	within
O	48
O	hours
O	before
O	or
O	24
O	hours
O	after
B-drug	verapamil
O	administration
O	.

O	Interaction
O	on
O	the
O	antinociceptive
O	effect
O	between
B-drug_n	neurotensin
O	and
B-drug_n	enkephalins
O	or
B-drug_n	tuftsin
O	.

O	It
O	is
O	recommended
O	that
O	these
O	tests
O	be
O	performed
O	weekly
O	or
O	every
O	other
O	week
O	until
O	the
O	lipid
O	response
O	to
B-brand	Soriatane
O	has
O	stabilized
O	.

O	Decreased
O	core
O	temperature
O	in
O	female
O	rats
O	was
O	investigated
O	as
O	one
O	possible
O	index
O	of
O	the
B-drug	disulfiram-ethanol
O	reaction
O	(
O	DER
O	)
O	.

O	There
O	were
O	transient
O	increases
O	in
O	liver
O	ALT
O	and
O	AST
O	when
B-brand	CANCIDAS
O	and
B-drug	cyclosporine
O	were
O	co-administered
O	.

O	Analyses
O	of
O	this
O	sequence
O	,
O	however
O	,
O	usually
O	give
O	little
O	consideration
O	to
O	the
O	nature
O	of
O	the
O	target
O	cell
O	or
O	to
O	the
O	characteristics
O	of
O	the
O	resultant
O	tumors
O	.

O	To
O	evaluate
O	the
O	impact
O	of
O	chemotherapy
O	plus
O	HAART
O	on
O	the
O	clinical
O	course
O	of
O	patients
O	with
O	HIV-related
O	,
O	systemic
O	,
O	non-Hodgkin
O	lymphoma
O	(
O	HIV-NHL
O	)
O	,
O	the
O	authors
O	compared
O	retrospectively
O	a
O	group
O	of
O	24
O	patients
O	with
O	HIV-NHL
O	who
O	were
O	treated
O	with
O	the
B-drug	cyclophosphamide
O	,
B-drug	doxorubicin
O	,
B-drug	vincristine
O	,
O	and
B-drug	prednisone
O	(
O	CHOP
O	)
O	chemotherapy
O	regimen
O	plus
O	HAART
O	with
O	a
O	group
O	of
O	80
O	patients
O	who
O	were
O	treated
O	with
O	CHOP
O	chemotherapy
O	or
O	a
O	CHOP-like
O	regimen
O	(
O	i.e.
O	,
B-drug	cyclophosphamide
O	,
B-drug	doxorubicin
O	,
B-drug	teniposide
O	,
O	and
B-drug	prednisone
O	with
B-drug	vincristine
O	plus
B-drug	bleomycin
O	)
O	without
O	receiving
B-group	antiretroviral
O	therapy
O	.

I-drug	indinavir
O	concentration

O	DRUG
O	INTERACTIONS

O	Changes
O	in
B-drug	omeprazole
O	pharmacokinetics
O	were
O	not
O	studied
O	.

O	In
O	general
O	,
O	these
O	are
O	drugs
O	that
O	have
O	one
O	or
O	more
O	pharmacologic
O	activities
O	similar
O	to
B-drug	bepridil
I-drug	hydrochloride
O	,
O	including
B-group	anti-arrhythmic
I-group	agents
O	such
O	as
B-drug	quinidine
O	and
B-drug	procainamide
O	,
B-group	cardiac
I-group	glycosides
O	and
B-group	tricyclic
I-group	anti-depressants
O	.

B-drug	Ranitidine
O	produced
O	smaller
O	,
O	nonsignificant
O	increases
O	.

B-group	Anesthetics/Sedatives/Hypnotics/Opioids
O	:
O	Co-administration
O	of
B-brand	PRECEDEX
O	with
B-group	anesthetics
O	,
B-group	sedatives
O	,
B-group	hypnotics
O	,
O	and
B-group	opioids
O	is
O	likely
O	to
O	lead
O	to
O	an
O	enhancement
O	of
O	effects
O	.

O	Drug-Drug
O	Interactions
O	Given
O	the
O	primary
O	CNS
O	effects
O	of
B-drug	aripiprazole
O	,
O	caution
O	should
O	be
O	used
O	when
B-brand	ABILIFY
O	is
O	taken
O	in
O	combination
O	with
O	other
B-group	centrally
I-group	acting
I-group	drugs
O	and
B-drug	alcohol
O	.

O	Rhabdomyolysis
O	secondary
O	to
O	a
O	drug
O	interaction
O	between
B-drug	simvastatin
O	and
B-drug	clarithromycin
O	.

B-drug	Phenytoin
O	:
O	If
B-drug	acitretin
O	is
O	given
O	concurrently
O	with
B-drug	phenytoin
O	,
O	the
O	protein
O	binding
O	of
B-drug	phenytoin
O	may
O	be
O	reduced
O	.

O	A
O	patient
O	had
O	phenytoin
O	intoxication
O	after
O	administration
O	of
B-drug	fluvoxamine
O	,
O	a
O	selective
O	serotonin
O	reuptake
O	inhibitor
O	.

O	There
O	were
O	no
O	differences
O	between
O	cecectomized
O	and
O	control
O	rats
O	in
O	basal
O	small
O	intestinal
O	transits
O	or
O	in
B-drug_n	dmPGE2
O	(
O	0.3
O	mg/kg
O	,
O	p.o
O	.
O	)
O	-induced
O	enhancements
O	.

B-group	MAO
I-group	inhibitors
O	prolong
O	and
O	intensify
O	the
O	anticholinergic
O	effects
O	of
B-group	antihistamines
O	.

O	Agents
O	Affecting
O	Sympathetic
O	Activity
O	The
O	sympathetic
O	nervous
O	system
O	may
O	be
O	especially
O	important
O	in
O	supporting
O	blood
O	pressure
O	in
O	patients
O	receiving
B-drug	captopril
O	alone
O	or
O	with
B-group	diuretics
O	.

O	Concurrent
O	use
O	of
B-drug	flurbiprofen
O	and
B-brand	aspirin
O	is
O	therefore
O	not
O	recommended
O	.

O	Coadministration
O	of
B-brand	VIRACEPT
O	and
O	drugs
O	primarily
O	metabolized
O	by
O	CYP3A
O	(
O	e.g.
O	,
B-group	dihydropyridine
I-group	calcium
I-group	channel
I-group	blockers
O	)
O	may
O	result
O	in
O	increased
O	plasma
O	concentrations
O	of
O	the
O	other
O	drug
O	that
O	could
O	increase
O	or
O	prolong
O	both
O	its
O	therapeutic
O	and
O	adverse
O	effects
O	.

O	(
O	Note
O	:
O	All
O	patients
O	receiving
B-drug	theophylline
O	should
O	be
O	monitored
O	appropriately
O	,
O	regardless
O	of
O	concomitant
O	drug
O	therapy
O	.
O	)

B-drug	valproate
O	and
B-drug	gabapentin
O	are
O	not
O	.

O	Therefore
O	,
O	when
B-drug	meclofenamate
I-drug	sodium
O	is
O	given
O	to
O	a
O	patient
O	receiving
B-drug	warfarin
O	,
O	the
O	dosage
O	of
B-drug	warfarin
O	should
O	be
O	reduced
O	to
O	prevent
O	excessive
O	prolongation
O	of
O	the
O	prothrombin
O	time
O	.

B-drug	Lithium
O	:
B-group	NSAIDs
O	have
O	produced
O	an
O	elevation
O	of
O	plasma
B-drug	lithium
O	levels
O	and
O	a
O	reduction
O	in
O	renal
B-drug	lithium
O	clearance
O	.

O	65
O	years
O	of
O	age
O	and
O	13
O	patients
O	were

O	The
O	minimal
O	inhibitory
O	concentrations
O	of
B-drug	clindamycin
O	and
B-drug	gentamicin
O	alone
O	and
O	in
O	combinations
O	were
O	determined
O	by
O	a
O	microdilution
O	method
O	for
O	163
O	aerobic
O	,
O	facultative
O	,
O	and
O	anaerobic
O	clinical
O	isolates
O	.

O	As
O	with
O	other
B-group	dialysis
I-group	solutions
O	,
O	blood
O	concentrations
O	of
O	dialyzable
O	drugs
O	may
O	be
O	reduced
O	by
O	dialysis
O	.

O	therefore
O	concomitant
O	administration
O	of
B-drug	Itraconazole
O	with
B-drug	cisapride
O	is
O	contraindicated
O	.

O	Particular
O	caution
O	is
O	recommended
O	when
O	administering
B-brand	Gleevec
O	with
O	CYP3A4
O	substrates
O	that
O	have
O	a
O	narrow
O	therapeutic
O	window
O	(
O	e.g.
O	,
B-drug	cyclosporine
O	or
B-drug	pimozide
O	)
O	.

O	Potassium
O	sparing
O	agents
O	should
O	generally
O	not
O	be
O	used
O	in
O	patients
O	with
O	heart
O	failure
O	receiving
B-drug	enalapril
O	.

O	clinically
O	significant
O	interactions
O	with
O	other
O	drugs
O	through
O	competition
O	for
O	protein
O	binding
O	sites
O	are
O	therefore
O	unlikely
O	.

O	This
O	was
O	expected
O	because
B-drug	zaleplon
O	is
O	primarily
O	metabolized
O	and
O	renal
O	excretion
O	of
O	unchanged
B-drug	zaleplon
O	accounts
O	for
O	less
O	than
O	1
O	%
O	of
O	the
O	administered
O	dose
O	.

O	A
O	muscle
O	biopsy
O	revealed
O	necrotizing
O	myopathy
O	secondary
O	to
O	a
O	toxin
O	.

B-drug	Cyclosporine
O	:
O	Elevated
O	serum
O	levels
O	of
B-drug	cyclosporine
O	have
O	been
O	reported
O	with
O	concomitant
O	use
O	of
B-drug	cyclosporine
O	with
O	other
O	members
O	of
O	the
B-group	quinolone
I-group	class
O	.

O	The
O	gastrointestinal
O	absorption
O	of
B-drug	cimetidine
O	and
B-drug	ranitidine
O	is
O	accelerated
O	when
O	they
O	are
O	coadministered
O	with
B-drug	cisapride
O	.

B-drug	Amprenavir
O	significantly
O	decreases
O	clearance
O	of
B-drug	rifabutin
O	and
B-drug_n	25-O-desacetylrifabutin
O	,
O	and
O	the
O	combination
O	is
O	poorly
O	tolerated
O	.

B-group	ACE-inhibitors
O	:
O	Reports
O	suggest
O	that
B-group	NSAIDs
O	may
O	diminish
O	the
O	antihypertensive
O	effect
O	of
B-group	ACE-inhibitors
O	.

O	Therefore
O	,
O	CYP3A4
O	substrates
O	known
O	to
O	have
O	a
O	narrow
O	therapeutic
O	index
O	such
O	as
B-drug	alfentanil
O	,
B-drug	astemizole
O	,
B-drug	terfenadine
O	,
B-drug	cisapride
O	,
B-drug	cyclosporine
O	,
B-drug	fentanyl
O	,
B-drug	pimozide
O	,
B-drug	quinidine
O	,
B-drug	sirolimus
O	,
B-drug	tacrolimus
O	,
O	or
B-group	ergot
I-group	alkaloids
O	(
B-drug	ergotamine
O	,
B-drug	dihydroergotamine
O	)
O	should
O	be
O	administered
O	with
O	caution
O	in
O	patients
O	receiving
B-brand	SPRYCEL
O	.

O	Thus
O	,
O	when
B-brand	VIOXX
O	and
B-drug	lithium
O	are
O	administered
O	concurrently
O	,
O	subjects
O	should
O	be
O	observed
O	carefully
O	for
O	signs
O	of
B-drug	lithium
O	toxicity
O	.

B-drug	aminosalicylic
I-drug	acid
O	;

O	Drug/Laboratory
O	Test
O	Interactions
O	Positive
O	direct
O	Coombs
O	tests
O	have
O	been
O	reported
O	during
O	treatment
O	with
O	the
B-group	cephalosporin
I-group	antibiotics
O	.

B-drug	Cimetidine
O	:
O	In
O	a
O	study
O	in
O	healthy
O	volunteers
O	,
O	a
O	one-week
O	course
O	of
B-drug	cimetidine
O	at
O	400
O	mg
O	b.i.d
O	.
O	with
O	a
O	single
O	5
O	mg
O	dose
O	of
B-drug	isradipine
O	on
O	the
O	sixth
O	day
O	showed
O	an
O	increase
O	in
B-drug	isradipine
O	mean
O	peak
O	plasma
O	concentrations
O	(
O	36
O	%
O	)
O	and
O	significant
O	increase
O	in
O	area
O	under
O	the
O	curve
O	(
O	50
O	%
O	)
O	.

O	Synergism
O	has
O	been
O	shown
O	between
B-drug	halothane
O	anesthesia
O	and
O	intravenously
O	administered
B-drug	labetalol
I-drug	HCl
O	.

B-drug	Methotrexate
O	:
O	In
O	an
O	interaction
O	study
O	of
O	rheumatoid
O	arthritis
O	patients
O	taking
B-drug	methotrexate
O	,
B-brand	CELEBREX
O	did
O	not
O	have
O	a
O	significant
O	effect
O	on
O	the
O	pharmacokinetics
O	of
B-drug	methotrexate
O	.

O	Even
O	though
O	such
O	interactions
O	have
O	not
O	been
O	seen
O	in
O	clinical
O	studies
O	with
B-brand	DynaCirc
O	(
B-drug	isradipine
O	)
O	,
O	an
O	increased
O	volume
O	of
O	circulating
O	fluids
O	might
O	be
O	required
O	if
O	such
O	an
O	interaction
O	were
O	to
O	occur
O	.

B-drug	Methadone
O	levels
O	may
O	be
O	decreased
O	;
O	increased
O	dosages
O	may
O	be
O	required
O	to
O	prevent
O	symptoms
O	of
B-group	opiate
O	withdrawal
O	.
B-drug	Methadone
O	maintained
O	patients
O	beginning
B-drug	nevirapine
O	therapy
O	should
O	be
O	monitored
O	forevidence
O	of
O	withdrawal
O	and
B-drug	methadone
O	dose
O	should
O	be
O	adjusted
O	accordingly
O	.

I-drug	Diazoxide
O	Hypotension

O	However
O	,
O	prudent
O	medical
O	practice
O	dictates
O	careful
O	monitoring
O	of
O	prothrombin
O	time
O	in
O	all
O	patients
O	treated
O	with
B-drug	azithromycin
O	and
B-drug	warfarin
O	concomitantly
O	.

O	The
O	preceding
O	lists
O	of
O	drugs
O	are
O	not
O	comprehensive
O	.

O	In
O	an
O	in
O	vitro
O	study
O	in
O	human
O	liver
O	microsomes
O	,
O	inhibition
O	of
O	CYP2A6
O	hydroxylation
O	of
B-group	coumarin
O	by
B-drug	fondaparinux
O	(
O	200
O	m
O	m
O	M
O	i.e.
O	,
O	350
O	mg/L
O	)
O	was
O	17-28
O	%
O	.

B-drug	Chlorpromazine
O	:
B-drug	Chlorpromazine
O	blocks
O	dopamine
O	and
O	norepinephrine
O	reuptake
O	,
O	thus
O	inhibiting
O	the
O	central
O	stimulant
O	effects
O	of
B-group	amphetamines
O	,
O	and
O	can
O	be
O	used
O	to
O	treat
B-group	amphetamine
O	poisoning
O	.

O	In
O	this
O	study
O	,
O	the
O	effects
O	of
B-drug	etofibrate
O	upon
O	chylomicron
O	metabolism
O	was
O	tested
O	by
O	determination
O	of
O	the
O	plasma
O	kinetics
O	of
O	a
O	chylomicron-like
O	emulsion
O	model
O	in
O	12
O	patients
O	with
O	coronary
O	artery
O	disease
O	,
O	aged
O	59+/-11
O	years
O	,
O	(
O	total
O	cholesterol
O	:
O	240+/-41
O	mg/dl
O	;
O	triglycerides
O	:
O	188+/-42
O	mg/dl
O	)
O	submitted
O	to
O	a
O	randomized
O	,
O	crossover
O	,
O	double-blind
O	,
O	placebo-controlled
O	study
O	with
O	administration
O	of
O	1
O	g
O	per
O	day
B-drug	etofibrate
O	or
O	placebo
O	for
O	1-month
O	.

O	When
B-drug	indinavir
O	at
O	an
O	increased
O	dose
O	(
O	1000
O	mg
O	every
O	8
O	hours
O	)
O	was
O	given
O	with
B-brand	SUSTIVA
O	(
O	600
O	mg
O	once
O	daily
O	)
O	,
O	the
B-drug	indinavir
O	AUC
O	and
O	Cmin
O	were
O	decreased
O	on
O	average
O	by
O	33-46
O	%
O	and
O	39-57
O	%
O	,
O	respectively
O	,
O	compared
O	to
O	when
B-drug	indinavir
O	(
O	800
O	mg
O	every
O	8
O	hours
O	)
O	was
O	given
O	alone
O	.

O	Onset
O	of
O	action
O	of
B-group	tricyclics
O	may
O	be
O	accelerated
O	.

O	Fatal
O	cardiac
O	arrests
O	have
O	occurred
O	in
O	patients
O	receiving
O	both
O	drugs
O	.

O	Drug-Laboratory
O	Test
O	Interactions
O	:
O	There
O	are
O	no
O	reported
O	drug-laboratory
O	test
O	interactions
O	.

B-brand	HEMABATE
O	may
O	augment
O	the
O	activity
O	of
O	other
B-group	oxytocic
I-group	agents
O	.

B-drug	Dexrazoxane
O	was
O	not
O	mutagenic
O	in
O	the
O	Ames
O	test
O	but
O	was
O	found
O	to
O	be
O	clastogenic
O	to
O	human
O	lymphocytes
O	in
O	vitro
O	and
O	to
O	mouse
O	bone
O	marrow
O	erythrocytes
O	in
O	vivo
O	(
O	micronucleus
O	test
O	)
O	.

O	Special
O	attention
O	should
O	be
O	given
O	to
O	electrolyte
O	and
O	acid-base
O	balance
O	in
O	patients
O	experiencing
O	severe
O	or
O	prolonged
O	diarrhea
O	or
O	in
O	patients
O	receiving
O	concomitant
B-drug	diuretics
O	.

O	Many
O	other
O	medicines
O	may
O	increase
O	or
O	decrease
O	the
O	effects
O	of
B-drug	glimepiride
O	or
O	affect
O	your
O	condition
O	.

O	-
O	Drugs
O	that
O	may
O	either
O	increase
O	or
O	decrease
O	plasma
B-drug	phenytoin
O	concentrations
O	include
O	:
B-drug	phenobarbital
O	,
O	vaiproic
O	acid
O	,
O	and
B-drug	sodium
I-drug	valproate
O	.

O	We
O	reviewed
O	the
O	clinical
O	data
O	relating
O	to
O	the
O	efficacy
O	and
O	safety
O	of
O	pharmacologic
O	doses
O	of
B-drug	ascorbic
I-drug	acid
O	in
O	the
O	prevention
O	and
O	treatment
O	of
O	the
O	common
O	cold
O	.

O	Concomitant
O	administration
O	of
B-drug	naproxen
O	and
B-brand	aspirin
O	is
O	not
O	recommended
O	because
B-drug	naproxen
O	is
O	displaced
O	from
O	its
O	binding
O	sites
O	during
O	the
O	concomitant
O	administration
O	of
B-brand	aspirin
O	,
O	resulting
O	in
O	lower
O	plasma
O	concentrations
O	and
O	peak
O	plasma
O	levels
O	.

O	Although
O	it
O	has
O	not
O	been
O	established
O	that
O	there
O	is
O	an
O	interaction
O	between
B-drug	Clozapine
O	and
B-group	benzodiazepines
O	or
O	other
B-group	psychotropics
O	,
O	caution
O	is
O	advised
O	when
B-drug	clozapine
O	is
O	initiated
O	in
O	patients
O	taking
O	a
B-group	benzodiazepine
O	or
O	any
O	other
B-group	psychotropic
I-group	drug
O	.

O	In
O	addition
O	,
O	certain
O	drugs
O	inhibit
O	the
O	activity
O	of
O	this
O	isozyme
O	and
O	make
O	normal
O	metabolizers
O	resemble
O	poor
O	metabolizers
O	.

B-drug	Aprepitant
O	is
O	a
O	substrate
O	for
O	CYP3A4
O	;

O	This
O	interaction
O	should
O	be
O	given
O	consideration
O	in
O	patients
O	taking
B-group	NSAIDs
O	concomitantly
O	with
B-group	ACE-inhibitors
O	.

O	No
O	formal
O	assessments
O	of
O	pharmacokinetic
O	drug-drug
O	interactions
O	between
B-brand	TRISENOX
O	and
O	other
O	agents
O	have
O	been
O	conducted
O	.

O	Studies
O	on
O	two
O	strains
O	of
O	pointer
O	dogs
O	have
O	demonstrated
O	that
O	administration
O	of
O	a
B-group	benzodiazepine
O	(
B-drug	chlordiazepoxide
O	)
O	facilitates
O	acquisition
O	of
O	goal-directed
O	behavior
O	in
O	"
O	genetically
O	nervous
O	"

O	+24
O	%
O	+14
O	%
O	+43
O	%
O	+40
O	%

B-group	Non-steroidal
I-group	anti-inflammatory
I-group	agents
O	:
O	Seizures
O	have
O	been
O	reported
O	in
O	patients
O	taking
B-drug	enoxacin
O	concomitantly
O	with
O	the
B-group	nonsteroidal
I-group	anti-inflammatory
I-group	drug
B-drug	fenbufen
O	.

O	In
O	humans
O	,
O	two
O	inhibitors
O	of
O	P450
O	3A4
O	have
O	been
O	studied
O	.

O	However
O	,
O	it
O	may
O	be
O	important
O	also
O	in
O	case
O	of
O	medical
O	examinations
O	for
O	insurances
O	and
O	job
O	appointments
O	,
O	since
O	some
O	patients
O	may
O	turn
O	out
O	to
O	need
O	expensive
O	drugs
O	or
O	to
O	be
O	susceptible
O	to
O	a
O	certain
O	disease
O	.

B-group	Tricyclic
I-group	antidepressants
O	may
O	antagonize
O	the
O	hypotensive
O	effects
O	of
B-drug	clonidine
O	.

B-drug	Flurbiprofen
O	did
O	not
O	affect
O	the
O	pharmacokinetic
O	profile
O	of
O	either
O	drug
O	,
O	and
O	the
O	mechanism
O	under
O	lying
O	the
O	interference
O	with
B-drug	propranolols
O	hypotensive
O	effect
O	is
O	unknown
O	.

O	MEASUREMENTS
O	AND
O	MAIN
O	RESULTS
O	:
O	In
O	December
O	1998
O	,
O	the
O	following
O	was
O	gathered
O	for
O	every
O	MAC
O	with
O	more
O	than
O	one
O	drug
O	treatment
O	:
O	age
O	,
O	sex
O	,
O	number
O	of
O	drugs
O	,
O	intrinsic
O	value
O	,
O	drugs
O	prescribed
O	,
O	daily
O	dose
O	and
O	pharmacological
O	interactions
O	(
O	PI
O	)
O	,
O	classified
O	(
O	using
O	the
O	scale
O	of
O	Hansten
O	1996
O	)
O	into
O	light
O	and
O	clinically
O	relevant
O	.

O	Drugs
O	Metabolized
O	by
O	P450IID6
O	A
O	subset
O	(
O	3
O	%
O	to
O	10
O	%
O	)
O	of
O	the
O	population
O	has
O	reduced
O	activity
O	of
O	certain
O	drug
O	metabolizing
O	enzymes
O	such
O	as
O	the
O	cytochrome
O	P450
O	isoenzyme
O	P450IID6
O	.

O	(
O	Concurrent
O	use
O	with
B-group	thiazide
I-group	diuretics
O	may
O	enhance
O	the
O	possibility
O	of
B-group	digitalis
O	toxicity
O	associated
O	with
O	hypokalemia
O	.
O	)

O	14
O	%
O	increase
O	[
O	CI
O	:
O	2
O	%
O	increase
O	,
O	24
O	%
O	increase
O	]
O	25
O	%
O	decrease
O	[
O	CI
O	:
O	12
O	%
O	decrease
O	,
O	51
O	%
O	decrease
O	]

O	Thus
O	,
O	results
O	of
O	the
O	DST
O	should
O	be
O	interpreted
O	with
O	caution
O	in
O	these
O	patients
O	.

B-drug	Furosemide
O	:
O	Clinical
O	studies
O	,
O	as
O	well
O	as
O	post-marketing
O	observations
O	,
O	have
O	shown
O	that
B-group	NSAIDs
O	can
O	reduce
O	the
O	natriuretic
O	effect
O	of
B-drug	furosemide
O	and
B-group	thiazides
O	in
O	some
O	patients
O	.

B-drug	Folic
I-drug	acid
O	in
O	large
O	amounts
O	may
O	counteract
O	the
O	antiepileptic
O	effect
O	of
B-drug	phenobarbital
O	,
B-drug	phenytoin
O	and
B-drug	primidone
O	,
O	and
O	increase
O	the
O	frequency
O	of
O	seizures
O	in
O	susceptible
O	pediatric
O	patients
O	.

O	It
O	is
O	important
O	that
O	health
O	care
O	professionals
O	be
O	aware
O	of
O	the
O	potential
O	for
O	medications
O	to
O	interfere
O	with
O	clinical
O	laboratory
O	tests
O	.

B-group	Antidiabetic
I-group	Agents
O	(
B-drug	Insulin
O	,
B-group	Sulfonylureas
O	)
O	:
O	Requirements
O	for
B-drug	insulin
O	or
O	oral
B-group	antidiabetic
I-group	agents
O	may
O	be
O	reduced
O	in
O	hypothyroid
O	patients
O	with
O	diabetes
O	mellitus
O	and
O	may
O	subsequently
O	increase
O	with
O	the
O	initiation
O	of
O	thyroid
O	hormone
O	replacement
O	therapy
O	.

B-drug	Antihypertensives
O	:
B-drug	Amiodarone
O	should
O	be
O	used
O	with
O	caution
O	in
O	patients
O	receiving
B-drug	-receptor
O	blocking
O	agents
O	(
O	e.g.
O	,
B-drug	propranolol
O	,
O	a
B-drug	CYP3A4
O	inhibitor
O	)
O	or
B-drug	calcium
I-drug	channel
O	antagonists
O	(
O	e.g.
O	,
B-drug	verapamil
O	,
O	a
B-drug	CYP3A4
O	substrate
O	,
O	and
B-drug	diltiazem
O	,
O	a
B-drug	CYP3A4
O	inhibitor
O	)
O	because
O	of
O	the
O	possible
O	potentiation
O	of
O	bradycardia
O	,
O	sinus
O	arrest
O	,
O	and
O	AV
O	block
O	;

O	Carcinogenesis
O	,
O	Mutagenesis
O	,
O	Impairment
O	of
O	Fertility
O	No
O	long-term
O	carcinogenicity
O	studies
O	have
O	been
O	carried
O	out
O	with
B-drug	dexrazoxane
O	in
O	animals
O	.

O	No
O	formal
O	drug
O	interaction
O	studies
O	have
O	been
O	conducted
O	with
B-brand	Rebif
O	.

O	Recurrence
O	of
O	skin
O	reactions
O	at
O	a
O	site
O	of
O	previous
O	extravasation
O	following
O	administration
O	of
B-brand	TAXOL
O	at
O	a
O	different
O	site
O	,
O	ie
O	,
O	recall
O	,
O	has
O	been
O	reported
O	rarely
O	.

O	Pharmacokinetic
O	studies
O	document
O	no
O	clinically
O	relevant
O	interactions
O	with
O	other
O	agents
O	given
O	concomitantly
O	,
O	including
B-group	thiazide
I-group	diuretics
O	,
B-drug	digoxin
O	,
O	and
B-drug	cimetidine
O	.

O	When
O	therapeutic
O	concentrations
O	of
B-drug	furosemide
O	,
B-drug	propranolol
O	,
B-drug	dipyridamole
O	,
B-drug	warfarin
O	,
B-drug	quinidine
O	,
O	or
B-drug	naproxen
O	were
O	added
O	to
O	human
O	plasma
O	(
O	in
O	vitro
O	)
O	,
O	the
O	plasma
O	protein
O	binding
O	of
B-drug	nicardipine
I-drug	HCl
O	was
O	not
O	altered
O	.

O	Drugs
O	which
O	inhibit
O	CYP
O	3A4
O	(
O	e.g.
O	,
B-drug	ketoconazole
O	,
B-group	macrolide
I-group	antibiotics
O	such
O	as
B-drug	erythromycin
O	)
O	have
O	the
O	potential
O	to
O	result
O	in
O	increased
O	plasma
O	concentrations
O	of
B-group	corticosteroids
O	.

O	No
O	dosage
O	adjustment
O	is
O	required
O	for
B-drug	Fluvoxamine
O	Tablets
O	.

B-group	Antimycobacterial
I-group	Agents
O	:
B-drug	rifampin
O	CONTRAINDICATED
O	since
O	the
O	coadministration
O	of
O	this
O	product
O	with
B-drug	saquinavir
O	in
O	an
B-group	antiretroviral
O	regimen
O	reduces
O	the
O	plasma
O	concentrations
O	of
B-drug	saquinavir
O	.

B-drug	Ethyl
I-drug	alcohol
O	is
O	known
O	to
O	effect
O	the
O	functional
O	integrity
O	of
O	the
O	limbic
O	system
O	,
O	particularly
O	the
O	hippocampus
O	,
O	and
O	to
O	alter
O	behaviors
O	which
O	are
O	thought
O	to
O	be
O	mediated
O	through
O	limbic
O	function
O	.

O	Prothrombin
O	times
O	were
O	not
O	affected
O	by
B-drug	tiagabine
O	.

O	The
O	specific
O	pharmacokinetic
O	changes
O	that
O	occur
O	with
O	co-administration
O	of
B-drug	nevirapine
O	and
O	other
O	drugs
O	are
O	listed
O	in
O	CLINICAL
O	PHARMACOLOGY
O	,
O	Table
O	1
O	.

O	No
O	formal
O	drug
O	interaction
O	studies
O	have
O	been
O	performed
O	with
B-brand	RAPTIVA
O	.

O	The
O	disposition
O	of
B-drug	theophylline
O	was
O	not
O	altered
O	by
O	concomitant
B-drug	cetirizine
O	administration
O	.

O	.

O	Toxicodynamic
O	interference
O	between
O	solvents
O	can
O	give
O	rise
O	to
O	additive
O	,
O	potentiation
O	,
O	synergistic
O	,
O	antagonistic
O	effects
O	.

O	Similarly
O	,
B-drug	nateglinide
O	had
O	no
O	influence
O	on
O	the
O	serum
O	protein
O	binding
O	of
B-drug	propranolol
O	,
B-drug	glyburide
O	,
B-drug	nicardipine
O	,
B-drug	warfarin
O	,
B-drug	phenytoin
O	,
B-drug	acetylsalicylic
I-drug	acid
O	,
O	and
B-drug	tolbutamide
O	in
O	vitro
O	.

B-brand	Dantrium
O	is
O	metabolized
O	by
O	the
O	liver
O	,
O	and
O	it
O	is
O	theoretically
O	possible
O	that
O	its
O	metabolism
O	may
O	be
O	enhanced
O	by
O	drugs
O	known
O	to
O	induce
O	hepatic
O	microsomal
O	enzymes
O	.

O	Oral
B-drug	neomycin
O	inhibits
O	the
O	gastrointestinal
O	absorption
O	of
B-drug	penicillin
I-drug	V
O	,
O	oral
B-drug	vitamin
I-drug	B-12
O	,
B-drug	methotrexate
O	and
B-drug	5-fluorouracil
O	.

O	If
O	concomitant
O	treatment
O	with
B-drug	sumatriptan
O	and
O	an
B-group	SSRI
O	(
O	e.g.
O	,
B-drug	fluoxetine
O	,
B-drug	fluvoxamine
O	,
B-drug	paroxetine
O	,
B-drug	sertraline
O	,
B-drug	citalopram
O	,
B-drug	escitalopram
O	)
O	is
O	clinically
O	warranted
O	,
O	appropriate
O	observation
O	of
O	the
O	patient
O	is
O	advised
O	.

O	however
O	,
O	the
O	second
O	contraction
O	was
O	potentiated
O	.

O	Nevertheless
O	,
O	caution
O	is
O	indicated
O	in
O	the
O	co-administration
O	of
O	TCA5
O	with
O	any
O	of
O	the
B-group	SSRIs
O	and
O	also
O	in
O	switching
O	from
O	one
O	class
O	to
O	the
O	other
O	.

O	-
O	a
B-group	beta-blocker
O	such
O	as
B-drug	propranolol
O	(
B-brand	Inderal
O	)
O	,
B-drug	atenolol
O	(
B-brand	Tenormin
O	)
O	,
B-drug	acebutolol
O	(
B-brand	Sectral
O	)
O	,
B-drug	metoprolol
O	(
B-brand	Lopressor
O	)
O	,
O	and
O	others
O	;

O	Caution
O	is
O	recommended
O	in
O	patients
O	with
O	hepatic
O	impairment
O	.

O	transaminases
O	(
O	AST

O	In
O	this
O	study
O	there
O	was
O	no
O	evidence
O	of
O	a
O	blunting
O	of
O	the
O	antihypertensive
O	action
O	of
B-brand	VASOTEC
O	.

O	The
O	effects
O	of
B-drug_n	DCG-IV
O	were
O	very
O	strong
O	and
O	completely
O	depressed
O	the
B-drug_n	PCP-induced
O	hyperlocomotion
O	.

B-drug	Carbamazepine

O	It
O	is
O	recommended
O	that
O	glucose
O	tests
O	based
O	on
O	enzymatic
O	glucose
O	oxidase
O	reactions
O	(
O	such
O	as
O	Clinistix
O	**
O	or
O	Tes-Tape
O	**
O	)
O	be
O	used
O	.

O	Therefore
O	,
O	concomitant
O	use
O	of
B-drug	ribavirin
O	with
O	either
O	of
O	these
O	drugs
O	should
O	be
O	avoided
O	.

O	No
O	trials
O	specifically
O	examining
O	potential
O	drug
O	interactions
O	with
B-brand	Natrecor
O	were
O	conducted
O	,
O	although
O	many
O	concomitant
O	drugs
O	were
O	used
O	in
O	clinical
O	trials
O	.

B-drug	Theophylline
O	:
O	A
O	single
O	10
O	mg
O	dose
O	of
B-drug	tiagabine
O	did
O	not
O	affect
O	the
O	pharmacokinetics
O	of
B-drug	theophylline
O	at
O	steady
O	state
O	.

B-drug	Valproic
I-drug	acid
O	diminished
O	binding
O	of
B-drug	phenobarbital
O	by
O	a
O	net
O	change
O	of
O	9.9
O	%
O	(
O	percentage
O	increase
O	in
O	FDF
O	,
O	21.2
O	%
O	)
O	at
O	1732
O	micromol/L
O	.

B-drug_n	Ibogaine
O	produces
O	whole
O	body
O	tremors
O	and
O	,
O	at
O	high
O	doses
O	(
O	>
O	or
O	=
O	100
O	mg/kg
O	)
O	,
O	cerebellar
O	damage
O	;

O	The
O	use
O	of
B-brand	NIMBEX
O	before
B-drug	succinylcholine
O	to
O	attenuate
O	some
O	of
O	the
O	side
O	effects
O	of
B-drug	succinylcholine
O	has
O	not
O	been
O	studied
O	.

O	Additionally
O	,
B-drug	saquinavir
O	is
O	a
O	substrate
O	for
O	P-Glycoprotein
O	(
O	Pgp
O	)
O	.

O	[
O	The
O	GABA-ergic
O	system
O	and
O	brain
O	edema
O	]
O	It
O	has
O	been
O	shown
O	in
O	rats
O	with
O	experimental
O	toxic
O	and
O	traumatic
O	edemas
O	that
B-drug_n	picrotoxin
O	(
O	1
O	mg/kg
O	)
O	removes
O	the
O	antiedematous
O	action
O	of
B-drug	diazepam
O	,
B-drug_n	phenazepam
O	,
B-drug_n	phenibut
O	and
B-drug_n	amizyl
O	and
O	reduces
O	the
O	action
O	of
B-drug	phentolamine
O	.

O	Patients
O	on
B-group	warfarin-type
I-group	anticoagulant
O	therapy
O	may
O	require
O	dosage
O	adjustment
O	of
O	the
O	anticoagulant
O	during
O	and
O	after
B-drug	griseofulvin
O	therapy
O	.

O	Concomitant
O	administration
O	of
B-drug	rifampin
O	with
B-drug	ketoconazole
O	tablets
O	reduces
O	the
O	blood
O	levels
O	of
O	the
O	latter
O	.

O	No
O	data
O	are
O	available
O	regarding
O	interactions
O	with
O	other
O	drugs
O	that
O	have
O	renal
O	clearance
O	mechanisms
O	similar
O	to
O	that
O	of
B-drug	lamivudine
O	.

O	In
O	13-day-old
O	embryos
O	,
B-drug	glycine
O	was
O	ineffective
O	in
O	both
O	doses
O	.

B-drug	Triazolam
O	:
B-drug	Erythromycin
O	has
O	been
O	reported
O	to
O	decrease
O	the
O	clearance
O	of
B-drug	triazolam
O	and
O	,
O	thus
O	,
O	may
O	increase
O	the
O	pharmacologic
O	effect
O	of
B-drug	triazolam
O	.

O	(
B-group	Thiazide
I-group	diuretics
O	may
O	raise
O	blood
O	glucose
O	levels
O	;

O	Consequently
O	,
O	the
O	combination
O	of
B-drug	methotrexate
O	with
B-drug	acitretin
O	is
O	also
O	contraindicated
O	.

O	The
O	role
O	of
B-drug	norepinephrine
O	uptake-1
O	was
O	studied
O	in
O	electrically
O	stimulated
O	(
O	1
O	Hz
O	,
O	37
O	degrees
O	C
O	)
O	human
O	ventricular
O	cardiac
O	preparations
O	and
O	isolated
O	myocardial
O	membranes
O	.

O	Drugs
O	that
O	induce
O	CYP3A4
O	activity
O	would
O	be
O	expected
O	to
O	increase
O	the
O	clearance
O	of
B-drug	indinavir
O	,
O	resulting
O	in
O	lowered
O	plasma
O	concentrations
O	of
B-drug	indinavir
O	.

B-drug	Fluconazole
O	:
O	Concomitant
O	administration
O	of
B-drug	fluconazole
O	at
O	200
O	mg
O	QD
O	resulted
O	in
O	a
O	two-fold
O	increase
O	in
B-drug	celecoxib
O	plasma
O	concentration
O	.

B-brand	Starlix
O	is
O	a
O	potential
O	inhibitor
O	of
O	the
O	CYP2C9
O	isoenzyme
O	in
O	vivo
O	as
O	indicated
O	by
O	its
O	ability
O	to
O	inhibit
O	the
O	in
O	vitro
O	metabolism
O	of
B-drug	tolbutamide
O	.

O	Healthcare
O	prescribers
O	are
O	advised
O	to
O	consult
O	the
O	package
O	inserts
O	of
O	medication
O	administered
O	concomitantly
O	with
O	oral
B-group	contraceptives
O	.

O	Catecholamine-depleting
O	Agents
O	:
O	Patients
O	taking
O	both
B-group	agents
I-group	with
I-group	b-blocking
I-group	properties
O	and
O	a
O	drug
O	that
O	can
O	deplete
O	catecholamines
O	(
O	e.g.
O	,
B-drug	reserpine
O	and
B-group	monoamine
I-group	oxidase
I-group	inhibitors
O	)
O	should
O	be
O	observed
O	closely
O	for
O	signs
O	of
O	hypotension
O	and/or
O	severe
O	bradycardia
O	.

O	Drugs
O	Metabolized
O	by
O	CYP3A
O	:
O	Results
O	of
O	in
O	vitro
O	studies
O	demonstrate
O	that
B-drug	duloxetine
O	does
O	not
O	inhibit
O	or
O	induce
O	CYP3A
O	activity
O	.

B-drug	astemizole
O	,
B-drug	bepridil
O	,
B-drug	sparfloxacin
O	,
O	and
B-drug	terodiline
O	.

O	for
O	adult-onset
O	diabetics
O	,
O	dosage
O	adjustment
O	of
B-group	hypoglycemic
I-group	medications
O	may
O	be
O	necessary
O	during
O	and
O	after
B-group	thiazide
I-group	diuretic
O	therapy
O	;

B-group	Beta
I-group	Blockers
O	:
O	Although
O	the
O	results
O	of
O	a
O	clinical
O	study
O	did
O	not
O	indicate
O	a
O	safe
O	problem
O	associated
O	with
O	the
O	administration
O	of
B-brand	D.H.E
I-brand	.
I-brand	45
O	(
B-drug	dihydroergotamine
I-drug	mesylate
O	)
O	Injection
O	,
O	USP
O	to
O	subjects
O	already
O	receiving
B-drug	propranolol
O	,
O	there
O	have
O	been
O	reports
O	that
B-drug	propranolol
O	may
O	potentiate
O	the
O	vasoconstrictive
O	action
O	of
B-drug	ergotamine
O	by
O	blocking
O	the
O	vasodilating
O	property
O	of
O	epinephrine
O	.

O	May
O	interact
O	with
O	skin
O	products
O	or
O	shampoos
O	for
O	dandruff
O	or
O	psoriasis
O	.

O	No
O	data
O	are
O	available
O	for
O	the
O	coadministration
O	of
B-brand	INVIRASE/ritonavir
O	or
B-brand	FORTOVASE/ritonavir
O	and
O	garlic
O	capsules
O	.

O	There
O	was
O	no
O	evidence
O	of
O	toxicity
O	.

B-brand	BROVANA
O	,
O	as
O	with
O	other
B-group	beta2-agonists
O	,
O	should
O	be
O	administered
O	with
O	extreme
O	caution
O	to
O	patients
O	being
O	treated
O	with
B-group	monoamine
I-group	oxidase
I-group	inhibitors
O	,
B-group	tricyclic
I-group	antidepressants
O	,
O	or
O	drugs
O	known
O	to
O	prolong
O	the
O	QTc
O	interval
O	because
O	the
O	action
O	of
B-group	adrenergic
I-group	agonists
O	on
O	the
O	cardiovascular
O	system
O	may
O	be
O	potentiated
O	by
O	these
O	agents
O	.

O	Drug
O	laboratory
O	Test
O	Interactions
O	Serum
O	Salicylate
O	Assays
O	:
O	Caution
O	should
O	be
O	used
O	in
O	interpreting
O	the
O	results
O	of
O	serum
O	salicylate
O	assays
O	when
B-drug	diflunisal
O	is
O	present
O	.

B-brand	CANCIDAS
O	did
O	not
O	increase
O	the
O	plasma
O	levels
O	of
B-drug	cyclosporine
O	.

B-drug	Levetiracetam
O	and
O	its
O	major
O	metabolite
O	,
O	at
O	concentrations
O	well
O	above
O	cmax
O	levels
O	achieved
O	within
O	the
O	therapeutic
O	dose
O	range
O	,
O	are
O	neither
O	inhibitors
O	of
O	nor
O	high
O	affinity
O	substrates
O	for
O	human
O	liver
O	cytochrome
O	P450
O	isoforms
O	,
O	epoxide
O	hydrolase
O	or
O	UDP-glucuronidation
O	enzymes
O	.

B-group	Beta-adrenergic
I-group	blocking
I-group	agents
O	:
O	Coadministration
O	of
B-group	beta-adrenergic
I-group	blocking
I-group	agents
O	did
O	not
O	have
O	any
O	effect
O	on
O	either
O	the
O	safety
O	or
O	efficacy
O	of
B-drug	ibutilide
O	in
O	the
O	clinical
O	trials
O	.

O	co-administration
O	of
B-drug	phenytoin
O	may
O	produce
O	a
O	synergistic
O	anticonvulsant
O	action
O	.

O	whereas
O	urinary
O	excretion
O	was
O	decreased
O	in
O	both
O	cases
O	.

O	A
O	drug-drug
O	interaction
O	study
O	evaluated
O	the
O	effect
O	of
O	the
O	use
O	of
B-brand	ACZONE
O	Gel
O	,
O	5
O	%
O	,
O	in
O	combination
O	with
O	double
O	strength
O	(
O	160
O	mg/800
O	mg
O	)
B-drug	trimethoprim/sulfamethoxazole
O	(
B-drug	TMP/SMX
O	)
O	.

O	An
O	intravenous
O	dose
O	of
O	50
O	mg
B-drug_n	perchlorate
O	was
O	in
O	respect
O	of
O	competitive
O	suppression
O	of
O	organs
O	actively
O	concentrating
B-drug	pertechnetate
O	as
O	effective
O	as
O	intravenous
O	1000
O	mg
O	ClO-4-
O	simultaneously
O	or
O	1000
O	mg
O	orally
O	30
O	min
O	before
O	the
O	injection
O	of
B-drug	radiopertechnetate
O	.

O	The
O	glucocorticoid-induced
O	gene
O	transcription
O	was
O	strongly
O	suppressed
O	by
O	synthetic
O	alkyl
O	esters
O	;

O	Administration
O	of
B-drug	diltiazem
I-drug	hydrochloride
O	concomitantly
O	with
B-drug	propranolol
O	in
O	five
O	normal
O	volunteers
O	resulted
O	in
O	increased
B-drug	propranolol
O	levels
O	in
O	all
O	subjects
O	and
O	bioavailability
O	of
B-drug	propranolol
O	was
O	increased
O	approximately
O	50
O	%
O	.

O	In
O	patients
O	in
O	whom
O	CYP3A4
O	inducers
O	(
O	eg
O	,
B-drug	dexamethasone
O	,
B-drug	phenytoin
O	,
B-drug	carbamazepine
O	,
B-drug	rifampicin
O	,
B-drug	phenobarbital
O	)
O	are
O	indicated
O	,
O	alternative
O	agents
O	with
O	less
O	enzyme
O	induction
O	potential
O	should
O	be
O	used
O	.

O	There
O	is
O	no
O	evidence
O	that
B-drug	EPA
O	supplements
O	have
O	detrimental
O	effects
O	on
O	glucose
O	tolerance
O	,
O	insulin
O	secretion
O	or
O	insulin
O	resistance
O	in
O	non-diabetic
O	subjects
O	.

O	The
O	behavioral
O	effects
O	of
O	the
O	stereoisomers
O	of
B-drug_n	N-allylnormetazocine
O	(
B-drug_n	NANM
O	)
O	were
O	compared
O	with
O	those
O	of
B-drug_n	phencyclidine
O	(
B-drug_n	PCP
O	)
O	in
O	pigeons
O	and
O	squirrel
O	monkeys
O	responding
O	under
O	a
O	multiple
O	fixed-interval
O	fixed-ratio
O	(
O	FI
O	FR
O	)
O	schedule
O	of
O	food
O	presentation
O	.

O	The
O	pharmacokinetics
O	and
O	protein
O	binding
O	of
B-drug	fosphenytoin
O	,
B-drug	phenytoin
O	,
O	and
B-drug	diazepam
O	were
O	not
O	altered
O	when
B-drug	diazepam
O	and
B-brand	Cerebyx
O	were
O	concurrently
O	administered
O	in
O	single
O	submaximal
O	doses
O	.

O	Since
O	higher
O	doses
O	of
B-drug	ketoconazole
O	(
O	400
O	mg
O	daily
O	)
O	may
O	result
O	in
O	higher
O	increases
O	in
O	Cmax
O	and
O	AUC
O	,
O	a
O	single
O	2.5
O	mg
O	dose
O	of
B-drug	Vardenafil
O	should
O	not
O	be
O	exceeded
O	in
O	a
O	24-hour
O	period
O	when
O	used
O	in
O	combination
O	with
B-drug	ketoconazole
O	400
O	mg
O	daily
O	.

O	Also
O	,
O	concomitant
O	administration
O	of
B-group	quinolones
O	with
O	products
O	containing
B-drug	iron
O	,
B-group	multivitamins
O	containing
B-drug	zinc
O	,
O	or
B-brand	Videx
O	(
B-drug	didanosine
O	)
O	chewable/buffered
O	tablets
O	or
O	the
O	pediatric
O	powder
O	for
O	oral
O	solution
O	may
O	result
O	in
O	low
O	urine
O	levels
O	.

O	The
O	risk
O	of
O	this
O	interaction
O	may
O	be
O	reduced
O	if
B-drug	digoxin
O	is
O	given
O	as
O	capsules
O	.

B-drug	CHOLESTYRAMINE
O	:
O	The
O	influence
O	of
O	the
O	bile-acidsequestering
O	agent
B-drug	cholestyramine
O	on
O	the
O	pharmacokinetits
O	of
B-drug	cerivastatin
I-drug	sodium
O	was
O	evaluated
O	in
O	12
O	healthy
O	males
O	in
O	2
O	separate
O	randomized
O	crossover
O	studies
O	.

B-drug	Cimetidine
O	:
B-drug	Cimetidine
O	increases
B-drug	nicardipine
I-drug	HCl
O	plasma
O	levels
O	.

O	Catecholamine-depleting
O	drugs
O	,
O	e.g.
O	,
B-drug	reserpine
O	,
O	may
O	have
O	an
O	additive
O	effect
O	when
O	given
O	with
B-group	beta
I-group	blocking
I-group	agents
O	.

O	Higher
O	dosage
O	of
O	oral
B-group	hypoglycemic
I-group	agents
O	may
O	be
O	required
O	.

O	(
O	In
O	some
O	patients
O	,
O	the
B-group	steroidal
I-group	anti-inflammatory
I-group	agent
O	can
O	reduce
O	the
O	diuretic
O	,
O	natriuretic
O	,
O	and
O	antihypertensive
O	effects
O	of
O	loop
O	,
O	potassium
O	sparing
O	,
O	and
B-group	thiazide
I-group	diuretics
O	.

O	Care
O	should
O	be
O	taken
O	if
B-drug	labetalol
O	is
O	used
O	concomitantly
O	with
B-group	calcium
O	antagonists
O	of
O	the
B-drug	verapamil
O	type
O	.

O	There
O	are
O	reports
O	of
O	enhanced
O	as
O	well
O	as
O	diminished
O	effects
O	of
B-group	anticoagulants
O	when
O	given
O	concurrently
O	with
B-group	corticosteroids
O	.

O	Effect
O	of
B-drug	probenecid
O	on
O	the
O	apparent
O	volume
O	of
O	distribution
O	and
O	elimination
O	of
B-drug	cloxacillin
O	.

O	They
O	may
O	be
O	administered
O	alternately
O	when
O	the
O	preceding
O	effect
O	of
O	other
O	such
O	drug
O	has
O	subsided
O	.

O	The
O	role
O	of
B-brand	AMEVIVE
O	in
O	the
O	development
O	of
O	the
O	lymphoid
O	malignancy
O	and
O	the
O	hyperplasia
O	observed
O	in
O	non-human
O	primates
O	and
O	the
O	relevance
O	to
O	humans
O	is
O	unknown
O	.

O	Impaired
O	glucose
O	tolerance
O	.

I-drug	ethinyl
I-drug	estradiol
O	concentration

O	There
O	was
O	a
O	small
O	decrease
O	in
O	the
O	clearance
O	of
B-drug	cetirizine
O	caused
O	by
O	a
O	400-mg
O	dose
O	of
B-drug	theophylline
O	;

O	These
O	drugs
O	should
O	be
O	coadministered
O	with
O	caution
O	,
O	and
O	frequent
O	monitoring
O	of
O	serum
B-drug	lithium
O	levels
O	is
O	recommended
O	.

B-drug	Alcohol
O	(
O	increases
O	bioavailability
O	by
O	50
O	%
O	)
O	,
B-drug	cimetidine
O	,
O	and
O	valproates
O	.

O	Other
O	:
O	Instances
O	of
O	rash
O	,
O	pruritus
O	,
O	ankle
O	edema
O	,
O	excessive
O	perspiration
O	,
O	weight
O	gain
O	,
O	nasal
O	congestion
O	.

O	Therefore
O	,
B-group	MAO
I-group	inhibitors
O	should
O	be
O	discontinued
O	at
O	least
O	two
O	weeks
O	prior
O	to
O	the
O	cautious
O	initiation
O	of
O	therapy
O	with
B-brand	SINEQUAN
O	.

B-drug	Cimetidine

B-drug	ADL
I-drug	8-2698
O	,
O	a
O	trans-3,4-dimethyl-4-
O	(
O	3-hydroxyphenyl
O	)
O	piperidine
O	,
O	prevents
O	gastrointestinal
O	effects
O	of
O	intravenous
B-drug	morphine
O	without
O	affecting
O	analgesia
O	.

O	The
O	change
O	in
B-drug	furosemide
O	clearance
O	value
O	is
O	not
O	likely
O	to
O	be
O	clinically
O	significant
O	.

B-drug	Methotrexate
O	-
O	There
O	is
O	one
O	report
O	that
B-drug	methotrexate
O	may
O	decrease
O	the
O	possible
O	effectiveness
O	of
O	supplemental
B-drug	L-glutamine
O	for
O	chemotherapy-induced
O	mucositis
O	.

B-drug	Methadone

O	Plasma
O	concentrations
O	and
O	effects
O	potentially
O	increased
O	or
O	decreased
O	by
B-brand	SUSTIVA
O	.

O	The
O	clearance
O	by
O	means
O	of
B-drug_n	4-hydroxytolbutamide
O	and
B-drug_n	carboxytolbutamide
O	was
O	significantly
O	reduced
O	in
O	both
O	groups
O	(
O	ie
O	,
O	from
O	901
O	mL/h
O	to
O	318
O	mL/h
O	in
O	the
O	group
O	that
O	received
O	150
O	mg
O	of
B-drug	tolbutamide
O	per
O	day
O	and
O	from
O	723
O	mL/h
O	to
O	457
O	mL/h
O	in
O	the
O	group
O	that
O	received
O	75
O	mg
O	of
B-drug	tolbutamide
O	per
O	day
O	)
O	.

B-brand	Aspirin
O	:
O	Concurrent
O	administration
O	of
B-brand	aspirin
O	and
B-drug	flurbiprofen
O	resulted
O	in
O	50
O	%
O	lower
O	serum
B-drug	flurbiprofen
O	concentrations
O	.

O	Therefore
O	,
O	simultaneous
O	use
O	of
O	creams
O	,
O	ointments
O	or
O	oils
O	should
O	be
O	avoided
O	.

B-brand	Aspirin
O	,
B-drug	warfarin
O	,
B-drug	heparin
O	,
B-group	NSAIDs

O	Approximately
O	2/3
O	of
O	the
O	patients
O	in
O	the
O	Phase
O	3
O	study
O	received
O	either
O	prophylactic
O	low
O	dose
B-drug	heparin
O	(
B-drug	unfractionated
I-drug	heparin
O	up
O	to
O	15,000
O	units/day
O	)
O	or
O	prophylactic
O	doses
O	of
B-group	low
I-group	molecular
I-group	weight
I-group	heparins
O	as
O	indicated
O	in
O	the
O	prescribing
O	information
O	for
O	the
O	specific
O	products
O	.

O	Patients
O	receiving
B-brand	SPRYCEL
O	should
O	not
O	take
O	St.
O	Johns
O	wort
O	.

O	Alternatively
O	,
O	provide
O	medical
O	supervision
O	for
O	at
O	least
O	one
O	hour
O	after
O	the
O	initial
O	dose
O	.

O	The
O	effects
O	of
B-group	HMG-CoA
I-group	reductase
I-group	inhibitors
O	on
O	male
O	fertility
O	have
O	not
O	been
O	studied
O	in
O	adequate
O	numbers
O	of
O	patients
O	.

O	No
O	drug
O	,
O	nutritional
O	supplement
O	,
O	food
O	or
O	herb
O	interactions
O	are
O	known
O	.

O	In
O	long
O	surgical
O	procedures
O	during
B-drug	enflurane
O	or
B-drug	isoflurane
O	anesthesia
O	,
O	less
O	frequent
O	maintenance
O	dosing
O	,
O	lower
O	maintenance
O	doses
O	,
O	or
O	reduced
O	infusion
O	rates
O	of
B-brand	NIMBEX
O	may
O	be
O	necessary
O	.

O	Other
O	substances
O	:
O	Grapefruit
O	juice
O	given
O	to
O	healthy
O	volunteers
O	increased
B-drug	amiodarone
O	AUC
O	by
O	50
O	%
O	and
O	Cmax
O	by
O	84
O	%
O	,
O	resulting
O	in
O	increased
O	plasma
O	levels
O	of
B-drug	amiodarone
O	.

O	With
O	simultaneous
O	dosing
O	of
B-drug	Vardenafil
O	20
O	mg
O	and
B-drug	terazosin
O	10
O	mg
O	,
O	2
O	of
O	9
O	subjects
O	experienced
O	a
O	standing
O	systolic
O	blood
O	pressure
O	of
O	less
O	than
O	85
O	mm
O	Hg
O	.

B-drug	Auranofin
O	should
O	not
O	be
O	used
O	together
O	with
B-drug	penicillamine
O	(
B-brand	Depen
O	,
B-brand	Cuprimine
O	)
O	,
O	another
O	arthritis
O	medication
O	.

O	This
O	practice
O	resulted
O	in
O	no
O	apparent
O	increase
O	in
O	local
O	breast
O	cancer
O	recurrence
O	relative
O	to
O	published
O	accounts
O	in
O	the
O	literature
O	.

O	Continuous
O	cardiac
O	monitoring
O	is
O	not
O	required
O	except
O	for
O	patients
O	with
O	serious
O	conduction
O	abnormalities
O	.

O	Agents
O	Affecting
O	Cytochrome
O	P450
O	3A4
O	Isoenzyme
O	System
B-drug	Fentanyl
O	is
O	metabolized
O	mainly
O	via
O	the
O	human
O	cytochrome
O	P450
O	3A4
O	isoenzyme
O	system
O	(
O	CYP3A4
O	)
O	,
O	therefore
O	potential
O	interactions
O	may
O	occur
O	when
B-brand	DURAGESIC
O	is
O	given
O	concurrently
O	with
O	agents
O	that
O	affect
O	CYP3A4
O	activity
O	.

B-drug_n	Thiolated
I-drug_n	carboxymethylcellulose
O	:
O	in
O	vitro
O	evaluation
O	of
O	its
O	permeation
O	enhancing
O	effect
O	on
O	peptide
O	drugs
O	.

B-drug	Ethoxzolamide
O	may
O	increase
O	the
O	action
O	of
B-group	tricyclics
O	,
B-group	amphetamines
O	,
B-drug	procainamide
O	,
O	and
B-drug	quinidine
O	.

O	General
O	:
O	Significant
O	interactions
O	may
O	occur
O	when
B-drug	celecoxib
O	is
O	administered
O	together
O	with
O	drugs
O	that
O	inhibit
O	P450
O	2C9
O	.

O	Commonly
O	used
O	drugs
O	such
O	as
B-drug	phenylpropanolamine
O	and
B-drug	pseudoephedrine
O	have
O	been
O	specifically
O	studied
O	.

O	May
O	interact
O	with
O	the
O	following
O	:
B-group	beta-adrenergic
I-group	blocking
I-group	agents
O	(
O	these
O	medicines
O	may
O	make
O	your
O	condition
O	worse
O	and
O	prevent
O	the
B-group	adrenergic
I-group	bronchodilators
O	from
O	working
O	properly
O	)
O	and
B-drug	disopyramide
O	,
B-drug	quinidine
O	,
B-group	phenothiazines
O	,
O	and
B-drug	procainamide
O	(
O	these
O	medicines
O	may
O	increase
O	the
O	risk
O	of
O	heart
O	problems
O	)
O	.

O	However
O	,
O	in
O	another
O	study
O	in
O	healthy
O	volunteers
O	,
O	the
O	pharmacokinetics
O	of
B-drug	butorphanol
O	were
O	significantly
O	altered
O	(
O	29
O	%
O	decrease
O	in
O	AUC
O	and
O	38
O	%
O	decrease
O	in
O	Cmax
O	)
O	when
O	a
O	1-mg
O	dose
O	of
B-brand	STADOL
I-brand	NS
O	was
O	administered
O	1
O	minute
O	after
O	a
O	20-mg
O	dose
O	of
B-drug	sumatriptan
O	nasal
O	spray
O	.

O	(
O	The
O	two
O	drugs
O	were
O	administered
O	in
O	opposite
O	nostrils
O	.
O	)

O	Limited
O	data
O	in
O	patients
O	receiving
O	known
O	enzyme
O	inducers
O	(
B-drug	phenytoin
O	,
B-drug	phenobarbital
O	,
B-drug	carbamazepine
O	)
O	indicate
O	only
O	a
O	30
O	%
O	increase
O	in
O	the
O	rate
O	of
B-drug	flecainide
O	elimination
O	.

O	Dosage
O	of
O	the
O	drugs
O	mentioned
O	above
O	and
O	other
O	similarly
O	metabolized
O	drugs
O	,
O	particularly
O	those
O	of
O	low
O	therapeutic
O	ratio
O	or
O	in
O	patients
O	with
O	renal
O	and/or
O	hepatic
O	impairment
O	,
O	may
O	require
O	adjustment
O	when
O	starting
O	or
O	stopping
O	concomitantly
O	administered
B-brand	Tagamet
O	to
O	maintain
O	optimum
O	therapeutic
O	blood
O	levels
O	.

O	However
O	,
O	because
O	some
B-group	quinolones
O	have
O	been
O	reported
O	to
O	enhance
O	the
O	effects
O	of
B-drug	warfarin
O	or
O	its
O	derivatives
O	,
O	prothrombin
O	time
O	or
O	other
O	suitable
O	anticoagulation
O	test
O	should
O	be
O	monitored
O	closely
O	if
O	a
B-group	quinolone
I-group	antimicrobial
O	is
O	administered
O	with
B-drug	warfarin
O	or
O	its
O	derivatives
O	.

O	In
O	five
O	men
O	,
B-drug	terfenadine
O	levels
O	were
O	undetectable
O	(
O	5
O	ng/mL
O	)
O	throughout
O	the
O	study
O	;

O	Therefore
O	,
B-drug	chloroprocaine
O	should
O	not
O	be
O	used
O	in
O	any
O	condition
O	in
O	which
O	a
B-group	sulfonamide
I-group	drug
O	is
O	being
O	employed
O	.

B-brand	Pletal
O	does
O	not
O	,
O	however
O	,
O	appear
O	to
O	cause
O	increased
O	blood
O	levels
O	of
O	drugs
O	metabolized
O	by
O	CYP3A4
O	,
O	as
O	it
O	had
O	no
O	effect
O	on
B-drug	lovastatin
O	,
O	a
O	drug
O	with
O	metabolism
O	very
O	sensitive
O	to
O	C.P.A
O	.
O	inhibition
O	.

O	When
O	administering
O	other
O	drugs
O	for
O	which
O	alterations
O	in
O	blood
O	levels
O	could
O	have
O	a
O	clinically
O	significant
O	effect
O	on
O	safety
O	or
O	efficacy
O	,
O	physicians
O	should
O	consider
O	monitoring
O	drug
O	levels
O	or
O	effects
O	.

O	Tacrolimus
B-drug	Felodipine
O	may
O	increase
O	the
O	blood
O	concentration
O	of
B-drug	tacrolimus
O	.

O	Drugs
O	That
O	Inhibit
B-drug	Alprazolam
O	Metabolism
O	Via
O	Cytochrome
O	P450
O	3A
O	:
O	The
O	initial
O	step
O	in
B-drug	alprazolam
O	metabolism
O	is
O	hydroxylation
O	catalyzed
O	by
O	cytochrome
O	P450
O	3A
O	(
O	CYP
O	3A
O	)
O	.

O	In
O	patients
O	who
O	have
O	received
B-group	muscle
I-group	relaxants
O	,
B-drug	doxapram
O	may
O	temporarily
O	mask
O	the
O	residual
O	effects
O	of
B-group	muscle
I-group	relaxant
I-group	drugs
O	.

O	Co-administration
O	of
B-drug	probenecid
O	with
B-drug	acyclovir
O	has
O	been
O	shown
O	to
O	increase
O	the
O	mean
O	half-life
O	and
O	the
O	area
O	under
O	the
O	concentration-time
O	curve
O	.

O	Pressor
O	agents
O	-
O	Because
O	of
O	possible
O	effects
O	on
O	blood
O	pressure
O	,
B-brand	STRATTERA
O	should
O	be
O	used
O	cautiously
O	with
O	pressor
O	agents
O	.

O	Increased
O	plasma
O	HDL
O	and
O	HDL2
O	cholesterol
O	subfraction
O	concentrations
O	,
O	reduced
O	LDL
O	cholesterol
O	concentration
O	,
O	increased
O	triglyceride
O	levels
O	.

B-group	Iron
I-group	Supplements
O	and
O	Foods
O	Fortified
O	With
B-drug	Iron
O	Concomitant
O	administration
O	of
B-drug	cefdinir
O	with
O	a
O	therapeutic
B-group	iron
I-group	supplement
O	containing
O	60
O	mg
O	of
O	elemental
B-drug	iron
O	(
O	as
O	FeSO4
O	)
O	or
B-group	vitamins
O	supplemented
O	with
O	10
O	mg
O	of
O	elemental
B-drug	iron
O	reduced
O	extent
O	of
O	absorption
O	by
O	80
O	%
O	and
O	31
O	%
O	,
O	respectively
O	.

O	Use
O	in
O	Conjunction
O	with
O	Other
B-group	Antiepileptic
I-group	Drugs
O	:
O	The
O	addition
O	of
B-brand	Felbatol
O	to
B-group	antiepileptic
I-group	drugs
O	(
B-group	AEDs
O	)
O	affects
O	the
O	steady-state
O	plasma
O	concentrations
O	of
B-group	AEDs
O	.

O	-
B-drug	isoniazid
O	(
B-brand	Nydrazid
O	)
O	;

O	Specific
O	Effects
O	of
B-brand	Felbatol
O	on
O	Other
B-group	Antiepileptic
I-group	Drugs
B-drug	Phenytoin
O	:
B-brand	Felbatol
O	causes
O	an
O	increase
O	in
O	steady-state
B-drug	phenytoin
O	plasma
O	concentrations
O	.

O	There
O	were
O	no
O	significant
O	effects
O	on
O	QTc
O	intervals
O	,
O	and
O	no
O	reports
O	of
O	sedation
O	or
O	syncope
O	.

O	monitor
O	closely
O	for
O	evidence
O	of
O	hypotension
O	and/or
O	excessive
O	bradycardia
O	(
O	e.g.
O	,
O	vertigo
O	,
O	syncope
O	,
O	postural
O	hypotension
O	)
O	.

O	Unmodified
B-drug_n	NaCMC
O	(
O	1
O	%
O	m/v
O	)
O	significantly
O	improved
O	the
O	transport
O	ratio
O	(
O	R=
O	P
O	(
O	app
O	)
O	polymer/
O	P
O	(
O	app
O	)
O	control
O	)
O	of
B-drug	NaFlu
O	to
O	1.3
O	and
O	1
O	%
O	(
O	m/v
O	)
B-drug_n	NaCMC
O	conjugated
O	with
B-drug	cysteine
O	further
O	enhanced
O	the
O	permeation
O	.

O	To
O	each
O	preparation
O	was
O	added
O	one
O	additional
O	drug
O	at
O	three
O	concentrations
O	ranging
O	from
O	therapeutic
O	to
O	toxic
O	.

O	To
O	investigate
O	the
O	effect
O	of
O	disease
O	states
O	or
O	concomitant
O	drug
O	administration
O	on
O	a
O	patient
O	's
O	response
O	to
B-drug	etodolac
O	,
O	additional
O	pharmacokinetic
O	studies
O	were
O	carried
O	out
O	in
O	special
O	populations
O	.

O	No
O	clinical
O	drug
O	interaction
O	studies
O	have
O	been
O	conducted
O	.

B-drug	Ergotamine
O	:
O	Concurrent
O	use
O	of
B-drug	erythromycin
O	and
B-drug	ergotamine
O	or
B-drug	dihydroergotamine
O	has
O	been
O	associated
O	in
O	some
O	patients
O	with
O	acute
O	ergot
O	toxicity
O	characterized
O	by
O	severe
O	peripheral
O	vasospasm
O	and
O	dysesthesia
O	.

O	Herbal
O	remedies
O	,
O	nephropathies
O	,
O	and
O	renal
O	disease
O	.

B-drug	Diclofenac
O	is
O	a
O	prostaglandin
O	synthetase
O	inhibitor
O	,
O	however
O	,
O	and
O	all
O	drugs
O	that
O	inhibit
O	prostaglandin
O	synthesis
O	interfere
O	with
O	platelet
O	function
O	to
O	some
O	degree
O	;

O	nonetheless
O	,
O	the
O	possibility
O	that
O	causative
O	factors
O	may
O	interact
O	synergistically
O	to
O	increase
O	the
O	risk
O	and/or
O	severity
O	of
O	bone
O	marrow
O	suppression
O	warrants
O	consideration
O	.

O	In
O	studies
O	in
O	female
O	rats
O	at
O	doses
O	0.01
O	mg/kg/day
O	(
O	IM
O	;

O	Mean
O	T
O	max
O	and
O	mean
O	plasma
O	elimination
O	half-life
O	of
B-drug	albendazole
I-drug	sulfoxide
O	were
O	unchanged
O	.

B-drug	Sildenafil
O	dose
O	should
O	not
O	exceed
O	a
O	maximum
O	of
O	25
O	mg
O	in
O	a
O	48-
O	hour
O	period
O	in
O	patients
O	receiving
O	concomitant
B-drug	indinavir
O	therapy
O	.

O	Herb/Nutraceutical
O	:
O	St
O	Johns
O	wort
O	may
O	decrease
O	the
O	effectiveness
O	of
B-group	combination
I-group	hormonal
I-group	contraceptives
O	by
O	inducing
O	hepatic
O	enzymes
O	.

O	urticaria

B-brand	Caverject
O	:
O	The
O	potential
O	for
O	pharmacokinetic
O	drug-drug
O	interactions
O	between
B-drug	alprostadil
O	and
O	other
O	agents
O	has
O	not
O	been
O	formally
O	studied
O	.

O	therefore
O	,
O	it
O	should
O	be
O	recognized
O	that
O	a
O	positive
O	Coombs
O	test
O	may
O	be
O	due
O	to
O	the
O	drug
O	.

O	Although
O	no
O	drug-drug
O	interaction
O	studies
O	have
O	been
O	conducted
O	in
O	vivo
O	,
O	it
O	is
O	expected
O	that
O	no
O	significant
O	interaction
O	would
O	occur
O	when
B-drug	nitazoxanide
O	is
O	co-administered
O	with
O	drugs
O	that
O	either
O	are
O	metabolized
O	by
O	or
O	inhibit
O	cytochrome
O	P450
O	enzymes
O	.

O	There
O	are
O	no
O	clinical
O	data
O	on
O	concomitant
O	use
O	of
B-brand	NUROMAX
O	and
O	other
O	nondepolarizing
B-group	neuromuscular
I-group	blocking
I-group	agents
O	.

O	Administration
O	of
B-group	thiazide
I-group	diuretics
O	to
O	hypoparathyroid
O	patients
O	who
O	are
O	concurrently
O	being
O	treated
O	with
B-drug	dihydrotachysterol
O	may
O	cause
O	hypercalcemia
O	.

B-group	antibiotics
O	;

O	These
O	agents
O	should
O	not
O	be
O	used
O	in
O	patients
O	treated
O	with
B-brand	NIZORAL
O	Tablets
O	.

B-drug	Amiodarone
O	,
B-drug	disopyramide
O	,
B-drug	lidocaine

O	The
O	pharmacokinetics
O	of
B-drug	ethanol
O	were
O	not
O	affected
O	by
O	multiple-dose
O	administration
O	of
B-drug	tiagabine
O	.

O	The
O	CNS
O	effects
O	of
B-drug	butalbital
O	may
O	be
O	enhanced
O	by
B-group	monoamine
I-group	oxidase
I-group	(
I-group	MAO
I-group	)
I-group	inhibitors
O	.

B-drug	Indinavir
O	may
O	be
O	taken
O	with
O	a
O	light
O	meal
O	1
O	h
O	following
O	the
O	administration
O	of
O	400
O	mg
O	of
B-drug	didanosine
O	.

B-group	Nitrates
O	:
O	The
O	concomitant
O	use
O	of
B-drug	Bepridil
O	with
O	long-
O	and
O	short-acting
B-group	nitrates
O	has
O	been
O	safely
O	tolerated
O	in
O	patients
O	with
O	stable
O	angina
O	pectoris
O	.

O	The
O	results
O	we
O	present
O	clearly
O	show
O	that
O	the
O	drug
O	alters
O	the
O	cellular
O	permeability
O	,
O	and
O	thus
O	the
O	exogenous
O	respiration
O	becomes
O	sensitive
O	to
O	the
O	drug
O	.

B-drug	Vardenafil
O	(
O	20
O	mg
O	)
O	did
O	not
O	potentiate
O	the
O	hypotensive
O	effects
O	of
B-drug	alcohol
O	during
O	the
O	4-hour
O	observation
O	period
O	in
O	healthy
O	volunteers
O	when
O	administered
O	with
B-drug	alcohol
O	(
O	0.5
O	g/kg
O	body
O	weight
O	)
O	.

O	In
O	addition
O	to
O	this
O	pharmacological
O	interaction
O	,
O	this
O	report
O	describes
O	a
O	novel
O	chemical
O	reaction
O	between
B-drug	temazepam
O	(
O	a
B-group	benzodiazepine
O	)
O	and
B-drug	ethanol
O	under
O	acidic
O	conditions
O	similar
O	to
O	those
O	found
O	in
O	vivo
O	,
O	resulting
O	in
O	a
O	3-ethoxylated
O	product
O	.

O	MEASUREMENTS
O	and
O	MAIN
O	RESULTS
O	:
O	Blood
O	samples
O	were
O	drawn
O	and
O	12-lead
O	electrocardiograms
O	performed
O	at
O	specified
O	time
O	points
O	after
O	the
O	last
O	morning
O	dose
O	of
B-drug	cisapride
O	in
O	phases
O	1
O	and
O	3
O	.

O	increased
O	liver

O	Still
O	other
O	pathways
O	have
O	been
O	proposed
O	.

B-group	Sympathomimetic
I-group	Agents
O	:
O	Possible
O	increased
O	risk
O	of
O	coronary
O	insufficiency
O	in
O	patients
O	with
O	coronary
O	artery
O	disease
O	.

O	In
O	addition
O	,
O	new
O	cases
O	of
O	diabetes
O	have
O	been
O	diagnosed
O	during
B-brand	Accutane
O	therapy
O	,
O	although
O	no
O	causal
O	relationship
O	has
O	been
O	established

O	This
O	may
O	potentiate
O	and
O	prolong
O	hypnotic
O	and
O	sedative
O	effects
O	,
O	especially
O	with
O	repeated
O	dosing
O	or
O	chronic
O	administration
O	of
O	these
O	agents
O	.

O	Several
O	of
O	the
B-group	tricyclic
I-group	antidepressants
O	have
O	been
O	cited
O	in
O	these
O	reports
O	.

O	Bleeding
O	from
O	a
O	number
O	of
O	sites
O	may
O	be
O	a
O	complication
O	of
B-drug	warfarin
O	treatment
O	and
O	GI
O	bleeding
O	a
O	complication
O	of
B-drug	ketoprofen
O	treatment
O	.

O	.

O	Between
O	1988
O	and
O	1993
O	,
O	more
O	than
O	7,000
O	patients
O	were
O	diagnosed
O	and
O	treated
O	.

O	Therefore
O	,
O	monitoring
O	of
B-drug	theophylline
O	plasma
O	levels
O	should
O	be
O	considered
O	and
O	dosage
O	of
B-drug	theophylline
O	adjusted
O	,
O	as
O	required
O	.

O	Both
O	CYP3A4
O	and
O	CYP2D6
O	are
O	responsible
O	for
B-drug	aripiprazole
O	metabolism
O	.

O	Separating
O	the
O	doses
O	of
B-group	antacid
O	and
B-drug	lomefloxacin
O	minimizes
O	this
O	decrease
O	in
O	bioavailability
O	;

B-group	TCAs
O	decrease
O	the
O	hypotensive
O	effect
O	of
B-drug	guanfacine
O	.

O	Poor
O	metabolizers
O	have
O	higher
O	than
O	expected
O	plasma
O	concentrations
O	of
B-group	tricyclic
I-group	antidepressants
O	(
B-group	TCAs
O	)
O	when
O	given
O	usual
O	doses
O	.

B-group	Non-selective
I-group	monoamine
I-group	oxidase
I-group	(
I-group	MAO
I-group	)
I-group	inhibitors
O	-
O	including
B-drug	phenelzine
I-drug	sulfate
O	,
B-drug	tranylcypromine
I-drug	sulfate
O	and
B-drug	pargyline
O	HC1
O	.

O	However
O	,
O	this
O	sample
O	size
O	is
O	too
O	small
O	to
O	allow
O	for
O	any
O	conclusions
O	to
O	be
O	drawn
O	regarding
O	the
O	risk
O	of
O	rashes
O	with
O	concomitant
B-brand	AUGMENTIN
I-brand	XR
O	and
B-drug	allopurinol
O	use
O	.

O	The
O	introductory
O	chapter
O	discusses
O	the
O	advantages
O	and
O	disadvantages
O	of
B-group	POCs
O	and
O	the
O	magnitude
O	and
O	prevalence
O	of
O	their
O	use
O	.

B-drug	Theophylline
O	:
O	The
O	effect
O	of
O	steady-state
B-drug	fluvoxamine
O	l50
O	mg
O	bid
O	on
O	the
O	pharmacokinetics
O	of
O	a
O	single
O	dose
O	of
B-drug	Theophylline
O	(
O	375
O	mg
O	)
O	as
O	442
O	mg
B-drug	aminophylline
O	was
O	evaluated
O	in
O	12
O	healthy
O	non-smoking
O	,
O	male
O	volunteers
O	.

O	The
O	effects
O	of
O	supplementary
O	oral
B-drug	cobalt
O	and
B-drug	iron
O	,
O	as
O	well
O	as
O	the
O	interaction
O	between
O	both
O	at
O	the
O	absorption
O	site
O	,
O	fecal
O	and
O	urinary
O	excretion
O	as
O	well
O	as
O	the
O	retention
O	of
O	these
O	trace
O	elements
O	were
O	determined
O	by
O	using
O	four
O	diets
O	containing
O	either
O	9
O	or
O	63
O	micrograms/kg
O	of
B-drug	Co
O	and
O	48
O	or
O	446
O	mg/kg
O	of
B-drug	Fe
O	over
O	a
O	period
O	of
O	19
O	days
O	in
O	a
O	total
O	of
O	24
O	rats
O	.

O	These
B-drug	fulvestrant
O	doses
O	correspond
O	to
O	approximately
O	2-
O	,
O	3-
O	,
O	and
O	3-fold
O	the
O	systemic
O	exposure
O	[
O	AUC0-30
O	days
O	]
O	achieved
O	in
O	women
O	.

O	This
O	review
O	discusses
O	the
O	actions
O	of
O	the
O	two
O	drugs
O	on
O	certain
O	brain
O	chemical
O	(
O	i.e.
O	,
O	neurotransmitter
O	)
O	systems
O	and
O	the
O	extent
O	to
O	which
O	the
O	effects
O	of
O	the
O	two
O	drugs
O	may
O	interact
O	.

B-drug	Cholestyramine
O	:
B-drug	Cholestyramine
O	binds
O	both
B-drug	T4
O	and
B-drug	T3
O	in
O	the
O	intestine
O	,
O	thus
O	impairing
O	absorption
O	of
O	these
B-group	thyroid
I-group	hormones
O	.

O	The
O	use
O	of
B-brand	Adenocard
O	in
O	patients
O	receiving
B-group	digitalis
O	may
O	be
O	rarely
O	associated
O	with
O	ventricular
O	fibrillation
O	.

B-drug	Cisapride

O	The
O	patient
O	was
O	also
O	chronically
O	receiving
B-drug	phenytoin
O	,
B-drug	phenobarbital
O	,
B-drug	digoxin
O	,
O	and
B-drug	levothyroxine
I-drug	sodium
O	.

O	Pregnancy
O	:
O	Category
O	X
O	:
O	Use
O	With
B-drug	Ribavirin
O	(
O	see
O	CONTRAINDICATIONS
O	)
O	Significant
O	teratogenic
O	and/or
O	embryocidal
O	effects
O	have
O	been
O	demonstrated
O	in
O	all
O	animal
O	species
O	exposed
O	to
B-drug	ribavirin
O	.

O	When
B-drug	Itraconazole
O	was
O	coadministered
O	with
B-drug	phenytoin
O	,
B-drug	rifampin
O	,
O	or
O	H2antagonists
O	,
O	reduced
O	plasma
O	concentrations
O	of
B-drug	itraconazole
O	were
O	reported
O	.

O	.

B-drug	phenytoin
O	;

B-drug	Azithromycin
O	had
O	no
O	significant
O	impact
O	on
O	the
O	Cmax
O	and
O	AUC
O	of
B-drug	zidovudine
O	,
O	although
O	it
O	significantly
O	decreased
O	the
B-drug	zidovudine
O	tmax
O	by
O	44
O	%
O	and
O	increased
O	the
O	intracellular
O	exposure
O	to
O	phosphorylated
B-drug	zidovudine
O	by
O	110
O	%
O	.

O	At
O	similar
O	median
O	follow-up
O	,
O	opportunistic
O	infection
O	(
O	OI
O	)
O	rates
O	and
O	mortality
O	were
O	significantly
O	lower
O	in
O	the
O	CHOP-HAART
O	patients
O	than
O	in
O	the
O	CHOP
O	patients
O	(
O	18
O	%
O	vs.
O	52
O	%
O	,
O	respectively
O	;
O	P
O	=
O	0.05
O	;
O	and
O	38
O	%
O	vs.
O	85
O	%
O	,
O	respectively
O	;
O	P
O	=
O	0.001
O	)
O	.

O	If
B-brand	ProSom
O	is
O	given
O	concomitantly
O	with
O	other
O	drugs
O	acting
O	on
O	the
O	central
O	nervous
O	system
O	,
O	careful
O	consideration
O	should
O	be
O	given
O	to
O	the
O	pharmacology
O	of
O	all
O	agents
O	.

O	Patients
O	taking
B-drug	Acamprosate
O	concomitantly
O	with
B-group	antidepressants
O	more
O	commonly
O	reported
O	both
O	weight
O	gain
O	and
O	weight
O	loss
O	,
O	compared
O	with
O	patients
O	taking
O	either
O	medication
O	alone
O	.

O	however
O	,
O	no
O	specific
O	drug
O	interaction
O	studies
O	have
O	been
O	performed
O	to
O	evaluate
O	potential
O	drug-drug
O	interaction
O	.

O	No
O	well-known
O	drug
O	interactions
O	with
B-drug	glutamic
I-drug	acid

O	It
O	was
O	established
O	that
O	both
O	angiotensins
O	inhibited
O	gastric
O	acid
O	secretion
O	stimulated
O	by
B-drug	pentagastrin
O	but
O	not
O	by
B-drug	histamine
O	.

O	As
O	with
O	other
O	agents
O	which
O	prolong
O	ECG
O	intervals
O	,
O	caution
O	should
O	be
O	exercised
O	in
O	patients
O	taking
O	drugs
O	which
O	prolong
O	ECG
O	intervals
O	,
O	particularly
O	QTc
O	.

O	Other
O	interactions
O	:
B-drug	Vardenafil
O	had
O	no
O	effect
O	on
O	the
O	pharmacodynamics
O	of
B-drug	glyburide
O	(
O	glucose
O	and
O	insulin
O	concentrations
O	)
O	and
B-drug	warfarin
O	(
O	prothrombin
O	time
O	or
O	other
O	pharmacodynamic
O	parameters
O	)
O	.

O	Patients
O	treated
O	with
B-brand	TENORMIN
O	plus
O	a
O	catecholamine
O	depletor
O	should
O	therefore
O	be
O	closely
O	observed
O	for
O	evidence
O	of
O	hypotension
O	and/or
O	marked
O	bradycardia
O	which
O	may
O	produce
O	vertigo
O	,
O	syncope
O	,
O	or
O	postural
O	hypotension
O	.

B-drug	diazoxide
O	;

B-brand	Aspirin
O	:
O	Concurrent
O	administration
O	of
B-brand	aspirin
O	may
O	lower
B-drug	meclofenamate
I-drug	sodium
O	plasma
O	levels
O	,
O	possibly
O	by
O	competing
O	for
O	protein-binding
O	sites
O	.

B-drug	Gentamicin
O	is
O	an
B-group	aminoglycoside
I-group	antibiotic
O	used
O	to
O	treat
O	a
O	wide
O	variety
O	of
O	infections
O	caused
O	by
O	gram-negative
O	organisms
O	,
O	but
O	it
O	is
O	potentially
O	toxic
O	to
O	the
O	kidneys
O	.

O	Drug/Laboratory
O	Test
O	Interactions
O	None
O	known
O	.

O	Interactions
O	attributed
O	to
O	the
O	combined
O	use
O	of
B-drug	baclofen
O	injection
O	and
O	epidural
B-drug	morphine
O	include
O	hypotension
O	and
O	dyspnea
O	.

B-group	Antiarrhythmics

B-drug	Isocarboxazid
O	should
O	be
O	administered
O	with
O	caution
O	to
O	patients
O	receiving
B-brand	Antabuse
O	(
B-drug	disulfiram
O	,
O	Wyeth-Ayerst
O	Laboratories
O	)
O	.

O	Since
B-drug	acetaminophen
O	in
O	high
O	doses
O	has
O	been
O	associated
O	with
O	hepatotoxicity
O	,
O	concomitant
O	administration
O	of
B-drug	diflunisal
O	and
B-drug	acetaminophen
O	should
O	be
O	used
O	cautiously
O	,
O	with
O	careful
O	monitoring
O	of
O	patients
O	.

O	The
O	appropriate
O	doses
O	for
O	this
O	combination
O	,
O	with
O	respect
O	to
O	efficacy
O	and
O	safety
O	,
O	have
O	not
O	been
O	established
O	.

O	These
O	observations
O	are
O	discussed
O	in
O	reference
O	to
O	possible
O	deleterious
O	effects
O	following
O	the
O	administration
O	of
B-drug	pargyline
O	to
O	patients
O	with
O	Parkinson
O	's
O	Disease
O	.

O	There
O	was
O	evidence
O	for
O	longitudinal
O	stability
O	in
O	AUC
O	of
B-drug	everolimus
O	during
O	the
O	course
O	of
O	the
O	study
O	.

O	It
O	is
O	recommended
O	that
O	the
O	combination
O	of
O	intravenous
B-drug	dantrolene
I-drug	sodium
O	and
B-group	calcium
I-group	channel
I-group	blockers
O	,
O	such
O	as
B-drug	verapamil
O	,
O	not
O	be
O	used
O	together
O	during
O	the
O	management
O	of
O	malignant
O	hyperthermia
O	crisis
O	until
O	the
O	relevance
O	of
O	these
O	findings
O	to
O	humans
O	is
O	established
O	.

B-drug	L-glutamine
O	has
O	orphan
O	drug
O	status
O	for
O	this
O	indication
O	.

O	BACKGROUND
O	:
O	The
O	feasibility
O	and
O	efficacy
O	of
O	concomitant
O	chemotherapy
O	and
B-group	highly
I-group	active
I-group	antiretroviral
O	therapy
O	(
O	HAART
O	)
O	is
O	still
O	unknown
O	in
O	patients
O	with
O	human
O	immunodeficiency
O	virus
O	(
O	HIV
O	)
O	-related
O	malignancies
O	.

O	Coadministration
O	of
B-brand	SULAR
O	with
B-drug	phenytoin
O	or
O	any
O	known
O	CYP3A4
O	inducer
O	should
O	be
O	avoided
O	and
O	alternative
B-group	antihypertensive
O	therapy
O	should
O	be
O	considered
O	.

O	The
O	concomitant
O	use
O	of
O	other
O	CYP3A4
O	inhibitors
O	such
O	as
B-drug	diltiazem
O	and
B-drug	erythromycin
O	with
O	transdermal
B-drug	fentanyl
O	may
O	also
O	result
O	in
O	an
O	increase
O	in
B-drug	fentanyl
O	plasma
O	concentrations
O	,
O	which
O	could
O	increase
O	or
O	prolong
O	adverse
O	drug
O	effects
O	and
O	may
O	cause
O	serious
O	respiratory
O	depression
O	.

O	This
O	information
O	should
O	be
O	considered
O	when
O	changing
O	from
O	intravenous
B-drug	amiodarone
O	to
O	oral
B-drug	amiodarone
O	.

B-drug	Alcohol
O	:
B-drug	Alcohol
O	(
O	0.5
O	g/kg
O	body
O	weight
O	:
O	approximately
O	40
O	mL
O	of
O	absolute
O	alcohol
O	in
O	a
O	70
O	kg
O	person
O	)
O	and
B-drug	vardenafil
O	plasma
O	levels
O	were
O	not
O	altered
O	when
O	dosed
O	simultaneously
O	.

B-drug	Ketoconazole
O	:
B-drug	Ketoconazole
O	may
O	inhibit
O	both
O	synthetic
O	and
O	catabolic
O	enzymes
O	of
B-group	vitamin
I-group	D
O	.

O	Although
O	the
O	mechanism
O	of
O	interaction
O	between
B-drug	fenoprofen
O	and
B-brand	aspirin
O	is
O	not
O	totally
O	known
O	,
O	enzyme
O	induction
O	and
O	displacement
O	of
B-drug	fenoprofen
O	from
O	plasma
O	albumin
O	binding
O	sites
O	are
O	possibilities
O	.

O	In
O	evaluating
O	the
O	potential
O	for
O	interactions
O	among
O	co-administered
O	antiepilepsy
O	drugs
O	(
B-group	AEDs
O	)
O	,
O	whether
O	or
O	not
O	an
B-group	AED
O	induces
O	or
O	does
O	not
O	induce
O	metabolic
O	enzymes
O	is
O	an
O	important
O	consideration
O	.

O	Other
O	drugs
O	that
O	increase
O	gastrointestinal
O	motility
O	may
O	produce
O	similar
O	effects
O	.

B-drug	Bromocriptine
I-drug	mesylate
O	may
O	interact
O	with
B-group	dopamine
I-group	antagonists
O	,
B-group	butyrophenones
O	,
O	and
O	certain
O	other
O	agents
O	.

O	Inhibition
O	and
O	stimulation
O	of
O	the
O	effect
O	of
B-drug	oxytocin
O	on
O	milk
O	ejection
O	by
O	vasopressin
O	was
O	demonstrated
O	.

O	Accelerated
O	prothrombin
O	time
O	,
O	partial
O	thromboplastin
O	time
O	,
O	and
O	platelet
O	aggregation
O	time
O	;

O	Care
O	should
O	be
O	taken
O	when
O	using
O	immunoanalytical
O	methods
O	to
O	measure
O	plasma
B-drug	phenytoin
O	concentrations
O	following
B-brand	Cerebyx
O	administration
O	.

O	Organometals
O	also
O	compromise
O	the
O	limbic
O	system
O	and
O	result
O	in
O	deficits
O	in
O	learning
O	and
O	memory
O	.

O	Furthermore
O	it
O	has
O	been
O	proposed
O	that
B-drug	isoniazid
O	resulted
O	In
O	induction
O	of
O	P-450IIE1
O	in
O	the
O	patients
O	liver
O	which
O	,
O	in
O	turn
O	,
O	resulted
O	in
O	a
O	greater
O	proportion
O	of
O	the
O	ingested
B-drug	acetaminophen
O	being
O	converted
O	to
O	the
O	toxic
O	metabolites
O	.

O	Based
O	on
O	the
O	above
O	data
O	from
O	in
O	vitro
O	and
O	in
O	vivo
O	studies
O	,
O	it
O	is
O	unlikely
O	that
B-drug	alosetron
O	will
O	inhibit
O	the
O	hepatic
O	metabolic
O	clearance
O	of
O	drugs
O	metabolized
O	by
O	the
O	major
O	CYP
O	enzyme
O	3A4
O	,
O	as
O	well
O	as
O	the
O	CYP
O	enzymes
O	2D6
O	,
O	2C9
O	,
O	2C19
O	,
O	2E1
O	,
O	or
O	1A2
O	.

O	This
O	may
O	lead
O	to
O	reduced
O	clearance
O	of
B-drug	caffeine
O	and
O	the
O	prolongation
O	of
O	its
O	plasma
O	half-life
O	.

B-drug	Cimetidine
O	-
O	In
O	subjects
O	who
O	had
O	received
O	21
O	days
O	of
O	40
O	mg/day
O	racemic
B-drug	citalopram
O	,
O	combined
O	administration
O	of
O	400
O	mg/day
B-drug	cimetidine
O	for
O	8
O	days
O	resulted
O	in
O	an
O	increase
O	in
B-drug	citalopram
O	AUC
O	and
O	Cmax
O	of
O	43
O	%
O	and
O	39
O	%
O	,
O	respectively
O	.

O	-
B-drug	Methotrexate
O	(
O	e.g.
O	,
B-brand	Mexate
O	)
O	Use
O	of
B-drug	methotrexate
O	with
B-drug	sulfapyridine
O	may
O	increase
O	the
O	chance
O	of
O	side
O	effects
O	affecting
O	the
O	liver
O	and/or
O	the
O	side
O	effects
O	of
B-drug	methotrexate

B-drug	Norepinephrine
O	:
B-group	Amphetamines
O	enhance
O	the
O	adrenergic
O	effect
O	of
B-drug	norepinephrine
O	.

O	A
O	possible
O	interaction
O	has
O	been
O	suggested
O	with
B-group	hormonal
I-group	contraceptives
O	and
O	the
O	herbal
O	supplement
O	St.
O	Johns
O	Wort
O	based
O	on
O	some
O	reports
O	of
O	oral
B-group	contraceptive
O	users
O	experiencing
O	breakthrough
O	bleeding
O	shortly
O	after
O	starting
O	St.
O	Johns
O	Wort
O	.

O	In
O	an
O	emergency
O	situation
O	when
O	opioid
O	analgesia
O	must
O	be
O	administered
O	to
O	a
O	patient
O	receiving
B-brand	REVIA
O	,
O	the
O	amount
O	of
B-group	opioid
O	required
O	may
O	be
O	greater
O	than
O	usual
O	,
O	and
O	the
O	resulting
O	respiratory
O	depression
O	may
O	be
O	deeper
O	and
O	more
O	prolonged
O	.

O	The
O	net
O	effect
O	of
O	these
O	interactions
O	is
O	summarized
O	in
O	the
O	following
O	table
O	:
B-group	AED
I-group	AED
B-brand	Felbatol

O	In
O	these
O	patients
O	,
O	approximately
O	half
O	of
O	the
O	CPK
O	elevations
O	returned
O	to
O	normal
O	within
O	2
O	weeks
O	and
O	half
O	returned
O	to
O	normal
O	within
O	4
O	weeks
O	.

O	Studies
O	on
O	the
O	mechanism
O	of
O	action
O	of
B-drug	miconazole
O	:
O	effect
O	of
B-drug	miconazole
O	on
O	respiration
O	and
O	cell
O	permeability
O	of
O	Candida
O	albicans
O	.

O	Concurrent
O	use
O	of
O	these
O	agents
O	should
O	generally
O	be
O	avoided
O	.

O	-
B-drug	Mephenytoin
O	(
O	e.g.
O	,
B-brand	Mesantoin
O	)
O	Use
O	of
B-drug	sulfapyridine
O	with
O	these
O	medicines
O	may
O	increase
O	the
O	chance
O	of
O	side
O	effects
O	of
O	these
O	medicines

O	Such
O	patients
O	may
O	be
O	unresponsive
O	to
O	the
O	usual
O	doses
O	of
B-drug	epinephrine
O	used
O	to
O	treat
O	allergic
O	reaction
O	.

O	1-
O	adrenergic
O	receptor
O	antagonism
O	,
B-drug	aripiprazole
O	has
O	the
O	potential
O	to
O	enhance
O	the
O	effect
O	of
O	certain
B-group	antihypertensive
I-group	agents
O	.

O	Nephrotoxicity
O	and
O	ototoxicity
O	were
O	not
O	noted
O	when
B-drug	ceftazidime
O	was
O	given
O	alone
O	in
O	clinical
O	trials
O	.

O	Median
O	gastric
O	pH
O	was
O	significantly
O	higher
O	when
B-drug	indinavir
O	was
O	taken
O	after
B-drug	didanosine
O	administration
O	;

B-drug	carbamazepine
O	;

O	Patients
O	taking
O	other
O	drugs
O	that
O	are
O	substrates
O	of
O	CYP450
O	3A4
O	,
O	especially
O	patients
O	with
O	renal
O	and/or
O	hepatic
O	impairment
O	,
O	may
O	require
O	dosage
O	adjustment
O	when
O	starting
O	or
O	stopping
O	concomitantly
O	administered
B-drug	diltiazem
O	in
O	order
O	to
O	maintain
O	optimum
O	therapeutic
O	blood
O	levels
O	.

O	The
O	initiated
O	cells
O	that
O	result
O	from
O	this
O	hit
O	may
O	vary
O	from
O	those
O	that
O	demonstrate
O	very
O	little
O	progression
O	in
O	cell
O	type
O	and
O	may
O	or
O	may
O	not
O	require
O	exogenous
O	enhancement
O	of
O	growth
O	to
O	those
O	that
O	can
O	progress
O	very
O	rapidly
O	to
O	fully
O	malignant
O	behavior
O	.

O	Exert
O	particular
O	caution
O	in
O	combining
B-drug	chlorprothixene
O	with
O	other
B-group	anticholinergic
I-group	drugs
O	(
B-group	tricyclic
I-group	antidepressants
O	and
B-group	antiparkinsonian
I-group	agents
O	)
O	:
O	Particularly
O	the
O	elderly
O	may
O	develop
O	delirium
O	,
O	high
O	fever
O	,
O	severe
O	obstipation
O	,
O	even
O	ileus
O	and
O	glaucoma
O	.

O	Poor
O	metabolizers
O	have
O	higher
O	than
O	expected
O	plasma
O	concentrations
O	of
B-group	tricyclic
I-group	antidepressants
O	(
B-group	TCAs
O	)
O	when
O	given
O	usual
O	doses
O	.

O	14C-cholesterol
O	ester
O	fractional
O	clearance
O	rate
O	was
O	260
O	%
O	greater
O	after
B-drug	etofibrate
O	than
O	after
O	placebo
O	.

O	The
O	mean
O	(
O	SD
O	)
O	cumulative
O	urinary
O	excretion
O	of
O	immunoreactive
B-drug	digoxin
O	after
O	concurrent
O	treatment
O	with
B-drug	rofecoxib
O	or
O	placebo
O	was
O	228.2
O	(
O	+/-
O	30.8
O	)
O	and
O	235.1
O	(
O	+/-
O	39.1
O	)
O	micrograms/120
O	hours
O	,
O	respectively
O	.

O	Therefore
O	,
B-drug	ketoconazole
O	should
O	be
O	administered
O	with
O	caution
O	with
O	intranasal
B-drug	ciclesonide
O	.

O	Since
O	the
O	renal
O	excretion
O	of
O	unchanged
B-drug	dasatinib
O	and
O	its
O	metabolites
O	is
O	4
O	%
O	,
O	a
O	decrease
O	in
O	total
O	body
O	clearance
O	is
O	not
O	expected
O	in
O	patients
O	with
O	renal
O	insufficiency
O	.

B-group	Estrogen
O	,
O	Oral
B-group	Contraceptives
O	:
B-group	Estrogens
O	tend
O	to
O	increase
O	serum
O	thyroxine-binding
O	globulin
O	(
O	TBg
O	)
O	.

O	Although
O	acid-base
O	and
O	electrolyte
O	disturbances
O	were
O	not
O	reported
O	in
O	the
O	clinical
O	trials
O	with
B-drug	dorzolamide
O	,
O	these
O	disturbances
O	have
O	been
O	reported
O	with
O	oral
B-group	carbonic
I-group	anhydrase
I-group	inhibitors
O	and
O	have
O	,
O	in
O	some
O	instances
O	,
O	resulted
O	in
O	drug
O	interactions
O	(
O	e.g.
O	,
O	toxicity
O	associated
O	with
O	high-dose
B-group	salicylate
O	therapy
O	)
O	.

O	This
O	is
O	also
O	to
O	be
O	considered
O	when
B-drug	leflunomide
O	treatment
O	is
O	followed
O	by
O	such
O	drugs
O	without
O	a
O	drug
O	elimination
O	procedure
O	.

O	Consequently
O	,
O	plasma
O	concentrations
O	of
O	drugs
O	metabolized
O	by
O	these
O	two
O	isoenzymes
O	will
O	be
O	decreased
O	when
B-brand	TRACLEER
O	is
O	co-administered
O	.

B-drug	Heparin
O	:
O	No
O	human
O	drug
O	interaction
O	studies
O	with
B-drug	heparin
O	were
O	conducted
O	.

O	The
O	effects
O	of
O	mixing
B-brand	NovoLog
O	with
B-group	insulins
O	of
O	animal
O	source
O	or
B-drug	insulin
O	preparations
O	produced
O	by
O	other
O	manufacturers
O	have
O	not
O	been
O	studied
O	.

B-drug	astemizole
I-drug	midazolam
O	,
B-drug	triazolam
I-drug	cisapride
O	ergot
O	derivatives
B-drug	voriconazole

O	In
O	a
O	study
O	in
O	normal
O	volunteers
O	,
O	concomitant
O	administration
O	of
B-drug	buspirone
I-drug	HCl
O	and
B-drug	haloperidol
O	resulted
O	in
O	increased
O	serum
B-drug	haloperidol
O	concentrations
O	.

O	The
O	inhibitory
O	potential
O	of
B-drug	ciclesonide
O	on
O	CYP450
O	isoenzymes
O	has
O	not
O	been
O	studied
O	.

O	prolonged
O	hot
O	weather
O	;

O	Thus
O	,
O	smaller
O	doses
O	of
B-drug	adenosine
O	may
O	be
O	effective
O	in
O	the
O	presence
O	of
B-drug	dipyridamole
O	.

O	Drugs
O	Prolonging
O	the
O	QT/QTc
O	Interval
O	Caution
O	should
O	be
O	exercised
O	when
O	prescribing
B-drug	apomorphine
O	concomitantly
O	with
O	drugs
O	that
O	prolong
O	the
O	QT/QTc
O	interval
O	.

O	In
O	healthy
O	subjects
O	receiving
B-drug	cimetidine
O	(
O	1
O	gm
O	daily
O	)
O	for
O	one
O	week
O	,
O	plasma
B-drug	flecainide
O	levels
O	increased
O	by
O	about
O	30
O	%
O	and
O	half-life
O	increased
O	by
O	about
O	10
O	%
O	.

O	The
O	effects
B-drug	celecoxib
O	on
O	the
O	pharmacokinetics
O	and/or
O	pharmacodynamics
O	of
B-drug	glyburide
O	,
B-drug	ketoconazole
O	,
B-drug	methotrexate
O	,
B-drug	phenytoin
O	,
B-drug	tolbutamide
O	,
O	and
B-drug	warfarin
O	have
O	been
O	studied
O	in
O	vivo
O	and
O	clinically
O	important
O	interactions
O	have
O	not
O	been
O	found
O	.

B-drug	Albuterol
O	,
B-group	Antihistamines
O	,
B-group	antidiabetic
I-group	drugs
O	,
B-group	diuretics
O	,
B-group	digitalis
O	.

O	Animal
O	data
O	indicated
O	that
B-drug	bupropion
O	may
O	be
O	an
O	inducer
O	of
O	drug-metabolizing
O	enzymes
O	in
O	humans
O	.

O	600-1800

O	Age
O	(
O	range
O	,
O	17-69
O	years
O	)
O	,
O	weight
O	(
O	range
O	,
O	49-106
O	kg
O	)
O	,
O	and
O	sex
O	(
O	65
O	men
O	and
O	36
O	women
O	)
O	were
O	not
O	significant
O	contributors
O	to
O	variability
O	.

O	Therefore
O	,
O	if
O	concomitant
O	administration
O	of
O	these
O	agents
O	is
O	indicated
O	,
O	dosing
O	should
O	be
O	separated
O	by
O	2
O	hours
O	.

O	No
O	separate
O	information
O	available

O	Therefore
O	the
O	,
O	combination
O	of
B-drug	anakinra
O	with
O	other
B-group	TNF-blocking
I-group	agents
O	,
O	including
B-brand	HUMIRA
O	,
O	may
O	also
O	result
O	i
O	n
O	similar
O	toxicities
O	.

O	Co-administration
O	of
B-drug	aliskiren
O	did
O	not
O	significantly
O	affect
O	the
O	pharmacokinetics
O	of
B-drug	lovastatin
O	,
B-drug	digoxin
O	,
B-drug	valsartan
O	,
B-drug	amlodipine
O	,
B-drug	metformin
O	,
B-drug	celecoxib
O	,
B-drug	atenolol
O	,
B-drug	atorvastatin
O	,
B-drug	ramipril
O	or
B-drug	hydrochlorothiazide
O	.

O	The
O	onset
O	of
O	neuromuscular
O	blockade
O	by
B-drug	succinylcholine
O	was
O	unaffected
O	by
B-brand	BREVIBLOC
O	,
O	but
O	the
O	duration
O	of
O	neuromuscular
O	blockade
O	was
O	prolonged
O	from
O	5
O	minutes
O	to
O	8
O	minutes
O	.

O	Therefore
O	,
O	patients
O	concurrently
O	taking
O	antiseizure
O	medication
O	and
B-drug	Mefloquine
O	should
O	have
O	the
O	blood
O	level
O	of
O	their
O	antiseizure
O	medication
O	monitored
O	and
O	the
O	dosage
O	adjusted
O	appropriately
O	.

O	Therefore
O	,
O	drugs
O	that
O	affect
O	CYP3A4
O	and/or
O	Pgp
O	,
O	may
O	modify
O	the
O	pharmacokinetics
O	of
B-drug	saquinavir
O	.

O	There
O	is
O	no
O	clinical
O	experience
O	to
O	date
O	on
O	the
O	use
O	of
B-brand	Femara
O	in
O	combination
O	with
O	other
O	anticancer
O	agents
O	.

O	Due
O	to
O	wide
O	interindividual
O	variability
O	in
O	the
O	dose
O	adjustment
O	required
O	,
O	it
O	is
O	recommended
O	that
B-drug	cyclosporine
O	concentrations
O	be
O	monitored
O	closely
O	after
O	initiation
O	of
B-drug	carvedilol
O	therapy
O	and
O	that
O	the
O	dose
O	of
B-drug	cyclosporine
O	be
O	adjusted
O	as
O	appropriate
O	.

O	Patients
O	who
O	are
O	treated
O	with
B-brand	ZYVOX
O	and
O	concomitant
B-group	serotonergic
I-group	agents
O	should
O	be
O	closely
O	observed
O	for
O	signs
O	and
O	symptoms
O	of
O	serotonin
O	syndrome
O	(
O	e.g.
O	,
O	cognitive
O	dysfunction
O	,
O	hyperpyrexia
O	,
O	hyperreflexia
O	,
O	incoordination
O	)
O	.

B-drug_n	Misonidazole
O	protects
O	mouse
O	tumour
O	and
O	normal
O	tissues
O	from
O	the
O	toxicity
O	of
O	oral
B-drug	CCNU
O	.

O	Serial
O	pharmacokinetic
O	dosing
O	has
O	been
O	proposed
O	as
O	a
O	method
O	to
O	accomplish
O	this
O	goal
O	.

I-drug	clarithromycin
O	concentration

O	Among
O	494
O	subjects
O	who
O	received
B-brand	Angiomax
O	in
O	clinical
O	trials
O	and
O	were
O	tested
O	for
O	antibodies
O	,
O	2
O	subjects
O	had
O	treatment-emergent
O	positive
B-drug	bivalirudin
O	antibody
O	tests
O	.

O	The
O	effect
O	of
B-drug	theophylline
O	on
O	the
O	pharmacokinetics
O	of
B-drug	citalopram
O	was
O	not
O	evaluated
O	.

O	Safety
O	and
O	effectiveness
O	in
O	children
O	has
O	not
O	been
O	established
O	.

O	Except
O	in
O	life-threatening
O	situations
O	,
O	avoid
O	this
O	combination
O	.

O	Evoked
O	hind
O	limb
O	digital
O	extensor
O	tension
O	(
O	hoof
O	twitch
O	)
O	was
O	maintained
O	at
O	40
O	%
O	of
O	baseline
O	for
O	1
O	h
O	by
B-drug	atracurium
O	infusion
O	in
O	7
O	horses
O	anaesthetised
O	with
B-drug	halothane
O	.

B-drug	Ritonavir
O	-
O	Combined
O	administration
O	of
O	a
O	single
O	dose
O	of
B-drug	ritonavir
O	(
O	600
O	mg
O	)
O	,
O	both
O	a
O	CYP3A4
O	substrate
O	and
O	a
O	potent
O	inhibitor
O	of
O	CYP3A4
O	,
O	and
B-drug	escitalopram
O	(
O	20
O	mg
O	)
O	did
O	not
O	affect
O	the
O	pharmacokinetics
O	of
O	either
B-drug	ritonavir
O	or
B-drug	escitalopram
O	.

O	We
O	investigated
O	the
O	effects
O	of
O	adenosine
O	receptor
O	antagonists
O	,
B-drug	caffeine
O	,
B-drug	theophylline
O	,
B-drug_n	8-phenyltheophylline
O	,
O	and
B-drug_n	8-cyclopentyl-1,3-dipropylxanthine
O	(
B-drug_n	DPCPX
O	)
O	,
O	in
O	a
O	light/dark
O	test
O	in
O	mice
O	.

B-group	b-Adrenergic
I-group	Blocking
I-group	Agents
O	:
O	Actions
O	of
O	some
O	of
B-group	beta-blocking
I-group	agents
O	may
O	be
O	impaired
O	when
O	hypothyroid
O	patients
O	become
O	euthyroid
O	.

O	In
O	these
O	trials
O	,
O	heart
O	rate
O	and
O	systolic
O	blood
O	pressure
O	were
O	approximately
O	2-3
O	bpm
O	and
O	6-8
O	mm
O	Hg
O	higher
O	,
O	respectively
O	,
O	in
O	subjects
O	on
O	concomitant
B-drug	theophylline
O	compared
O	with
O	the
O	overall
O	population
O	.

O	(
O	Both
O	drugs
O	were
O	thus
O	dosed
O	to
O	steady
O	state
O	.
O	)

B-drug	Efavirenz

O	Concomitant
O	treatment
O	with
B-group	thrombolytics
O	(
O	eg
O	,
O	rt-PA
O	or
B-drug	streptokinase
O	)
O	may
O	:
O	-
O	increase
O	the
O	risk
O	of
O	bleeding
O	complications
O	-
O	considerably
O	enhance
O	the
O	effect
O	of
B-brand	REFLUDAN
O	on
O	aPTT
O	prolongation

O	When
B-drug	duloxetine
O	was
O	administered
O	(
O	at
O	a
O	dose
O	of
O	60
O	mg
O	BID
O	)
O	in
O	conjunction
O	with
O	a
O	single
O	50-mg
O	dose
O	of
B-drug	desipramine
O	,
O	a
O	CYP2D6
O	substrate
O	,
O	the
O	AUC
O	of
B-drug	desipramine
O	increased
O	3-fold
O	.

B-drug	WARFARIN
O	:
O	Co-
O	administration
O	of
B-drug	warfarin
O	and
B-drug	cerivastatin
O	to
O	healthy
O	volunteers
O	did
O	not
O	result
O	in
O	any
O	changes
O	in
O	prothrombin
O	time
O	or
O	clotting
O	factor
O	VII
O	when
O	compared
O	to
O	co-administration
O	of
B-drug	warfarin
O	and
O	placebo
O	.

O	It
O	would
O	be
O	expected
O	that
B-group	laxative
O	use
O	during
O	therapy
O	with
B-brand	CAMPTOSAR
O	would
O	worsen
O	the
O	incidence
O	or
O	severity
O	of
O	diarrhea
O	,
O	but
O	this
O	has
O	not
O	been
O	studied
O	.

O	Pharmacokinetic
O	evaluation
O	of
O	the
B-drug	digoxin-amiodarone
O	interaction
O	.

O	Increasing
O	the
B-drug	indinavir
O	dose
O	to
O	1000
O	mg
O	every
O	8
O	hours
O	does
O	not
O	compensate
O	for
O	the
O	increased
B-drug	indinavir
O	metabolism
O	due
O	to
B-brand	SUSTIVA
O	.

O	Convulsions
O	have
O	been
O	reported
O	with
O	this
O	concurrent
O	use
O	.

O	The
O	effect
O	of
B-drug	desflurane
O	on
O	the
O	disposition
O	of
O	other
O	drugs
O	has
O	not
O	been
O	determined
O	.

O	Hormonal
B-group	contraceptives
O	Co-administration
O	of
B-brand	Trileptal
O	with
O	an
O	oral
B-group	contraceptive
O	has
O	been
O	shown
O	to
O	influence
O	the
O	plasma
O	concentrations
O	of
O	the
O	two
O	hormonal
O	components
O	,
B-drug	ethinylestradiol
O	(
O	EE
O	)
O	and
B-drug	levonorgestrel
O	(
O	LNG
O	)
O	.

B-brand	RAPTIVA
O	should
O	not
O	be
O	used
O	with
O	other
B-group	immunosuppressive
I-group	drugs
O	.

O	In
O	5
O	other
O	schizophrenic
O	patients
O	treated
O	with
O	oral
B-drug	haloperidol
O	and
B-drug	rifampin
O	,
O	discontinuation
O	of
B-drug	rifampin
O	produced
O	a
O	mean
O	3.3-fold
O	increase
O	in
B-drug	haloperidol
O	concentrations
O	.

O	When
O	such
O	drugs
O	are
O	withdrawn
O	from
O	a
O	patient
O	receiving
B-drug	glipizide
O	,
O	the
O	patient
O	should
O	be
O	observed
O	closely
O	for
O	loss
O	of
O	control
O	.

O	This
O	may
O	be
O	due
O	to
O	an
O	improved
O	glucose
O	utilization
O	with
O	simultaneous
O	reduction
O	in
B-drug	insulin
O	requirement

B-drug	Cyclopropane
O	or
B-group	halogenated
I-group	hydrocarbon
I-group	anesthetics
O	increase
O	cardiac
O	autonomic
O	irritability
O	and
O	may
O	sensitize
O	the
O	myocardium
O	to
O	the
O	action
O	of
O	certain
O	intravenously
O	administered
B-group	catecholamines
O	,
O	such
O	as
B-drug	dopamine
O	.

B-drug	Esomeprazole
O	may
O	potentially
O	interfere
O	with
O	CYP2C19
O	,
O	the
O	major
B-drug	esomeprazole
O	metabolizing
O	enzyme
O	.

B-drug	Ketoconazole
O	:
B-drug	Ketoconazole
O	may
O	inhibit
O	both
O	synthetic
O	and
O	catabolic
O	enzymes
O	of
B-group	vitamin
I-group	D
O	.

O	*
O	This
O	table
O	is
O	not
O	all
O	inclusive
O	**
B-brand	VIRACEPT
O	may
O	not
O	be
O	effective
O	due
O	to
O	decreased
B-drug	nelfinavir
O	plasma
O	concentrations
O	in
O	patients
O	taking
O	these
O	agents
O	concomitantly

O	The
O	effects
O	of
B-drug	allopurinol
O	on
B-drug	didanosine
O	pharmacokinetics
O	in
O	subjects
O	with
O	normal
O	renal
O	function
O	are
O	not
O	known
O	.

O	Therefore
O	,
B-drug	diphenoxylate
O	has
O	the
O	potential
O	to
O	prolong
O	the
O	biological
O	half-lives
O	of
O	drugs
O	for
O	which
O	the
O	rate
O	of
O	elimination
O	is
O	dependent
O	on
O	the
O	microsomal
O	drug
O	metabolizing
O	enzyme
O	system
O	.

B-drug	Digoxin
O	-
O	In
O	subjects
O	who
O	had
O	received
O	21
O	days
O	of
O	40
O	mg/day
O	racemic
B-drug	citalopram
O	,
O	combined
O	administration
O	of
B-drug	citalopram
O	and
B-drug	digoxin
O	(
O	single
O	dose
O	of
O	1
O	mg
O	)
O	did
O	not
O	significantly
O	affect
O	the
O	pharmacokinetics
O	of
O	either
B-drug	citalopram
O	or
B-drug	digoxin
O	.

B-drug	Valproic
I-drug	Acid
O	:
O	The
O	mean
O	steady-state
O	trough
O	serum
B-drug	valproic
I-drug	acid
O	concentrations
O	prior
O	to
O	and
O	during
O	concomitant
B-drug	gabapentin
O	administration
O	(
O	400
O	mg
O	TID
O	;

B-group	Tricyclic
I-group	antidepressants
O	have
O	been
O	reported
O	to
O	blunt
O	the
O	hypotensive
O	effect
O	of
O	systemic
B-drug	clonidine.It
O	is
O	not
O	known
O	whether
O	the
O	concurrent
O	use
O	of
O	these
O	agents
O	with
B-brand	ALPHAGAN
I-brand	P
O	in
O	humans
O	can
O	lead
O	to
O	resulting
O	interference
O	with
O	the
O	IOP
O	lowering
O	effect
O	.

O	DIAGNOSTIC
O	INTERFERENCE
O	With
O	expected
O	physiologic
O	effects
O	:
O	Blood
O	and
O	urine
O	glucose
O	levels
O	(
O	usually
O	only
O	in
O	patients
O	with
O	a
O	predisposition
O	for
O	glucose
O	intolerance
O	)
O	and
O	Serum
O	bilirubin
O	levels
O	(
O	by
O	displacement
O	from
O	albumin
O	binding
O	)
O	and
O	Serum
O	calcium
O	levels
O	(
B-group	thiazide
I-group	diuretics
O	should
O	be
O	discontinued
O	before
O	parathyroid-function
O	tests
O	are
O	carried
O	out
O	)
O	and
O	Serum
O	uric
O	acid
O	levels
O	(
O	may
O	be
O	increased
O	)
O	Serum
O	magnesium
O	,
O	potassium
O	,
O	and
O	sodium
O	levels
O	(
O	may
O	be
O	decreased
O	;

B-drug	Anastrozole
O	did
O	not
O	inhibit
O	P450
O	2A6
O	or
O	the
O	polymorphic
O	P450
O	2D6
O	in
O	human
O	liver
O	microsomes
O	.

O	In
O	addition
O	,
B-drug	oxcarbazepine
O	and
B-drug_n	MHD
O	induce
O	a
O	subgroup
O	of
O	the
O	cytochrome
O	P450
O	3A
O	family
O	(
O	CYP3A4
O	and
O	CYP3A5
O	)
O	responsible
O	for
O	the
O	metabolism
O	of
B-group	dihydropyridine
I-group	calcium
I-group	antagonists
O	and
O	oral
B-group	contraceptives
O	,
O	resulting
O	in
O	a
O	lower
O	plasma
O	concentration
O	of
O	these
O	drugs
O	.

B-drug	Gentamicin
O	did
O	not
O	interfere
O	with
O	the
O	activity
O	of
B-drug	clindamycin
O	within
O	the
O	range
O	of
O	concentrations
O	tested
O	(
O	0.1
O	to
O	100
O	mug/ml
O	)
O	;

O	Plasma
O	concentrations
O	may
O	be
O	increased
O	by
B-brand	CRIXIVAN
O	.

O	Intraventricular
O	injection
O	of
B-drug_n	beta-endorphin
O	and
B-drug	morphine
O	produced
O	an
O	inhibition
O	of
O	the
O	tail-flick
O	response
O	to
O	the
O	heat
O	stimulus
O	in
O	rats
O	.

O	Interaction
O	of
B-brand	GABITRIL
O	with
O	Other
O	Drugs
O	:
B-drug	Cimetidine
O	:
O	Co-administration
O	of
B-drug	cimetidine
O	(
O	800
O	mg/day
O	)
O	to
O	patients
O	taking
B-drug	tiagabine
O	chronically
O	had
O	no
O	effect
O	on
B-drug	tiagabine
O	pharmacokinetics
O	.

O	The
O	following
O	are
O	examples
O	of
O	substances
O	that
O	may
O	increase
O	the
O	blood-glucose-lowering
O	effect
O	and
O	susceptibility
O	to
O	hypoglycemia
O	:
O	oral
B-group	antidiabetic
I-group	products
O	,
B-group	ACE
I-group	inhibitors
O	,
B-drug	disopyramide
O	,
B-group	fibrates
O	,
B-drug	fluoxetine
O	,
B-group	monoamine
I-group	oxidase
I-group	(
I-group	MAO
I-group	)
I-group	inhibitors
O	,
B-drug	propoxyphene
O	,
B-group	salicylates
O	,
B-group	somatostatin
I-group	analog
O	(
O	e.g.
O	,
B-drug	octreotide
O	)
O	,
B-group	sulfonamide
I-group	antibiotics
O	.

O	However
O	,
O	the
O	pharmacodynamic
O	effect
O	increased
O	by
O	190
O	%
O	(
O	QTc
O	increase
O	over
O	time
O	)
O	and
O	by
O	84
O	%
O	(
O	Maximum
O	QTc
O	increase
O	)
O	.

O	Mutagenesis
B-brand	PEGASYS
O	did
O	not
O	cause
O	DNA
O	damage
O	when
O	tested
O	in
O	the
O	Ames
O	bacterial
O	mutagenicity
O	assay
O	and
O	in
O	the
O	in
O	vitro
O	chromosomal
O	aberration
O	assay
O	in
O	human
O	lymphocytes
O	,
O	either
O	in
O	the
O	presence
O	or
O	absence
O	of
O	metabolic
O	activation
O	.

B-drug	Ganciclovir
O	:
O	Administration
O	of
B-brand	VIDEX
O	2
O	hours
O	prior
O	to
O	or
O	concurrent
O	with
O	oral
B-drug	ganciclovir
O	was
O	associated
O	with
O	a
O	111
O	(
O	114
O	)
O	%
O	increase
O	in
O	the
O	steady-state
O	AUC
O	of
B-drug	didanosine
O	(
O	n
O	=
O	12
O	)
O	.

O	In
O	addition
O	,
O	certain
O	drugs
O	that
O	are
O	metabolized
O	by
O	this
O	isoenzyme
O	,
O	including
O	many
B-group	antidepressants
O	(
B-group	tricyclic
I-group	antidepressants
O	,
B-group	selective
I-group	serotonin
I-group	reuptake
I-group	inhibitors
O	,
O	and
O	others
O	)
O	,
O	may
O	inhibit
O	the
O	activity
O	of
O	this
O	isoenzyme
O	,
O	and
O	thus
O	may
O	make
O	normal
O	metab-olizers
O	resemble
O	poor
O	metabolizers
O	with
O	regard
O	to
O	concomitant
O	therapy
O	with
O	other
O	drugs
O	metabolized
O	by
O	this
O	enzyme
O	system
O	,
O	leading
O	to
O	drug
O	interactions
O	.

O	in
O	one
O	man
O	,
O	the
O	C
O	max
O	of
B-drug	terfenadine
O	was
O	8.1
O	ng/mL
O	with
B-drug	terfenadine
O	alone
O	and
O	7.2
O	ng/mL
O	with
B-drug	terfenadine
O	plus
B-drug	dirithromycin
O	.

O	The
O	mechanism
O	(
O	s
O	)
O	of
O	altered
O	topo
O	I
O	expression
O	in
O	certain
O	tumor
O	types
O	is
O	unknown
O	,
O	but
O	may
O	be
O	related
O	to
O	the
O	central
O	importance
O	of
O	topoisomerases
O	in
O	proliferating
O	cell
O	functions
O	(
O	transcription
O	,
O	replication
O	,
O	etc
O	.
O	)
O	,
O	and
O	the
O	aberrant
O	and
O	chronic
O	activation
O	of
O	these
O	functions
O	as
O	a
O	result
O	of
O	specific
O	tumorigenic
O	alterations
O	.

O	All
O	subjects
O	received
B-drug	amprenavir
O	(
O	1,200
O	mg
O	twice
O	a
O	day
O	)
O	for
O	4
O	days
O	,
O	followed
O	by
O	a
O	7-day
O	washout
O	period
O	,
O	followed
O	by
O	either
B-drug	rifabutin
O	(
O	300
O	mg
O	once
O	a
O	day
O	[
O	QD
O	]
O	)
O	(
O	cohort
O	1
O	)
O	or
B-drug	rifampin
O	(
O	600
O	mg
O	QD
O	)
O	(
O	cohort
O	2
O	)
O	for
O	14
O	days
O	.

O	Prospective
O	,
O	long-term
O	studies
O	on
O	concomitant
O	administration
O	of
B-brand	VIOXX
O	and
B-brand	aspirin
O	have
O	not
O	been
O	conducted
O	.

O	therefore
O	,
O	it
O	is
O	theoretically
O	possible
O	that
B-drug	lansoprazole
O	may
O	interfere
O	with
O	the
O	absorption
O	of
O	drugs
O	where
O	gastric
O	pH
O	is
O	an
O	important
O	determinant
O	of
O	bioavailability
O	(
O	e.g
O	.
B-drug	ketoconazole
O	,
B-drug	ampicillin
O	esters
O	,
B-drug	iron
O	salts
O	,
B-drug	digoxin
O	)
O	.

O	Use
O	of
B-group	MAO
I-group	inhibitors
O	may
O	cause
O	an
O	excessive
O	increase
O	in
O	blood
O	pressure
O	and
O	heart
O	stimulation
O	.

O	Dosage
O	adjustment
O	of
B-brand	STRATTERA
O	may
O	be
O	necessary
O	when
O	coadministered
O	with
O	CYP2D6
O	inhibitors
O	,
O	e.g.
O	,
B-drug	paroxetine
O	,
B-drug	fluoxetine
O	,
O	and
B-drug	quinidine
O	.

O	Data
O	from
O	a
O	randomized
O	trial
O	of
B-brand	HEXALEN
O	and
B-drug	cisplatin
O	plus
O	or
O	minus
B-drug	pyridoxine
O	in
O	ovarian
O	cancer
O	indicated
O	that
B-drug	pyridoxine
O	significantly
O	reduced
O	neurotoxicity
O	;

O	May
O	lead
O	to
O	loss
O	of
O	virologic
O	response
O	and
O	possible
O	resistance
O	to
B-brand	CRIXIVAN
O	or
O	to
O	the
O	class
O	of
B-group	protease
I-group	inhibitors
O	.

B-group	Antineoplastic
I-group	agents
O	(
O	e.
O	g.
O	,
B-drug	nitrogen
I-drug	mustard
O	,
O	etc
O	.
O	)
O	should
O	be
O	given
O	concomitantly
O	only
O	with
O	great
O	caution
O	.

O	These
O	observations
O	suggest
O	that
O	exogenous
O	co-factors
O	could
O	be
O	involved
O	in
O	the
O	occurrence
O	of
O	ARE
O	.

B-drug	bromelains
O	;

B-group	Anticholinesterases
O	(
O	neostgmine
O	,
B-drug	physostigmine
O	)
O	,
B-drug	lignocaine
O	,
B-drug	quinine
O	,
B-drug	procainamide
O	can
O	enhance
O	toxicity
O	and
O	cause
O	cardio
O	respiratory
O	depression
O	.

O	increased
O	norepinephrine-induced
O	platel
O	et
O	aggregation
O	;

B-drug	Vardenafil

O	Binding
O	to
O	Serum
O	Proteins
O	:
O	The
O	following
O	agents
O	may
O	either
O	inhibit
B-drug	levothyroxine
I-drug	sodium
O	binding
O	to
O	serum
O	proteins
O	or
O	alter
O	the
O	concentrations
O	of
O	serum
O	binding
O	proteins
O	:
B-group	androgens
O	and
O	related
B-group	anabolic
I-group	hormones
O	,
B-drug	asparaginase
O	,
B-drug	clofibrate
O	,
B-group	estrogens
O	and
B-group	estrogen-containing
I-group	compounds
O	,
B-drug	5-fluorouracil
O	,
B-drug	furosemide
O	,
B-group	glucocorticoids
O	,
B-drug	meclofenamic
I-drug	acid
O	,
B-drug	mefenamic
I-drug	acid
O	,
B-drug	methadone
O	,
B-drug	perphenazine
O	,
B-drug	phenylbutazone
O	,
B-drug	phenytoin
O	,
B-group	salicylates
O	,
B-drug	tamoxifen
O	.

B-drug	Paroxetine
O	:
O	Coadministration
O	of
O	once
O	daily
O	doses
O	of
B-drug	aprepitant
O	,
O	as
O	a
O	tablet
O	formulation
O	comparable
O	to
O	85
O	mg
O	or
O	170
O	mg
O	of
O	the
O	capsule
O	formulation
O	,
O	with
B-drug	paroxetine
O	20
O	mg
O	once
O	daily
O	,
O	resulted
O	in
O	a
O	decrease
O	in
O	AUC
O	by
O	approximately
O	25
O	%
O	and
O	Cmax
O	,
O	by
O	approximately
O	20
O	%
O	of
O	both
B-drug	aprepitant
O	and
B-drug	paroxetine
O	.

B-drug	Sumatriptan
O	:
B-drug	Sumatriptan
O	has
O	been
O	reported
O	to
O	cause
O	coronary
O	artery
O	vasospasm
O	,
O	and
O	its
O	effect
O	could
O	be
O	additive
O	with
B-brand	D.H.E
I-brand	.
I-brand	45
O	(
B-drug	dihydroergotamine
I-drug	mesylate
O	)
O	Injection
O	,
O	USP
O	.

O	It
O	was
O	shown
O	that
B-drug_n	neurotensin
O	antagonized
O	evidently
O	the
O	antinociceptive
O	effect
O	of
B-drug_n	enkephalins
O	and
O	their
O	analogue
O	.

O	If
O	signs
O	and
O	symptoms
O	suggestive
O	of
B-drug	digoxin
O	toxicity
O	occur
O	when
B-drug	enoxacin
O	and
B-drug	digoxin
O	are
O	given
O	concomitantly
O	,
O	physicians
O	are
O	advised
O	to
O	obtain
O	serum
B-drug	digoxin
O	levels
O	and
O	adjust
B-drug	digoxin
O	doses
O	appropriately
O	.

B-group	Antidiabetic
I-group	drugs
O	(
O	oral
O	agents
O	and
B-drug	insulin
O	)
O	:
O	hypoglycemia
O	or
O	hyperglycemia
O	;

O	The
O	effect
O	of
B-drug	rifampin
O	on
O	the
B-drug	warfarin
O	requirement
O	of
O	our
O	patient
O	appeared
O	to
O	be
O	maximal
O	5
O	to
O	7
O	days
O	after
O	the
O	initiation
O	of
B-drug	rifampin
O	and
O	extended
O	a
O	similar
O	length
O	of
O	time
O	after
B-drug	rifampin
O	withdrawal
O	.

O	The
O	ratio
O	between
O	the
O	liver
O	weight
O	and
O	body
O	weight
O	was
O	found
O	to
O	be
O	lower
O	in
O	the
O	treated
O	animals
O	than
O	in
O	the
O	control
O	group
O	.

O	Other
O	Potentially
O	Clinically
O	Significant
O	Drug
O	or
O	Herbal
O	Product
O	Interactions
O	With
O	SUSTIVAb

O	With
O	oral
B-drug	dapsone
O	treatment
O	,
B-group	folic
I-group	acid
I-group	antagonists
O	such
O	as
B-drug	pyrimethamine
O	have
O	been
O	noted
O	to
O	possibly
O	increase
O	the
O	likelihood
O	of
O	hematologic
O	reactions

B-drug	Ketoconazole
O	increased
O	mean
B-drug	alosetron
O	plasma
O	concentrations
O	(
O	AUC
O	)
O	by
O	29
O	%
O	.

O	Although
O	the
O	specific
O	drug
O	interaction
O	was
O	not
O	studied
O	in
O	a
O	clinical
O	trial
O	,
O	there
O	have
O	been
O	more
O	than
O	50
O	episodes
O	of
O	concomitant
O	use
O	of
O	antifibrinolytic
O	therapies
O	(
O	i.e.
O	,
B-drug	tranexamic
I-drug	acid
O	,
B-drug	aminocaproic
I-drug	acid
O	)
O	and
B-brand	NovoSeven
O	.

O	Urinary
O	excretion
O	and
O	renal
O	clearance
O	were
O	correspondingly
O	reduced
O	.

O	During
O	transfer
O	to
O	oral
B-drug	amiodarone
O	,
O	the
O	dose
O	levels
O	of
O	previously
O	administered
O	agents
O	should
O	be
O	reduced
O	by
O	30
O	to
O	50
O	%
O	several
O	days
O	after
O	the
O	addition
O	of
O	oral
B-drug	amiodarone
O	.

B-drug	Ketoconazole
O	:
O	Coadministration
O	of
B-drug	ketoconazole
O	(
O	200
O	mg/day
O	for
O	14
O	days
O	)
O	with
O	a
O	15-mg
O	single
O	dose
O	of
B-drug	aripiprazole
O	increased
O	the
O	AUC
O	of
B-drug	aripiprazole
O	and
O	its
O	active
O	metabolite
O	by
O	63
O	%
O	and
O	77
O	%
O	,
O	respectively
O	.

B-brand	Survanta
O	also
O	increased
O	rate
O	of
O	dissolution
O	,
O	in
O	a
O	manner
O	similar
O	to
B-drug_n	sodium
I-drug_n	dodecyl
I-drug_n	sulfate
O	.

O	Since
O	drowsiness
O	may
O	occur
O	with
O	use
O	of
O	this
O	drug
O	,
O	patients
O	should
O	be
O	warned
O	of
O	this
O	possibility
O	and
O	cautioned
O	against
O	driving
O	a
O	car
O	or
O	operating
O	dangerous
O	machinery
O	while
O	taking
B-brand	Atarax
O	.

B-drug	Dolasetron
I-drug	mesylate
O	did
O	not
O	inhibit
O	the
O	antitumor
O	activity
O	of
O	four
B-group	chemotherapeutic
I-group	agents
O	(
B-drug	cisplatin
O	,
B-drug	5-fluorouracil
O	,
B-drug	doxorubicin
O	,
B-drug	cyclophosphamide
O	)
O	in
O	four
O	murine
O	models
O	.

B-group	Bisphosphonates
O	are
O	known
O	to
O	interfere
O	with
O	the
O	use
O	of
O	bone-imaging
O	agents
O	.

O	An
O	additive
O	hypotensive
O	effect
O	has
O	been
O	reported
O	with
O	the
O	combination
O	of
O	systemic
B-drug	clonidine
O	and
B-group	neuroleptic
O	therapy
O	.

B-drug	Nizatidine
O	does
O	not
O	inhibit
O	the
O	cytochrome
O	P-450-linked
O	drug-metabolizing
O	enzyme
O	system
O	;

B-brand	Aspirin
O	should
O	be
O	used
O	cautiously
O	in
O	conjunction
O	with
B-group	cortico-steroids
O	in
O	patients
O	suffering
O	from
O	hypopro-thrombinemia
O	.

O	RATIONALE
O	:
O	Stress
O	and
B-group	glucocorticoids
O	facilitate
O	and
O	reinstate
O	psychostimulant
O	self-administration
O	in
O	rodents
O	.

B-drug	Methotrexate
O	:
B-group	NSAIDs
O	have
O	been
O	reported
O	to
O	competitively
O	inhibit
B-drug	methotrexate
O	accumulation
O	in
O	rabbit
O	kidney
O	slices
O	.

O	However
O	,
O	co-administration
O	of
B-drug	Duloxetine
O	with
B-drug	aluminum-
O	and
B-drug	magnesium-containing
B-group	antacids
O	(
O	51
O	mEq
O	)
O	or
B-drug	Duloxetine
O	with
B-drug	famotidine
O	,
O	had
O	no
O	significant
O	effect
O	on
O	the
O	rate
O	or
O	extent
O	of
B-drug	duloxetine
O	absorption
O	after
O	administration
O	of
O	a
O	40-mg
O	oral
O	dose
O	.

O	It
O	is
O	indicated
O	that
O	the
O	first
O	and
O	second
O	contractile
O	responses
O	to
B-drug_n	PTX
O	have
O	entirely
O	different
O	properties
O	.

O	Dopamine
O	(
O	DA
O	)
O	levels
O	did
O	not
O	differ
O	significantly
O	in
O	either
O	striatum
O	(
O	STR
O	)
O	or
O	nucleus
O	accumbens
O	(
O	NAC
O	)
O	for
O	the
B-drug	cocaine-treated
O	animals
O	to
O	their
O	corresponding
O	saline-treated
O	controls
O	.

O	Other
O	:
O	Coadministration
O	of
O	grapefruit
O	juice
O	with
B-drug	cisapride
O	increases
O	the
O	bioavailability
O	of
B-drug	cisapride
O	and
O	concomitant
O	use
O	should
O	be
O	avoided
O	.

B-group	ACE
I-group	inhibitors
O	:
O	Reports
O	suggest
O	that
B-group	NSAIDs
O	may
O	diminish
O	the
O	antihypertensive
O	effect
O	of
B-group	Angiotensin
I-group	Converting
I-group	Enzyme
I-group	(
I-group	ACE
I-group	)
I-group	inhibitors
O	.

O	Similarly
O	,
O	the
O	acute
O	toxicity
O	was
O	also
O	diminished
O	by
O	a
O	DMF
O	of
O	0.74
O	.

O	Therefore
O	,
O	careful
O	monitoring
O	of
O	blood
O	glucose
O	is
O	recommended
O	when
O	these
O	agents
O	are
O	coadministered
O	.

O	Drug-drug
O	interactions
O	In
O	vitro
O	studies
O	using
O	human
O	liver
O	microsomes
O	indicate
O	that
B-drug	fenofibrate
O	and
B-drug_n	fenofibric
I-drug_n	acid
O	are
O	not
O	inhibitors
O	of
O	cytochrome
O	(
O	CYP
O	)
O	P450
O	isoforms
O	CYP3A4
O	,
O	CYP2D6
O	,
O	CYP2E1
O	,
O	or
O	CYP1A2
O	.

O	Drugs
O	that
O	may
O	have
O	their
O	plasma
O	concentration
O	altered
O	by
B-drug	dasatinib
O	CYP3A4
O	Substrates
O	:
B-drug	Dasatinib
O	is
O	a
O	time-dependent
O	inhibitor
O	of
O	CYP3A4
O	.

O	Evidence
O	for
O	reduction
O	of
B-drug	norepinephrine
O	uptake
O	sites
O	in
O	the
O	failing
O	human
O	heart
O	.

O	metabolizers
O	.

O	The
O	effects
O	of
B-group	tricyclic
I-group	antidepressants
O	on
B-drug	clonidines
O	analgesic
O	actions
O	are
O	not
O	known
O	.

O	All
O	subjects
O	received
B-drug	glipizide
O	alone
O	and
O	following
O	treatment
O	with
O	100
O	mg
O	of
B-drug	fluconazole
O	as
O	a
O	single
O	daily
O	oral
O	dose
O	for
O	seven
O	days
O	.

O	Therefore
B-brand	FORADIL
O	should
O	not
O	be
O	given
O	together
O	with
O	-adrenergic
O	blockers
O	(
O	including
O	eye
O	drops
O	)
O	unless
O	there
O	are
O	compelling
O	reasons
O	for
O	their
O	use
O	.

O	In
O	addition
O	,
O	deaths
O	have
O	been
O	reported
O	rarely
O	with
O	concomitant
O	administration
O	of
B-drug	terfenadine
O	and
B-drug	erythromycin
O	.

O	It
O	reduced
O	the
O	number
O	of
O	deaths
O	induced
O	by
O	nonlethal
O	(
O	2
O	mg/kg
O	)
O	dose
O	of
B-drug_n	endotoxin
O	but
O	increased
O	the
O	number
O	of
O	deaths
O	induced
O	by
O	a
O	highly
O	lethal
O	dose
O	(
O	8
O	mg/kg
O	)
O	.

O	and
O	phase
O	3
O	(
O	days
O	45-52
O	)
O	:
B-drug	cisapride
O	10
O	mg
O	4
O	times/day
O	(
O	days
O	45-51
O	)
O	plus
B-drug	fluoxetine
O	20
O	mg/day
O	(
O	days
O	45-52
O	)
O	.

B-drug	Digoxin
O	:
O	Concomitant
O	administration
O	of
B-drug	tiagabine
O	did
O	not
O	affect
O	the
O	steady-state
O	pharmacokinetics
O	of
B-drug	digoxin
O	or
O	the
O	mean
O	daily
O	trough
O	serum
O	level
O	of
B-drug	digoxin
O	.

O	No
O	dose
O	relationship
O	has
O	been
O	observed
O	.

B-drug	Acetazolamide
O	may
O	prevent
O	the
O	urinary
O	antiseptic
O	effect
O	of
B-drug	methenamine
O	.

O	When
O	administered
O	concurrently
O	,
O	the
O	following
O	drugs
O	may
O	interact
O	with
B-drug	amphotericin
I-drug	B
O	:
B-group	Antineoplastic
I-group	agents
O	:
O	may
O	enhance
O	the
O	potential
O	for
O	renal
O	toxicity
O	,
O	bronchospasm
O	and
O	hypotension
O	.

O	The
O	last
O	4
O	chapters
O	cover
O	interactions
O	with
O	drugs
O	and
O	laboratory
O	tests
O	,
O	common
O	side
O	effects
O	,
O	breast
O	feeding
O	,
O	and
O	effective
O	use
O	of
B-group	POCs
O	.

O	Patients
O	who
O	have
O	previously
O	received
O	pelvic/
O	abdominal
O	irradiation
O	are
O	at
O	increased
O	risk
O	of
O	severe
O	myelosuppression
O	following
O	the
O	administration
O	of
B-brand	CAMPTOSAR
O	.

O	Five
O	days
O	of
B-drug	dofetilide
O	treatment
O	did
O	not
O	significantly
O	affect
O	steady-state
O	pharmacokinetic
O	variables
O	of
B-drug	digoxin
O	compared
O	with
O	placebo
O	;

O	For
O	patients
O	with
O	advanced
O	HIV
O	disease
O	and
O	poor-risk
O	AIDS-related
O	Kaposi
O	s
O	sarcoma
O	,
B-brand	TAXOL
O	,
O	at
O	the
O	recommended
O	dose
O	for
O	this
O	disease
O	,
O	can
O	be
O	initiated
O	and
O	repeated
O	if
O	the
O	neutrophil
O	count
O	is
O	at
O	least
O	1000
O	cells/mm3
O	.

O	If
O	co-administration
O	is
O	essential
O	,
O	close
O	monitoring
O	may
O	be
O	appropriate
O	.

O	These
O	results
O	suggest
O	that
O	the
O	analgesic
O	effect
O	of
B-brand	STADOL
I-brand	NS
O	may
O	be
O	diminished
O	when
O	it
O	is
O	administered
O	shortly
O	after
B-drug	sumatriptan
O	nasal
O	spray
O	,
O	but
O	by
O	30
O	minutes
O	any
O	such
O	reduction
O	in
O	effect
O	should
O	be
O	minimal
O	.

O	Clinical
O	significance
O	of
O	reduced
B-drug	efavirenz
O	concentrations
O	unknown
O	.

B-drug	Acetylsalicylic
I-drug	acid
O	did
O	not
O	alter
O	the
O	clearance
O	(
O	pharmacokinetics
O	)
O	of
B-drug	iloprost
O	.

B-group	Anticoagulants
O	predispose
O	a
O	patient
O	to
O	bleeding
O	problems
O	.

O	Review
O	of
O	these
O	case
O	reports
O	indicates
O	that
O	the
O	patients
O	were
O	mainly
O	receiving
B-group	thiazide
I-group	diuretics
O	for
O	hypertension
O	and
O	that
O	tests
O	to
O	rule
O	out
O	decreased
O	renal
O	function
O	secondary
O	to
O	hypertensive
O	nephropathy
O	were
O	not
O	often
O	performed
O	.

O	Inhibitors
O	of
O	CYP1A2
O	:
O	Concomitant
O	use
O	of
B-drug	duloxetine
O	with
B-drug	fluvoxamine
O	,
O	an
O	inhibitor
O	of
O	CYP1A2
O	,
O	results
O	in
O	approximately
O	a
O	6-fold
O	increase
O	in
O	AUC
O	and
O	about
O	a
O	2.5-fold
O	increase
O	in
O	Cmax
O	of
B-drug	duloxetine
O	.

B-group	Benzodiazepines
O	were
O	administered
O	to
O	mice
O	30
O	min
O	before
O	applying
O	the
B-group	analgesic
I-group	drugs
O	.

O	We
O	previously
O	reported
O	that
O	seeds
O	of
O	Artocarpus
O	integrifolia
O	(
O	jackfruit
O	)
O	contain
O	a
O	lectin
O	,
O	which
O	we
O	call
B-drug_n	jacalin
O	,
O	that
O	is
O	both
O	a
O	potent
O	T
O	cell
O	mitogen
O	and
O	an
O	apparently
O	T
O	cell-independent
O	activator
O	of
O	human
O	B
O	cells
O	for
O	the
O	secretion
O	of
O	immunoglobulins
O	.

O	Thus
O	in
O	order
O	to
O	avoid
O	bleeding
O	,
O	reduced
O	dosage
O	of
B-drug	heparin
O	is
O	recommended
O	during
O	treatment
O	with
B-drug	antithrombin
I-drug	III
O	(
O	human
O	)
O	.

O	Phosphate-Binding
O	Agents
O	:
O	Since
B-group	vitamin
I-group	D
O	also
O	has
O	an
O	effect
O	on
O	phosphate
O	transport
O	in
O	the
O	intestine
O	,
O	kidneys
O	and
O	bones
O	,
O	the
O	dosage
O	of
O	phosphate-binding
O	agents
O	must
O	be
O	adjusted
O	in
O	accordance
O	with
O	the
O	serum
O	phosphate
O	concentration
O	.

O	Limited
O	clinical
O	experience
O	indicates
O	that
O	requirements
O	for
B-group	volatile
I-group	inhalation
I-group	anesthetics
O	are
O	reduced
O	by
O	30
O	to
O	50
O	%
O	for
O	the
O	first
O	sixty
O	(
O	60
O	)
O	minutes
O	following
B-brand	ALFENTA
O	induction
O	The
O	concomitant
O	use
O	of
B-drug	erythromycin
O	with
B-brand	ALFENTA
O	can
O	significantly
O	inhibit
B-brand	ALFENTA
O	clearance
O	and
O	may
O	increase
O	the
O	risk
O	of
O	prolonged
O	or
O	delayed
O	respiratory
O	depression
O	.

O	The
O	clinical
O	significance
O	of
O	this
O	finding
O	is
O	unknown
O	.

O	When
B-drug	paroxetine
O	,
O	a
O	potent
O	inhibitor
O	of
O	CYP2D6
O	,
O	was
O	co-administered
O	with
B-brand	BROVANA
O	at
O	steady-state
O	,
O	exposure
O	to
O	either
O	drug
O	was
O	not
O	altered
O	.

O	This
O	effect
O	has
O	been
O	attributed
O	to
O	inhibition
O	of
O	renal
O	prostaglandin
O	synthesis
O	by
B-drug	ibuprofen
O	.

O	While
O	additional
O	research
O	is
O	needed
O	,
O	the
O	initial
O	clinical
O	data
O	in
O	kidney
O	recipients
O	suggest
O	that
B-drug	sirolimus
O	,
O	in
O	combination
O	with
B-drug	cyclosporine
O	or
B-drug	tacrolimus
O	,
O	might
O	have
O	the
O	potential
O	to
O	reduce
O	the
O	frequency
O	of
O	rejection
O	episodes
O	,
O	permit
O	reductions
O	in
B-drug	cyclosporine
O	or
B-drug	tacrolimus
O	dosage
O	,
O	and
O	permit
O	steroid
O	withdrawal
O	(
O	Kelly
O	,
O	1999
O	)
O	.

O	The
O	findings
O	of
O	these
O	studies
O	are
O	summarized
O	in
O	the
O	following
O	table
O	:
O	Effects
O	on
O	steady-state
B-drug	fexofenadine
O	pharmacokinetics
O	after
O	7
O	days
O	of
O	co-administration
O	with
B-drug	fexofenadine
I-drug	hydrochloride
O	120
O	mg
O	every
O	12
O	hours
O	(
O	two
O	times
O	the
O	recommended
O	twice
O	daily
O	dose
O	)
O	in
O	healthy
O	volunteers
O	(
O	n=24
O	)

B-drug	Apraclonidine
O	should
O	not
O	be
O	used
O	in
O	patients
O	receiving
B-group	MAO
O	inhibitors..

B-group	Corticosteroids
O	:
O	A
O	relationship
O	of
O	functional
O	antagonism
O	exists
O	between
B-group	vitamin
I-group	D
O	analogues
O	,
O	which
O	promote
O	calcium
O	absorption
O	,
O	and
B-group	corticosteroids
O	,
O	which
O	inhibit
O	calcium
O	absorption
O	.

O	No
O	formal
O	drug
O	interaction
O	studies
O	have
O	been
O	performed
O	with
B-brand	ZEVALIN
O	.

O	In
O	patients
O	receiving
O	nonselective
B-group	monoamine
I-group	oxidase
I-group	inhibitors
O	(
B-group	MAOIs
O	)
O	(
O	e.g.
O	,
B-drug	selegiline
I-drug	hydrochloride
O	)
O	in
O	combination
O	with
B-group	serotoninergic
I-group	agents
O	(
O	e.g.
O	,
B-drug	fluoxetine
O	,
B-drug	fluvoxamine
O	,
B-drug	paroxetine
O	,
B-drug	sertraline
O	,
B-drug	venlafaxine
O	)
O	,
O	there
O	have
O	been
O	reports
O	of
O	serious
O	,
O	sometimes
O	fatal
O	,
O	reactions
O	.

O	In
O	a
O	first
O	experiment
O	,
O	male
O	adult
O	Wistar
O	rats
O	were
O	fasted
O	for
O	12
O	h
O	.

O	In
O	a
O	study
O	with
O	concomitant
O	administration
O	of
B-brand	aspirin
O	and
B-drug	fosinopril
I-drug	sodium
O	,
O	the
O	bioavailability
O	of
O	unbound
B-drug_n	fosinoprilat
O	was
O	not
O	altered
O	.

O	The
O	toxicity
O	of
O	cadmium
O	,
B-drug	zinc
O	and
O	cadmium/zinc
O	mixtures
O	at
O	concentrations
O	ranging
O	from
O	1000
O	to
O	50000
O	microg/l
O	were
O	investigated
O	against
O	cercariae
O	and
O	metacercariae
O	of
O	Parorchis
O	acanthus
O	obtained
O	from
O	the
O	dog
O	whelk
O	Nucella
O	lapillus
O	.

O	The
O	emerging
O	roles
O	of
B-group	non-nucleoside
I-group	reverse
I-group	transcriptase
I-group	inhibitors
O	in
B-group	antiretroviral
O	therapy
O	.

O	The
O	safety
O	and
O	efficacy
O	of
B-drug	anakinra
O	used
O	in
O	combination
O	with
B-brand	HUMIRA
O	has
O	not
O	been
O	studied
O	.

O	Both
B-drug_n	ibogaine
O	and
B-drug_n	18-MC
O	ameliorate
B-group	opioid
O	withdrawal
O	signs
O	.

B-drug	Rofecoxib
O	did
O	not
O	influence
O	the
O	plasma
O	pharmacokinetics
O	or
O	renal
O	elimination
O	of
O	a
O	single
O	oral
O	dose
O	of
B-drug	digoxin
O	.

O	Resting
O	membrane
O	potential
O	,
O	input
O	impedance
O	and
O	the
O	proportion
O	of
O	neurons
O	displaying
O	transient
O	outward
O	rectification
O	were
O	each
O	significantly
O	altered
O	for
O	neurons
O	recorded
O	with
O	1
O	%
O	but
O	not
O	0.05-0.2
O	%
O	biocytin
O	.

B-group	Anticholinergic
I-group	drugs
O	may
O	antagonize
O	the
O	effects
O	of
O	the
O	drugs
O	that
O	alter
O	gastrointestinal
O	motility
O	,
O	such
O	as
B-drug	metoclopramide
O	.

O	In
O	clinical
O	trials
O	,
B-brand	FLOLAN
O	was
O	used
O	with
B-drug	digoxin
O	,
B-group	diuretics
O	,
B-group	anticoagulants
O	,
O	oral
B-group	vasodilators
O	,
O	and
O	supplemental
B-drug	oxygen.In
O	a
O	pharmacokinetic
O	substudy
O	in
O	patients
O	with
O	congestive
O	heart
O	failure
O	receiving
B-drug	furosemide
O	or
B-drug	digoxin
O	in
O	whom
O	therapy
O	with
B-brand	FLOLAN
O	was
O	initiated
O	,
O	apparent
O	oral
O	clearance
O	values
O	for
B-drug	furosemide
O	(
O	n
O	=
O	23
O	)
O	and
B-drug	digoxin
O	(
O	n
O	=
O	30
O	)
O	were
O	decreased
O	by
O	13
O	%
O	and
O	15
O	%
O	,
O	respectively
O	,
O	on
O	the
O	second
O	day
O	of
O	therapy
O	and
O	had
O	returned
O	to
O	baseline
O	values
O	by
O	day
O	87
O	.

O	The
O	changes
O	in
O	plasma
O	levels
O	were
O	within
O	the
O	range
O	of
O	plasma
O	levels
O	achieved
O	in
O	adequate
O	and
O	well-controlled
O	clinical
O	trials
O	.

O	.

O	In
O	an
O	uncontrolled
O	study
O	of
O	over
O	200
O	patients
O	with
O	congestive
O	heart
O	failure
O	during
O	which
B-drug	digoxin
O	blood
O	levels
O	were
O	not
O	measured
O	,
O	digitalis
O	toxicity
O	was
O	not
O	observed
O	.

B-drug	Cyclophosphamide
O	used
O	concurrently
O	with
B-brand	Cerubidine
O	may
O	also
O	result
O	in
O	increased
O	cardiotoxicity
O	.

B-drug	Naproxen
O	:
O	The
O	concomitant
O	administration
O	of
B-drug	diflunisal
O	and
B-drug	naproxen
O	in
O	normal
O	volunteers
O	had
O	no
O	effect
O	on
O	the
O	plasma
O	levels
O	of
B-drug	naproxen
O	,
O	but
O	significantly
O	decreased
O	the
O	urinary
O	excretion
O	of
B-drug	naproxen
O	and
O	its
O	glucuronide
O	metabolite
O	.

O	Drug
O	Class
O	:
O	Drug
O	Name
O	Clinical
O	Comment

B-drug	phenobarbital
O	reduced
O	it
O	by
O	a
O	net
O	change
O	of
O	6.6
O	%
O	(
O	percentage
O	increase
O	in
O	FDF
O	,
O	8.5
O	%
O	)
O	at
O	431
O	micromol/L
O	.

O	No
O	clinically
O	important
O	pharmacokinetic
O	interactions
O	occurred
O	when
B-brand	PRINIVIL
O	was
O	used
O	concomitantly
O	with
B-drug	propranolol
O	or
B-drug	hydrochlorothiazide
O	.

O	Experience
O	with
B-group	nonsteroidal
I-group	anti-inflammatory
I-group	drugs
O	(
B-group	NSAIDs
O	)
O	suggests
O	the
O	potential
O	for
O	interactions
O	with
B-drug	furosemide
O	and
B-group	ACE
I-group	inhibitors
O	.

O	Drug/Laboratory
O	Test
O	Interactions
O	The
O	administration
O	of
B-drug	cefepime
O	may
O	result
O	in
O	a
O	false-positive
O	reaction
O	for
O	glucose
O	in
O	the
O	urine
O	when
O	using
O	Clinitest
O	tablets
O	.

B-drug	Furosemide
O	:
O	Clinical
O	studies
O	,
O	as
O	well
O	as
O	random
O	observations
O	,
O	have
O	shown
O	that
B-drug	ibuprofen
O	can
O	reduce
O	the
O	natriuretic
O	effect
O	of
B-drug	furosemide
O	and
B-group	thiazides
O	in
O	some
O	patients
O	.

B-drug	Aminoglutethimide
O	diminishes
O	the
O	effect
O	of
B-group	coumarin
O	and
B-drug	warfarin
O	.

O	There
O	was
O	no
O	effect
O	of
B-brand	ZEBETA
O	on
O	prothrombin
O	time
O	in
O	patients
O	on
O	stable
O	doses
O	of
B-drug	warfarin
O	.

O	To
O	avoid
O	potentiation
O	,
O	the
O	physician
O	wishing
O	to
O	terminate
O	treatment
O	with
B-drug	Isocarboxazid
O	and
O	begin
O	therapy
O	with
O	another
O	agent
O	should
O	allow
O	for
O	an
O	interval
O	of
O	10
O	days
O	.

O	Studies
O	in
O	healthy
O	volunteers
O	have
O	shown
O	that
B-drug	Acarbose
O	has
O	no
O	effect
O	on
O	either
O	the
O	pharmacokinetics
O	or
O	pharmacodynamics
O	of
B-drug	digoxin
O	,
B-drug	nifedipine
O	,
B-drug	propranolol
O	,
O	or
B-drug	ranitidine
O	.

O	CONCLUSIONS
O	:
B-drug	Sildenafil
O	is
O	an
O	effective
O	first-line
O	therapy
O	for
O	erectile
O	dysfunction
O	in
O	men
O	.

B-group	Monoamine
I-group	oxidase
I-group	(
I-group	MAO
I-group	)
I-group	inhibitors
O	such
O	as
B-drug	isocarboxazid
O	(
O	e.g.
O	,
B-brand	Marplan
O	)
O	,
B-drug	phenelzine
O	(
O	e.g.
O	,
B-brand	Nardil
O	)
O	,
B-drug	procarbazine
O	(
O	e.g.
O	,
B-brand	Matulane
O	)
O	,
B-drug	selegiline
O	(
O	e.g.
O	,
B-brand	Eldepryl
O	)
O	,
O	and
B-drug	tranylcypromine
O	(
O	e.g.
O	,
B-brand	Parnate
O	)
O	:
O	Using
O	these
O	medicines
O	with
B-drug	L-tryptophan
O	may
O	increase
O	the
O	chance
O	of
O	side
O	effects
O	.

O	Furthermore
O	,
O	whenever
O	one
O	of
O	these
O	other
O	drugs
O	is
O	withdrawn
O	from
O	co-therapy
O	,
O	an
O	increased
O	dose
O	of
B-drug	tricyclic
I-drug	antidepressant
O	may
O	be
O	required
O	.

O	These
O	in
O	vitro
O	studies
O	suggest
O	that
O	concomitant
O	administration
O	of
B-drug	zalcitabine
O	and
B-drug	lamivudine
O	in
O	humans
O	may
O	result
O	in
O	sub-therapeutic
O	concentrations
O	of
O	active
O	phosphorylated
B-drug	zalcitabine
O	,
O	which
O	may
O	lead
O	to
O	a
O	decreased
B-group	antiretroviral
O	effect
O	of
B-drug	zalcitabine
O	.

O	CONTRAINDICATED
O	due
O	to
O	potential
O	for
O	serious
O	and/or
O	life-threatening
O	reactions
O	such
O	as
O	prolonged
O	or
O	increased
O	sedation
O	or
O	respiratory
O	depression
O	.

O	Pancreatic
O	content
O	after
O	perfusion
O	did
O	not
O	correlate
O	with
O	release
O	during
O	perfusion
O	.

O	Patients/Guardians
O	should
O	be
O	given
O	the
O	following
O	information
O	:
O	i
O	.

O	Epidemiological
O	studies
O	of
O	the
O	case-control
O	and
O	cohort
O	design
O	that
O	have
O	demonstrated
O	an
O	association
O	between
O	use
O	of
B-group	psychotropic
I-group	drugs
O	that
O	interfere
O	with
O	serotonin
O	reuptake
O	and
O	the
O	occurrence
O	of
O	upper
O	gastrointestinal
O	bleeding
O	have
O	also
O	shown
O	that
O	concurrent
O	use
O	of
O	an
B-group	NSAID
O	or
B-brand	aspirin
O	potentiated
O	the
O	risk
O	of
O	bleeding
O	.

B-drug	Carbamazepine

O	Plasma
O	concentrations
O	(
O	AUC
O	0-24
O	hrs
O	)
O	of
B-drug	erythromycin
O	decreased
O	15
O	%
O	with
O	coadministration
O	of
B-drug	loratadine
O	relative
O	to
O	that
O	observed
O	with
B-drug	erythromycin
O	alone
O	.

O	Relative
O	to
O	the
O	general
O	population
O	,
O	plasma
O	concentrations
O	of
B-drug	fluvastatin
O	do
O	not
O	vary
O	as
O	a
O	function
O	of
O	either
O	age
O	or
O	gender
O	.

O	Patients
O	who
O	are
O	applying
B-brand	Panretin
O	gel
O	should
O	not
O	concurrently
O	use
O	products
O	that
O	contain
B-drug	DEET
O	(
O	N
O	,
B-drug	N-diethyl-m-toluamide
O	)
O	,
O	a
O	common
O	component
O	of
O	insect
O	repellent
O	products
O	.

O	-
B-drug	Alcohol
O	,
B-group	barbiturates
O	,
O	or
B-group	narcotics
O	:
O	Potentiation
O	of
O	otthostatic
O	hypotension
O	may
O	occur

O	The
O	concomitant
O	use
O	of
B-drug	alcohol
O	or
O	other
B-group	central
I-group	nervous
I-group	system
I-group	depressants
O	may
O	have
O	an
O	additive
O	effect
O	.

B-drug	Fluconazole

O	Therefore
O	,
O	serum
O	levels
O	of
B-drug	methotrexate
O	should
O	be
O	monitored
O	in
O	patients
O	to
O	avoid
O	drug
O	toxicity
O	.

O	Therefore
O	,
O	if
O	concomitant
O	use
O	of
O	such
O	agents
O	is
O	indicated
O	,
O	they
O	should
O	be
O	given
O	with
O	caution
O	,
O	and
O	the
O	patients
O	serum
O	potassium
O	should
O	be
O	monitored
O	frequently
O	.

B-drug	Nelfinavir

O	The
O	results
O	generated
O	to
O	date
O	in
O	clinical
O	pharmacokinetic
O	studies
O	with
B-drug	fluvastatin
O	thus
O	support
O	its
O	use
O	in
O	a
O	broad
O	population
O	of
O	hypercholesterolaemic
O	patients
O	.

B-drug	Ritonavir
O	significantly
O	prolonged
O	the
O	half-life
O	of
B-drug	vardenafil
O	to
O	26
O	hours
O	.

O	In
O	separate
O	studies
O	of
O	patients
O	receiving
O	maintenance
O	doses
O	of
B-drug	warfarin
O	,
B-drug	hydrochlorothiazide
O	,
O	or
B-drug	digoxin
O	,
B-drug	irbesartan
O	administration
O	for
O	7
O	days
O	had
O	no
O	effect
O	on
O	the
O	pharmacodynamics
O	of
B-drug	warfarin
O	(
O	prothrombin
O	time
O	)
O	or
O	pharmacokinetics
O	of
B-drug	digoxin
O	.

O	Concurrent
O	administration
O	of
B-drug	oxyphenbutazone
O	and
B-group	androgens
O	may
O	result
O	in
O	elevated
O	serum
O	levels
O	of
B-drug	oxyphenbutazone
O	.

O	Potentiation
O	occurs
O	with
O	ganglionic
O	or
B-group	peripheral
I-group	adrenergic
I-group	blocking
I-group	drugs
O	.

O	The
O	metabolism
O	of
B-drug	saquinavir
O	is
O	mediated
O	by
O	cytochrome
O	P450
O	,
O	with
O	the
O	specific
O	isoenzyme
O	CYP3A4
O	responsible
O	for
O	90
O	%
O	of
O	the
O	hepatic
O	metabolism
O	.

O	Inhibitors
O	of
B-drug	CYP3A4-Eplerenone
O	metabolism
O	is
O	predominantly
O	mediated
O	via
O	CYP3A4
O	.

O	Like
B-drug	isoflurane
O	,
B-drug	desflurane
O	does
O	not
O	predispose
O	to
O	premature
O	ventricular
O	arrhythmias
O	in
O	the
O	presence
O	of
O	exogenously
O	infused
B-drug	epinephrine
O	in
O	swine
O	.

O	(
O	May
O	inhibit
O	gastrointestinal
O	absorption
O	of
O	the
B-group	thiazide
I-group	diuretics
O	;

O	No
O	dose
O	adjustment
O	of
B-brand	SUSTIVA
O	is
O	recommended
O	when
O	given
O	with
B-drug	clarithromycin
O	.

O	By
O	contrast
O	,
B-drug_n	spermidine
O	(
O	1
O	mM
O	)
O	and
B-drug_n	putrescine
O	(
O	1
O	mM
O	)
O	had
O	no
O	significant
O	effect
O	on
O	the
O	translocation
O	when
O	added
O	alone
O	.

B-group	Antidepressants
O	:
O	In
O	vitro
O	data
O	indicate
O	that
B-drug	nefazodone
O	inhibits
O	the
O	metabolism
O	of
B-drug	cisapride
O	,
O	which
O	can
O	result
O	in
O	an
O	increase
O	in
O	plasma
B-drug	cisapride
O	levels
O	and
O	prolongation
O	of
O	the
O	QT
O	interval
O	on
O	the
O	ECG
O	.

O	In
O	this
O	study
O	we
O	investigated
O	whether
O	also
B-drug	glycine
O	fulfils
O	the
O	function
O	as
O	co-activator
O	in
O	glutamatergic
O	activation
O	of
O	NMDA
O	receptors
O	in
O	the
O	neuronal
O	apparatus
O	of
O	spontaneous
O	motility
O	in
O	chick
O	embryos
O	.

O	Treatment
O	of
O	RAS-3T3
O	cells
O	with
O	nucleophosmin/B23
O	antisense
O	oligomer
O	significantly
O	potentiated
O	the
O	apoptosis
O	induced
O	by
O	serum
O	deprivation
O	.

O	However
O	,
O	when
O	addiction
O	is
O	defined
O	as
O	compulsion
O	,
O	loss
O	of
O	control
O	and
O	continued
O	use
O	in
O	spite
O	of
O	adverse
O	consequences
O	,
B-drug	cocaine
O	drug
O	hunger
O	can
O	be
O	seen
O	as
O	an
O	agent
O	of
O	addictive
O	disease
O	.

O	Micro-dosed
B-drug	Progesterone
O	Preparations
O	:
O	Micro-dosed
B-drug	progesterone
O	preparations
O	(
O	minipills
O	that
O	do
O	not
O	contain
O	an
B-group	estrogen
O	)
O	may
O	be
O	an
O	inadequate
O	method
O	of
O	contraception
O	during
B-brand	Accutane
O	therapy
O	.

O	.

O	The
O	use
O	of
B-brand	NUROMAX
O	before
B-drug	succinylcholine
O	to
O	attenuate
O	some
O	of
O	the
O	side
O	effects
O	of
B-drug	succinylcholine
O	has
O	not
O	been
O	studied
O	.

O	Drug-drug
O	interactions
O	with
B-drug	Mefloquine
O	have
O	not
O	been
O	explored
O	in
O	detail
O	.

I-drug	indinavir
O	concentration

B-drug	Dopamine-induced
O	renal
O	and
O	mesenteric
O	vasodilation
O	is
O	not
O	antagonized
O	by
O	either
O	alpha-
O	or
B-group	beta-adrenergic
B-drug	blocking
I-drug	agents
O	.

O	These
O	results
O	suggest
O	that
O	acute
O	dosing
O	with
B-drug	clozapine
O	would
O	not
O	affect
O	behaviors
O	most
O	closely
O	associated
O	with
B-drug_n	PCP
O	intoxication
O	.

O	In
O	clinical
O	trials
O	,
O	similar
O	changes
O	in
B-drug	carbamazepine
O	and
B-drug_n	carbamazepine
I-drug_n	epoxide
O	were
O	seen
O	.

O	However
O	,
O	it
O	has
O	been
O	established
O	that
B-drug	acitretin
O	interferes
O	with
O	the
O	contraceptive
O	effect
O	of
O	microdosed
B-drug	progestin
O	minipill
O	preparations
O	.

B-drug	quinidine
O	;

O	Statistically
O	significant
O	changes
O	in
O	prothrombin
O	and
O	partial
O	thromboplastin
O	times
O	have
O	been
O	reported
O	in
O	normal
O	volunteers
O	.

O	Persons
O	taking
O	most
B-group	antibiotics
O	,
B-drug	methotrexate
O	and
B-drug	pyrimethamine
O	invalidate
B-drug	folic
I-drug	acid
O	and
B-drug	vitamin
I-drug	B12
O	diagnostic
O	blood
O	assays
O	.

O	Other
O	plasma
O	proteins
O	may
O	be
O	increased
O	(
O	angiotensinogen/renin
O	substrate
O	,
O	alpha-1-antitrypsin
O	,
O	ceruloplasmin
O	)
O	.

O	use
O	caution
O	.

O	DRUG/LABORATORY
O	TEST
O	INTERACTIONS
O	:
O	EFFECT
O	ON
O	BLOOD
O	COAGULATION
B-drug	Ketoprofen
O	decreases
O	platelet
O	adhesion
O	and
O	aggregation
O	.

O	Even
O	when
O	an
B-group	aminoglycoside
O	and
O	a
B-group	penicillin-type
O	drug
O	are
O	administered
O	separately
O	by
O	different
O	routes
O	,
O	a
O	reduction
O	in
B-group	aminoglycoside
O	serum
O	half-life
O	or
O	serum
O	levels
O	has
O	been
O	reported
O	in
O	patients
O	with
O	impaired
O	renal
O	function
O	and
O	in
O	some
O	patients
O	with
O	normal
O	renal
O	function
O	.

O	Therefore
O	,
O	administration
O	of
B-group	quinolones
O	with
B-group	antacids
O	containing
B-drug	calcium
O	,
B-drug	magnesium
O	,
O	or
B-drug	aluminum
O	;

O	Substances
O	that
O	are
O	potent
O	inhibitors
O	of
O	CYP3A4
O	activity
O	(
O	eg
O	,
B-drug	ketoconazole
O	and
B-drug	itraconazole
O	)
O	decrease
B-drug	gefitinib
O	metabolism
O	and
O	increase
B-drug	gefitinib
O	plasma
O	concentrations
O	.

B-group	Beta-adrenergic
I-group	blocking
I-group	agents
O	:
O	concurrent
O	use
O	may
O	blunt
O	the
O	response
O	to
B-drug	arbutamine
O	.

O	2
O	.

B-drug	Rifampin
O	:
O	Co-administration
O	of
B-brand	VIOXX
O	with
B-drug	rifampin
O	600
O	mg
O	daily
O	,
O	a
O	potent
O	inducer
O	of
O	hepatic
O	metabolism
O	,
O	produced
O	an
O	approximate
O	50
O	%
O	decrease
O	in
B-drug	rofecoxib
O	plasma
O	concentrations
O	.

O	Certain
O	endocrine
O	and
O	liver
O	function
O	tests
O	may
O	be
O	affected
O	by
B-group	estrogen-containing
O	oral
B-group	contraceptives
O	.

O	Caution
O	should
O	be
O	exercised
O	with
O	simultaneous
O	use
O	of
B-drug	clonidine
O	and
O	other
O	similar
O	pharmacologic
O	agents

B-brand	Aspirin
O	:
O	Concomitant
O	administration
O	of
O	low-dose
B-brand	aspirin
O	with
B-brand	VIOXX
O	may
O	result
O	in
O	an
O	increased
O	rate
O	of
O	GI
O	ulceration
O	or
O	other
O	complications
O	,
O	compared
O	to
O	use
O	of
B-brand	VIOXX
O	alone
O	.

O	Although
O	additional
O	drug
O	interaction
O	studies
O	have
O	not
O	been
O	conducted
O	,
O	the
O	most
O	common
O	medications
O	used
O	concomitantly
O	with
B-drug	anagrelide
O	in
O	clinical
O	trials
O	were
B-brand	aspirin
O	,
B-drug	acetaminophen
O	,
B-drug	furosemide
O	,
B-drug	iron
O	,
B-drug	ranitidine
O	,
B-drug	hydroxyurea
O	,
O	and
B-drug	allopurinol
O	.

O	Drug
O	Class
O	:
O	Drug
O	Name
O	Clinical
O	Comment

B-brand	VIRACEPT
O	and
B-drug	rifampin
O	should
O	not
O	be
O	coadministered
O	.

O	Potential
B-drug	Terfenadine
O	,
B-drug	Astemizole
O	,
O	and
B-drug	Cisapride
O	Interactions

O	The
O	pharmacokinetics
O	of
B-drug	praziquantel
O	were
O	unchanged
O	following
O	coadministration
O	with
B-drug	albendazole
O	(
O	400
O	mg
O	)
O	.

O	-
O	Reduced
O	serum
O	folate
O	concentration

O	Concurrent
O	administration
O	of
B-drug	dyphylline
O	and
B-drug	probenecid
O	,
O	which
O	competes
O	for
O	tubular
O	secretion
O	,
O	has
O	been
O	shown
O	to
O	increase
O	the
O	plasma
O	half-life
O	of
B-drug	dyphylline
O	.

O	H-2
O	Antagonists
O	:
O	In
O	studies
O	with
O	human
O	volunteers
O	,
O	co-administration
O	of
B-drug	cimetidine
O	or
B-drug	ranitidine
O	with
B-drug	ibuprofen
O	had
O	no
O	substantive
O	effect
O	on
B-drug	ibuprofen
O	serum
O	concentrations
O	.

B-drug	dextran
O	;

O	Caution
O	should
O	be
O	exercised
O	when
O	administering
B-drug	nabumetone
O	with
B-drug	warfarin
O	since
O	interactions
O	have
O	been
O	seen
O	with
O	other
B-group	NSAIDs
O	.

O	Drugs
O	that
O	reportedly
O	may
O	increase
O	oral
B-group	anticoagulant
O	response
O	,
O	ie
O	,
O	increased
O	prothrombin
O	response
O	,
O	in
O	man
O	include
O	:
B-drug	alcohol*
O	;
B-drug	allopurinol
O	;
B-drug	aminosalicylic
I-drug	acid
O	;
B-drug	amiodarone
O	;
B-group	anabolic
I-group	steroids
O	;
B-group	antibiotics
O	;
B-drug	bromelains
O	;
B-drug	chloral
O	hydrate*
O	;
B-drug	chlorpropamide
O	;
B-drug	chymotrypsin
O	;
B-drug	cimetidine
O	;
B-drug	cinchophen
O	;
B-drug	clofibrate
O	;
B-drug	dextran
O	;
B-drug	dextrothyroxine
O	;
B-drug	diazoxide
O	;
O	dietary
O	deficiencies
O	;
B-drug	diflunisal
O	;
B-drug	disulfiram
O	;
O	drugs
O	affecting
O	blood
O	elements
O	;
B-drug	ethacrynic
I-drug	acid
O	;
B-drug	fenoprofen
O	;
B-drug	glucagon
O	;
O	hepatotoxic
O	drugs
O	;
B-drug	ibuprofen
O	;
B-drug	indomethacin
O	;
B-group	influenza
I-group	virus
I-group	vaccine
O	;
O	inhalation
B-group	anesthetics
O	;
B-drug	mefenamic
I-drug	acid
O	;
B-drug	methyldopa
O	;
B-drug	methylphenidate
O	;
B-drug	metronidazole
O	;
B-drug	miconazole
O	;
B-group	monoamine
I-group	oxidase
I-group	inhibitors
O	;
B-drug	nalidixic
I-drug	acid
O	;
B-drug	naproxen
O	;
B-drug	oxolinic
I-drug	acid
O	;
B-drug	oxyphenbutazone
O	;
B-drug	pentoxifylline
O	;
B-drug	phenylbutazone
O	;
B-drug_n	phenyramidol
O	;
B-drug	phenytoin
O	;
O	prolonged
O	hot
O	weather
O	;
B-group	prolonged
I-group	narcotics
O	;
B-group	pyrazolones
O	;
B-drug	quinidine
O	;
B-drug	quinine
O	;
B-drug	ranitidine*
O	;
B-group	salicylates
O	;
B-drug	sulfinpyrazone
O	;
B-group	sulfonamides
O	,
O	long
O	acting
O	;
B-drug	sulindac
O	;
B-group	thyroid
I-group	drugs
O	;
B-drug	tolbutamide
O	;
B-drug	triclofos
I-drug	sodium
O	;
B-drug	trimethoprim/sulfamethoxazole
O	;
O	unreliable
O	prothrombin
O	time
O	determinations
O	;
B-drug	warfarin
I-drug	sodium
O	overdosage
O	.

O	Nephrotoxicity
O	frequently
O	limits
O	the
O	dose
O	of
B-drug	cisplatin
O	to
O	less
O	than
O	120
O	mg/m2
O	per
O	injection
O	.

O	If
B-drug	isradipine
O	therapy
O	is
O	initiated
O	in
O	a
O	patient
O	currently
O	receiving
B-drug	cimetidine
O	careful
O	monitoring
O	for
O	adverse
O	reactions
O	is
O	advised
O	and
O	downward
O	dose
O	adjustment
O	may
O	be
O	required
O	.

O	Long
O	Acting
B-group	Nitrates
O	:
B-drug	Nifedipine
O	may
O	be
O	safely
O	co-administered
O	with
B-group	nitrates
O	,
O	but
O	there
O	have
O	been
O	no
O	controlled
O	studies
O	to
O	evaluate
O	the
O	antianginal
O	effectiveness
O	of
O	this
O	combination
O	.

O	These
O	steps
O	include
O	regular
O	reevaluations
O	of
O	dosages
O	and
O	plasma
O	drug
O	concentrations
O	,
O	recognition
O	and
O	understanding
O	of
O	drug
O	side
O	effects
O	,
O	and
O	avoidance
O	of
O	certain
O	agents
O	.

O	This
O	interaction
O	should
O	be
O	given
O	consideration
O	in
O	patients
O	taking
B-group	NSAIDs
O	concomitantly
O	with
B-group	ACE
I-group	inhibitors
O	.

O	In
O	addition
O	,
O	based
O	on
O	the
O	population
O	pharmacokinetics
O	analysis
O	of
O	the
O	combined
O	data
O	from
O	grapefruit
O	and
O	orange
O	juices
O	studies
O	with
O	the
O	data
O	from
O	a
O	bioequivalence
O	study
O	,
O	the
O	bioavailability
O	of
B-drug	fexofenadine
O	was
O	reduced
O	by
O	36
O	%
O	.

O	Agents
O	that
O	Induce
O	Cytochrome
O	P450
O	Isoenzymes
B-drug	Carbamazepine
O	is
O	metabolized
O	by
O	CYP3A4
O	.

O	All
O	77
O	strains
O	of
O	Staphylococcus
O	aureus
O	,
O	Diplococcus
O	pneumoniae
O	,
O	Streptococcus
O	pyogenes
O	,
O	and
O	anaerobic
O	bacteria
O	(
O	except
O	for
O	three
O	strains
O	of
O	Clostridium
O	)
O	were
O	inhibited
O	by
O	1.6
O	mug
O	or
O	less
O	of
B-drug	clindamycin
O	per
O	ml
O	.

O	Several
B-group	tricyclic
I-group	antidepressants
O	have
O	been
O	reported
O	to
O	block
O	the
O	pharmacologic
O	effects
O	of
B-drug	guanethidine
O	,
B-drug	clonidine
O	,
O	or
O	similar
O	agents
O	,
O	and
O	such
O	an
O	effect
O	may
O	be
O	anticipated
O	with
B-drug	CMI
O	because
O	of
O	its
O	structural
O	similarity
O	to
O	other
B-group	tricyclic
I-group	antidepressants
O	.

O	The
O	consumption
O	of
B-drug	alcohol
O	during
O	treatment
O	with
B-brand	WELLBUTRIN
O	should
O	be
O	minimized
O	or
O	avoided
O	(
O	also
O	see
O	a
O	href=
O	bupropz_od.htm
O	#
O	CI
O	CONTRAINDICATIONS
O	)

O	Intravenous
O	infusion
O	of
B-drug	iloprost
O	had
O	no
O	effect
O	on
O	the
O	pharmacokinetics
O	of
B-drug	digoxin
O	.

B-drug	Zalcitabine
O	also
O	has
O	no
O	significant
O	effect
O	on
O	the
O	intracellular
O	phosphorylation
O	of
B-drug	ZDV
O	,
O	as
O	shown
O	in
O	vitro
O	in
O	peripheral
O	blood
O	mononuclear
O	cells
O	or
O	in
O	two
O	other
O	cell
O	lines
O	(
O	U937
O	and
O	Molt-4
O	)
O	.

O	-
B-drug	Mercaptopurine
O	(
O	e.g.
O	,
B-brand	Purinethol
O	)
O	or

O	Therefore
O	,
O	patients
O	under
B-drug	methotrexate
O	therapy
O	should
O	be
O	carefully
O	monitored
O	when
O	concomitant
B-drug	ciprofloxacin
O	therapy
O	is
O	indicated
O	.

O	Additionally
O	,
B-drug	aripiprazole
O	and
B-drug_n	dehydroaripiprazole
O	did
O	not
O	show
O	potential
O	for
O	altering
O	CYP1A2-mediated
O	metabolism
O	in
O	vitro
O	.

O	75
O	years
O	of
O	age
O	.

O	The
O	use
O	of
B-brand	FLUDARA
O	FOR
O	INJECTION
O	in
O	combination
O	with
B-drug	pentostatin
O	is
O	not
O	recommended
O	due
O	to
O	the
O	risk
O	of
O	severe
O	pulmonary
O	toxicity
O	.

O	The
O	homodimeric
O	disintegrin
B-drug_n	contortrostatin
O	was
O	compared
O	directly
O	to
O	the
O	monomeric
O	disintegrins
B-drug_n	echistatin
O	and
B-drug_n	flavoridin
O	for
O	the
O	ability
O	to
O	affect
O	protein
O	tyrosine
O	phosphorylation
O	in
O	tumor
O	cells
O	.

O	Extreme
O	caution
O	should
O	be
O	exercised
O	when
O	administering
B-brand	TAXOL
O	to
O	such
O	patients
O	,
O	with
O	dose
O	reduction
O	as
O	recommended
O	in
O	DOSAGE
O	AND
O	ADMINISTRATION
O	,
O	Table
O	17
O	.

O	The
O	carcinogenic
O	potential
O	of
B-drug	ribavirin
O	has
O	not
O	been
O	fully
O	determined
O	.

B-drug	Warfarin
O	:
B-group	Quinolones
O	may
O	enhance
O	the
O	effects
O	of
O	the
O	oral
B-group	anticoagulant
O	,
B-drug	warfarin
O	,
O	or
O	its
O	derivatives
O	.

O	however
O	,
O	it
O	is
O	considered
O	to
O	be
O	unlikely
O	that
O	this
O	decrease
O	of
O	phosphorylated
B-drug	lamivudine
O	concentration
O	is
O	of
O	clinical
O	significance
O	,
O	as
B-drug	lamivudine
O	is
O	a
O	more
O	efficient
O	substrate
O	for
O	deoxycytidine
O	kinase
O	than
B-drug	zalcitabine
O	.

O	Therefore
O	,
O	when
B-brand	EDECRIN
O	and
B-group	non-
I-group	steroidal
I-group	anti-
I-group	inflammatory
I-group	agents
O	are
O	used
O	concomitantly
O	,
O	the
O	patient
O	should
O	be
O	observed
O	closely
O	to
O	determine
O	if
O	the
O	desired
O	effect
O	of
O	the
B-group	diuretic
O	is
O	obtained
O	.

O	Cardiovascular
O	disease
O	is
O	considered
O	in
O	the
O	next
O	chapter
O	,
O	and
O	chapter
O	7
O	presents
O	findings
O	on
O	endometrial
O	,
O	ovarian
O	,
O	cervical
O	,
O	breast
O	,
O	and
O	other
O	cancers
O	.

O	aeruginosa
O	as
O	common
O	pathogens
O	of
O	drug
O	addicts
O	in
O	areas
O	where
O	abuse
O	of
O	this
O	combination
O	of
O	drugs
O	has
O	increased
O	.

B-group	Antihypertensive
O	Medications
O	and
B-group	Vasodilators
O	:
O	The
O	following
O	adverse
O	events
O	were
O	experienced
O	more
O	commonly
O	in
O	patients
O	receiving
O	concomitant
B-group	antihypertensive
I-group	medications
O	or
B-group	vasodilators
O	(
O	n
O	=
O	94
O	)
O	compared
O	to
O	patients
O	not
O	receiving
O	these
O	concomitant
O	drugs
O	(
O	n
O	=
O	456
O	)
O	:
O	hypotension
O	10
O	%
O	vs
O	4
O	%
O	,
O	myocardial
O	infarction
O	3
O	%
O	vs
O	1
O	%
O	,
O	serious
O	pneumonia
O	5
O	%
O	vs
O	3
O	%
O	,
O	serious
O	falls
O	9
O	%
O	vs
O	3
O	%
O	,
O	and
O	bone
O	and
O	joint
O	injuries
O	6
O	%
O	vs
O	2
O	%
O	.

B-group	Antacids
O	(
B-drug	aluminum-
O	or
B-drug	magnesium-containing
O	)
O	:
O	Concomitant
O	administration
O	of
O	300-mg
B-drug	cefdinir
O	capsules
O	with
O	30
O	mL
B-brand	Maalox
I-brand	TC
O	suspension
O	reduces
O	the
O	rate
O	(
O	Cmax
O	)
O	and
O	extent
O	(
O	AUC
O	)
O	of
O	absorption
O	by
O	approximately
O	40
O	%
O	.

B-drug	Acetazolamide
O	may
O	increase
O	or
O	decrease
O	blood
O	glucose
O	levels
O	.

B-drug	Etodolac
O	is
O	characterised
O	by
O	a
O	high
O	oral
O	bioavailability
O	,
O	low
O	clearance
O	,
O	a
O	small
O	volume
O	of
O	distribution
O	,
O	and
O	a
O	7-hour
O	half-life
O	.

B-group	Antacids
O	or
B-drug	sucralfate
O	substantially
O	interfere
O	with
O	the
O	absorption
O	of
O	some
B-group	quinolones
O	,
O	resulting
O	in
O	low
O	urine
O	levels
O	.

B-drug	amiodarone
O	;

O	Effects
O	of
B-brand	GABITRIL
O	on
O	other
O	Antiepilepsy
O	Drugs
O	(
B-group	AEDs
O	)
O	:
B-drug	Phenytoin
O	:
B-drug	Tiagabine
O	had
O	no
O	effect
O	on
O	the
O	steady-state
O	plasma
O	concentrations
O	of
B-drug	phenytoin
O	in
O	patients
O	with
O	epilepsy
O	.

O	It
O	is
O	not
O	known
O	whether
B-brand	AMEVIVE
O	is
O	excreted
O	in
O	human
O	milk
O	.

O	When
O	prescribing
O	for
O	older
O	patients
O	,
O	some
O	physicians
O	are
O	overly
O	cautious
O	,
O	and
O	this
O	strategy
O	can
O	result
O	in
O	a
O	less
O	than
O	optimal
O	treatment
O	outcome
O	.

O	Long-term
O	studies
O	are
O	needed
O	to
O	determine
O	whether
O	the
O	insulin-sensitizing
O	effects
O	of
O	the
B-group	glitazones
O	can
O	prevent
O	or
O	delay
O	premature
O	atherosclerotic
O	cardiovascular
O	disease
O	,
O	morbidity
O	,
O	and
O	death
O	.

O	.

O	Low
O	initial
O	dosing
O	and
O	small
O	gradual
O	dose
O	increases
O	should
O	be
O	employed
O	.

B-drug	Etodolac
O	is
O	highly
O	protein
O	bound
O	.

O	Caution
O	should
O	be
O	used
O	when
O	coadministering
O	medications
O	that
O	are
O	substrates
O	,
O	inhibitors
O	,
O	or
O	inducers
O	of
O	CYP3A4
O	,
O	or
O	potentially
O	toxic
O	medications
O	that
O	are
O	metabolized
O	by
O	CYP3A4
O	.

O	Of
O	particular
O	importance
O	,
O	sufficient
O	time
O	must
O	elapse
O	before
O	initiating
B-group	TCAtreatment
O	in
O	a
O	patient
O	being
O	withdrawn
O	from
B-drug	fluoxetine
O	,
O	given
O	the
O	long
O	half-life
O	of
O	the
O	parent
O	and
O	active
O	metabolite
O	(
O	at
O	least
O	5
O	weeks
O	may
O	be
O	necessary
O	)
O	.

O	In
O	some
O	cases
O	where
O	serious
O	ventricular
O	arrhythmias
O	,
O	QT
O	prolongation
O	,
O	and
O	torsades
O	de
O	pointes
O	have
O	occurred
O	when
B-drug	cisapride
O	was
O	taken
O	in
O	conjunction
O	with
O	one
O	of
O	the
O	cytochrome
O	P450
O	3A4
O	inhibitors
O	,
O	elevated
O	blood
B-drug	cisapride
O	levels
O	were
O	noted
O	at
O	the
O	time
O	of
O	the
O	QT
O	prolongation
O	.

O	After
O	stopping
B-drug	Fluvoxamine
O	Tablets
O	,
O	at
O	least
O	2
O	weeks
O	should
O	be
O	allowed
O	before
O	starting
O	a
B-group	MAOI
O	.

O	cardiovascular
O	effects
O	can
O	be
O	potentiated
O	.

O	When
O	these
O	products
O	are
O	administered
O	concomitantly
O	,
O	prothrombin
O	time
O	or
O	other
O	suitable
O	coagulation
O	tests
O	should
O	be
O	closely
O	monitored
O	.

O	These
O	results
O	,
O	together
O	with
O	the
O	known
O	relationships
O	between
B-group	estrogen
O	and
O	the
O	immune
O	response
O	,
O	suggest
O	that
B-group	estrogens
O	affect
O	the
O	course
O	of
O	septic
O	shock
O	in
O	a
O	complex
O	fashion
O	and
O	may
O	have
O	either
O	protective
O	or
O	deleterious
O	effect
O	.

B-drug	Warfarin
O	:
O	When
B-drug	fluvoxamine
I-drug	maleate
O	(
O	50
O	mg
O	tid
O	)
O	was
O	administered
O	concomitantly
O	with
B-drug	warfarin
O	for
O	two
O	weeks
O	,
B-drug	warfarin
O	plasma
O	concentrations
O	increased
O	by
O	98
O	%
O	and
O	prothrombin
O	times
O	were
O	prolonged
O	.

O	Nonketotic
O	,
O	genetically
O	diabetic
O	Cinese
O	hamsters
O	show
O	subnormal
O	pancreatic
O	insulin
O	release
O	and
O	impaired
O	suppression
O	of
O	glucagon
O	in
O	response
O	to
O	glucose
O	.

O	If
O	a
O	patient
O	requires
B-brand	TIKOSYN
O	and
B-group	anti-ulcer
O	therapy
O	,
O	it
O	is
O	suggested
O	that
B-drug	omeprazole
O	,
B-drug	ranitidine
O	,
B-drug	or
B-group	antacids
O	(
O	aluminum
O	and
B-drug	magnesium
O	hydroxides
O	)
O	be
O	used
O	as
O	alternatives
O	to
B-drug	cimetidine
O	,
O	as
O	these
O	agents
O	have
O	no
O	effect
O	on
O	the
O	pharmacokinetic
O	profile
O	of
B-brand	TIKOSYN
O	.

O	Altered
O	mental
O	status
O	in
O	an
O	adolescent
O	presents
O	a
O	diagnostic
O	challenge
O	,
O	and
O	the
O	clinician
O	depends
O	on
O	clinical
O	evaluation
O	and
O	laboratory
O	studies
O	to
O	determine
O	therapy
O	and
O	prognosis
O	.

O	This
O	increased
O	incidence
O	of
O	atherosclerotic
O	disease
O	is
O	intricately
O	associated
O	with
O	insulin
O	resistance
O	,
O	which
O	is
O	a
O	major
O	pathophysiologic
O	abnormality
O	in
O	type
O	2
O	diabetes
O	.

O	Twenty-four
O	h
O	exposures
O	of
O	fully
O	formed
O	cysts
O	had
O	no
O	effect
O	on
O	excystment
O	in
O	vitro
O	.

O	Co-administration
O	of
B-drug	atorvastatin
O	resulted
O	in
O	about
O	a
O	50
O	%
O	increase
O	in
B-drug	aliskiren
O	Cmax
O	and
O	AUC
O	after
O	multiple
O	dosing
O	.

O	The
O	clinical
O	relevance
O	of
O	this
O	in
O	vitro
O	finding
O	is
O	unknown
O	.

O	As
O	with
O	other
B-group	antipsychotic
I-group	agents
O	,
O	it
O	should
O	be
O	noted
O	that
B-brand	HALDOL
O	may
O	be
O	capable
O	of
O	potentiating
B-group	CNS
I-group	depressants
O	such
O	as
B-group	anesthetics
O	,
B-group	opiates
O	,
O	and
B-drug	alcohol
O	.

O	Clinical
O	trials
O	of
O	such
O	combinations
O	should
O	be
O	accompanied
O	by
O	detailed
O	pharmacokinetic
O	evaluation
O	.

B-group	Beta-adrenergic
I-group	blocking
I-group	agents
O	should
O	be
O	withdrawn
O	at
O	least
O	48
O	hours
O	before
O	conducting
O	an
B-drug	arbutamine-mediated
O	stress
O	test
O	.

O	Of
O	the
O	remaining
O	cases
O	,
O	two
O	were
O	cardiac
O	,
O	two
O	hepatic
O	and
O	the
O	rest
O	were
O	mixed
O	drug
O	overdose
O	.

B-group	Loop
I-group	Diuretics
O	:
B-drug	Furosemide
O	administered
O	concurrently
O	with
B-drug	captopril
O	does
O	not
O	alter
O	the
O	pharmacokinetics
O	of
B-drug	captopril
O	in
O	renally
O	impaired
O	hypertensive
O	patients
O	.

O	Preliminary
O	data
O	which
O	suggest
O	that
B-drug	dapsone
O	may
O	inhibit
O	the
O	anti-inflammatory
O	activity
O	of
B-brand	Lamprene
O	have
O	not
O	been
O	confirmed
O	.

O	Other
O	drugs
O	which
O	may
O	enhance
O	the
O	neuromuscular
O	blocking
O	action
O	of
O	nondepolarizing
O	agents
O	such
O	as
B-brand	NUROMAX
O	include
O	certain
B-group	antibiotics
O	(
O	e.
O	g.
O	,
B-group	aminoglycosides
O	,
B-group	tetracyclines
O	,
B-group	bacitracin
O	,
B-group	polymyxins
O	,
B-drug	lincomycin
O	,
B-drug	clindamycin
O	,
B-drug	colistin
O	,
O	and
B-drug	sodium
I-drug	colistimethate
O	)
O	,
B-drug	magnesium
O	salts
O	,
B-drug	lithium
O	,
O	local
B-group	anesthetics
O	,
B-drug	procainamide
O	,
O	and
B-drug	quinidine
O	.

O	No
O	differences
O	in
O	adverse
O	events
O	or
O	QTc
O	interval
O	were
O	observed
O	when
O	subjects
O	were
O	administered
B-drug	fexofenadine
I-drug	hydrochloride
O	alone
O	or
O	in
O	combination
O	with
O	either
B-drug	erythromycin
O	or
B-drug	ketoconazole
O	.

B-drug	Ergotamine

B-drug	Aminosalicylic
I-drug	acid
O	may
O	also
O	decrease
O	the
O	absorption
O	of
B-drug	vitamin
I-drug	B12
O	,
O	which
O	can
O	lead
O	to
O	a
O	deficiency
O	.

O	Increasing
O	the
B-drug	felbamate
O	dose
O	to
O	2400
O	mg/day
O	increased
O	the
O	steadystate
B-drug	valproate
O	Cmin
O	to
O	96
O	25
O	micrograms/mL
O	.

O	St.
O	John
O	s
O	Wort
O	should
O	be
O	avoided
O	while
O	taking
O	this
O	medicine
O	due
O	to
O	the
O	additive
O	effects
O	of
O	serotonin
O	.

O	Accordingly
O	,
O	careful
O	patient
O	monitoring
O	and
O	dose
O	adjustment
O	of
B-drug	metformin
O	is
O	recommended
O	in
O	patients
O	concomitantly
O	taking
B-drug	cephalexin
O	and
B-drug	metformin
O	.

O	Read
O	circulars
O	for
B-drug	lithium
O	preparations
O	before
O	use
O	of
O	such
O	concomitant
O	therapy
O	.

O	In
O	two
O	controlled
O	crossover
O	clinical
O	pharmacology
O	studies
O	in
O	healthy
O	male
O	(
O	n=12
O	in
O	each
O	study
O	)
O	a
O	nd
O	female
O	(
O	n=12
O	in
O	each
O	study
O	)
O	volunteers
O	,
B-drug	desloratadine
O	7.5
O	mg
O	(
O	1.5
O	times
O	the
O	daily
O	dose
O	)
O	once
O	daily
O	was
O	coadministered
O	with
B-drug	erythromycin
O	500
O	mg
O	every
O	8
O	hours
O	or
B-drug	ketoconazole
O	200
O	mg
O	every
O	12
O	hours
O	for
O	10
O	days
O	.

O	reproductive
O	tract
O	infections
O	;

O	If
B-group	iron
I-group	supplements
O	are
O	required
O	during
B-brand	OMNICEF
O	therapy
O	,
B-brand	OMNICEF
O	should
O	be
O	taken
O	at
O	least
O	2
O	hours
O	before
O	or
O	after
O	the
O	supplement
O	.

O	Women
O	of
O	childbearing
O	potential
O	make
O	up
O	a
O	considerable
O	segment
O	of
O	the
O	patient
O	population
O	affected
O	by
O	psoriasis
O	.

O	Generally
O	,
O	this
O	phenomenon
O	has
O	not
O	been
O	associated
O	with
O	other
O	clinically
O	significant
O	events
O	.

O	.

B-drug	Methotrexate
O	:
O	Concomitant
O	administration
O	of
B-drug	methotrexate
O	and
O	some
B-group	NSAIDs
O	has
O	been
O	reported
O	to
O	reduce
O	the
O	clearance
O	of
B-drug	methotrexate
O	,
O	enhancing
O	the
O	toxicity
O	of
B-drug	methotrexate
O	.

B-group	Digitalis
O	:
B-group	Vitamin
I-group	D
O	dosage
O	must
O	be
O	determined
O	with
O	care
O	in
O	patients
O	undergoing
O	treatment
O	with
B-group	digitalis
O	,
O	as
O	hypercalcemia
O	in
O	such
O	patients
O	may
O	precipitate
O	cardiac
O	arrhythmias
O	.

O	include
B-drug	terfenadine
O	,
B-drug	astemizole
O	,
B-drug	cisapride
O	,
B-drug	midazolam
O	,
O	and
B-drug	triazolam
O	.

O	Stimulation
O	of
O	the
O	glands
O	with
B-drug	carbachol
O	synergistically
O	augmented
O	the
O	response
O	to
O	dibutyryl
O	cAMP
O	.

O	There
O	were
O	no
O	clinically
O	significant
O	drug
O	interactions
O	for
O	any
O	of
O	these
O	drugs

O	Caution
O	should
O	be
O	observed
O	when
B-drug	anileridine
O	is
O	coadministered
O	with
O	other
B-group	opioids
O	,
B-group	sedatives
O	,
B-group	phenothiazines
O	,
O	or
B-group	anesthetics
O	,
O	as
O	these
O	agents
O	may
O	increase
O	respiratory
O	and
O	circulatory
O	depression
O	.

O	However
O	,
O	no
O	adverse
O	effects
O	on
O	fertility
O	were
O	observed
O	in
O	male
O	Rhesus
O	monkeys
O	treated
O	with
B-drug	non-pegylated
I-drug	interferon
I-drug	alfa-2a
O	for
O	5
O	months
O	at
O	doses
O	up
O	to
O	25
O	x
O	106
O	IU/kg/day
O	.

O	The
O	most
O	potent
O	inhibitory
O	activity
O	was
O	observed
O	for
O	vardenafil
O	metabolite
O	M1
O	,
O	which
O	had
O	a
O	Ki
O	of
O	1.4
O	uM
O	toward
O	CYP3A4
O	,
O	which
O	is
O	about
O	20
O	times
O	higher
O	than
O	the
O	M1
O	Cmax
O	values
O	after
O	an
O	80
O	mg
B-drug	Vardenafil
O	dose
O	.

O	This
O	effect
O	did
O	not
O	depend
O	on
O	the
O	order
O	of
O	application
O	of
O	the
O	drugs
O	.

B-drug	Tizoxanide
O	is
O	highly
O	bound
O	to
O	plasma
O	protein
O	(
O	99.9
O	%
O	)
O	.

O	combination
O	therapy
O	is
O	contemplated
O	,
O	the
O	dosage
O	of
O	one
O	or
O	both
O	agents
O	should
O	be
O	reduced
O	.

O	There
O	was
O	no
O	significant
O	difference
O	in
O	the
O	pharmacodynamic
O	effect
O	of
B-drug	warfarin
O	administered
O	alone
O	and
B-drug	warfarin
O	administered
O	with
B-brand	Lodine
O	as
O	measured
O	by
O	prothrombin
O	time
O	.

O	Since
O	the
O	concomitant
O	administration
O	of
B-drug	warfarin
O	with
B-drug	amiodarone
O	increases
O	the
O	prothrombin
O	time
O	by
O	100
O	%
O	after
O	3
O	to
O	4
O	days
O	,
O	the
O	dose
O	of
O	the
B-drug	anticoagulant
O	should
O	be
O	reduced
O	by
O	one-third
O	to
O	one-half
O	,
O	and
O	prothrombin
O	times
O	should
O	be
O	monitored
O	closely
O	.

O	The
O	clinical
O	presentation
O	and
O	natural
O	history
O	of
O	neoplasia
O	are
O	also
O	affected
O	by
O	aging
O	.

O	In
O	period
O	A
O	,
O	all
O	volunteers
O	took
O	500
O	mg
O	of
B-drug	tolbutamide
O	orally
O	.

B-drug	Warfarin
O	:
O	Concomitant
O	administration
O	of
B-drug	daptomycin
O	(
O	6
O	mg/kg
O	once
O	every
O	24
O	hours
O	for
O	5
O	days
O	)
O	and
B-drug	warfarin
O	(
O	25
O	mg
O	single
O	oral
O	dose
O	)
O	had
O	no
O	significant
O	effect
O	on
O	the
O	pharmacokinetics
O	of
O	either
O	drug
O	,
O	and
O	the
O	INR
O	was
O	not
O	significantly
O	altered
O	.

B-group	ACE-inhibitors
O	Reports
O	suggest
O	that
B-group	NSAIDs
O	may
O	diminish
O	the
O	antihypertensive
O	effect
O	of
B-group	ACE-inhibitors
O	.

O	Caution
O	is
O	recommended
O	during
O	the
O	coadministration
O	of
O	any
O	of
O	these
O	with
B-drug	alprazolam
O	.

B-drug	Metformin
O	:
O	When
B-brand	Starlix
O	120
O	mg
O	three
O	times
O	daily
O	before
O	meals
O	was
O	administered
O	in
O	combination
O	with
B-drug	metformin
O	500
O	mg
O	three
O	times
O	daily
O	to
O	patients
O	with
O	Type
O	2
O	diabetes
O	,
O	there
O	were
O	no
O	clinically
O	relevant
O	changes
O	in
O	the
O	pharmacokinetics
O	of
O	either
O	agent
O	.

O	.

O	Drugs
O	Metabolized
O	by
O	P450
O	2D6
O	:
O	The
O	biochemical
O	activity
O	of
O	the
O	drug
O	metabolizing
O	isozyme
O	cytochrome
O	P450
O	2D6
O	(
O	debrisoquin
O	hydroxylase
O	)
O	is
O	reduced
O	in
O	a
O	subset
O	of
O	the
O	aucasian
O	population
O	(
O	about
O	7
O	%
O	-10
O	%
O	of
O	Caucasians
O	are
O	so-called
O	poor
O	metabolizers
O	)
O	;

O	The
O	clinical
O	significance
O	of
O	these
O	findings
O	has
O	not
O	been
O	established
O	.

O	Administration
O	of
B-drug_n	1,3-difluoroacetone
O	(
O	100
O	mg
O	kg
O	(
O	-1
O	)
O	body
O	weight
O	)
O	to
O	rats
O	in
O	vivo
O	resulted
O	in
B-drug_n	(
I-drug_n	-
I-drug_n	)
I-drug_n	-erythro-fluorocitrate
O	synthesis
O	in
O	the
O	kidney
O	,
O	which
O	was
O	preceded
O	by
O	an
O	elevation
O	in
O	fluoride
O	levels
O	and
O	followed
O	by
O	citrate
O	accumulation
O	.

O	The
O	following
O	are
O	examples
O	of
O	substances
O	that
O	may
O	reduce
O	the
O	blood-glucose-lowering
O	effect
O	:
B-group	corticosteroids
O	,
B-drug	niacin
O	,
B-drug	danazol
O	,
B-group	diuretics
O	,
B-group	sympathomimetic
I-group	agents
O	(
O	e.g.
O	,
B-drug	epinephrine
O	,
B-drug	salbutamol
O	,
B-drug	terbutaline
O	)
O	,
B-drug	isoniazid
O	,
B-group	phenothiazine
I-group	derivatives
O	,
B-drug	somatropin
O	,
B-group	thyroid
I-group	hormones
O	,
B-group	estrogens
O	,
B-group	progestogens
O	(
O	e.g.
O	,
O	in
O	oral
B-group	contraceptives
O	)
O	.

O	In
O	EMs
O	,
O	selective
O	inhibitors
O	of
O	CYP2D6
O	increase
B-drug	atomoxetine
O	steady-state
O	plasma
O	concentrations
O	to
O	exposures
O	similar
O	to
O	those
O	observed
O	in
O	PMs
O	.

O	If
O	these
O	preparations
O	have
O	been
O	used
O	it
O	is
O	advisable
O	not
O	to
O	start
O	therapy
O	with
B-brand	DIFFERIN
O	Gel
O	until
O	the
O	effects
O	of
O	such
O	preparations
O	in
O	the
O	skin
O	have
O	subsided
O	.

O	Based
O	on
O	clinical
O	and
O	pharmacokinetic
O	results
O	from
O	the
O	ATAC
O	trial
O	,
B-drug	tamoxifen
O	should
O	not
O	be
O	administered
O	with
B-drug	anastrozole
O	(
O	see
O	CLINICAL
O	PHARMACOLOGY
O	Drug
O	Interactions
O	and
O	CLINICAL
O	PHARMACOLOGY
O	-
O	Clinical
O	Studies
O	-
O	Adjuvant
O	Treatment
O	of
O	Breast
O	Cancer
O	in
O	Postmenopausal
O	Women
O	subsections
O	)
O	.

B-drug	Naproxen
O	may
O	interfere
O	with
O	some
O	urinary
O	assays
O	of
O	5-hydroxy
O	indoleacetic
O	acid
O	(
O	5HIAA
O	)
O	.

B-drug	Chlorpromazine
O	:
B-drug	Chlorpromazine
O	blocks
O	dopamine
O	and
O	norepinephrine
O	receptors
O	,
O	thus
O	inhibiting
O	the
O	central
O	stimulant
O	effects
O	of
B-group	amphetamines
O	and
O	can
O	be
O	used
O	to
O	treat
B-group	amphetamine
O	poisoning
O	.

O	The
O	pharmacokinetic
O	interactions
O	listed
O	below
O	are
O	potentially
O	clinically
O	important
O	.

B-drug	Quinidine
O	:
O	Coadministration
O	of
O	a
O	10-mg
O	single
O	dose
O	of
B-drug	aripiprazole
O	with
B-drug	quinidine
O	(
O	166
O	mg/day
O	for
O	13
O	days
O	)
O	,
O	a
O	potent
O	inhibitor
O	of
O	CYP2D6
O	,
O	increased
O	the
O	AUC
O	of
B-drug	aripiprazole
O	by
O	112
O	%
O	but
O	decreased
O	the
O	AUC
O	of
O	its
O	active
O	metabolite
O	,
B-drug_n	dehydroaripiprazole
O	,
O	by
O	35
O	%
O	.

O	The
O	effect
O	of
B-drug	clonazepam
O	on
O	the
O	metabolism
O	of
O	other
O	drugs
O	has
O	not
O	been
O	investigated
O	.

O	Patients
O	receiving
O	these
O	drugs
O	who
O	are
O	given
B-brand	Lodine
O	,
O	or
O	any
O	other
B-group	NSAID
O	,
O	and
O	particularly
O	those
O	patients
O	with
O	altered
O	renal
O	function
O	,
O	should
O	be
O	observed
O	for
O	the
O	development
O	of
O	the
O	specific
O	toxicities
O	of
O	these
O	drugs
O	.

O	RESULTS
O	:
O	The
O	geometric
O	mean
O	(
O	90
O	%
O	confidence
O	interval
O	)
O	whole
O	blood
B-drug	sirolimus
O	area
O	under
O	the
O	plasma
O	concentration
O	time-curve
O	increased
O	60
O	%
O	(
O	35
O	%
O	-90
O	%
O	)
O	,
O	from
O	736
O	to
O	1178
O	ng
O	x
O	h/mL
O	,
O	and
O	maximum
O	concentration
O	increased
O	43
O	%
O	(
O	14
O	%
O	-81
O	%
O	)
O	,
O	from
O	67
O	to
O	96
O	ng/mL
O	,
O	with
B-drug	diltiazem
O	coadministration
O	,
O	whereas
O	the
O	mean
O	elimination
O	half-life
O	of
B-drug	sirolimus
O	decreased
O	slightly
O	,
O	from
O	79
O	to
O	67
O	hours
O	.

O	This
O	might
O	be
O	explained
O	by
O	a
O	blockade
O	by
B-drug	probenecid
O	of
O	the
O	elimination
O	of
B-drug	cloxacillin
O	by
O	the
O	liver
O	.

O	*CBZ
O	epoxide

B-drug	Levothyroxine
I-drug	Sodium
O	Absorption
O	:
O	The
O	following
O	agents
O	may
O	bind
O	and
O	decrease
O	absorption
O	of
B-drug	levothyroxine
I-drug	sodium
O	from
O	the
O	gastrointestinal
O	tract
O	:
B-drug	aluminum
I-drug	hydoxide
O	,
B-drug	cholestyramine
O	resin
O	,
B-drug	colestipol
I-drug	hydrochloride
O	,
B-drug	ferrous
I-drug	sulfate
O	,
B-drug	sodium
I-drug	polystyrene
I-drug	sulfonate
O	,
O	soybean
O	flour
O	(
O	e.g.
O	,
O	infant
O	formula
O	)
O	,
B-drug	sucralfate
O	.

B-drug	Fulvestrant
O	was
O	associated
O	with
O	an
O	increased
O	incidence
O	of
O	fetal
O	variations
O	in
O	rabbits
O	(
O	backwards
O	displacement
O	of
O	the
O	pelvic
O	girdle
O	,
O	and
O	27
O	pre-sacral
O	vertebrae
O	at
O	0.25
O	mg/kg/day
O	IM
O	;

B-drug	Didanosine
O	:
O	It
O	is
O	recommended
O	that
B-drug	didanosine
O	be
O	administered
O	on
O	an
O	empty
O	stomach
O	;

O	While
O	not
O	systematically
O	studied
O	,
O	certain
O	drugs
O	may
O	induce
O	the
O	metabolism
O	of
B-drug	bupropion
O	(
O	e.g.
O	,
B-drug	carbamazepine
O	,
B-drug	phenobarbital
O	,
B-drug	phenytoin
O	)
O	.

O	Changes
O	in
O	the
O	testes
O	and
O	epididymides
O	had
O	not
O	recovered
O	20
O	weeks
O	after
O	cessation
O	of
O	dosing
O	.

O	The
O	incidence
O	of
O	ARE
O	suddenly
O	exceeded
O	10
O	%
O	of
O	the
O	patients
O	treated
O	by
B-drug	melarsoprol
O	during
O	August
O	1992
O	and
O	September
O	1993
O	.

B-group	Monoamine
I-group	oxidase
I-group	(
I-group	MAO
I-group	)
I-group	inhibitors
O	prolong
O	and
O	intensify
O	the
O	anticholinergic
O	effects
O	of
B-group	antihistamines
O	.

O	Potential
O	for
B-drug	Duloxetine
O	to
O	Affect
O	Other
O	Drugs
O	:
O	Drugs
O	Metabolized
O	by
O	CYP1A2
O	:
O	In
O	vitro
O	drug
O	interaction
O	studies
O	demonstrate
O	that
B-drug	duloxetine
O	does
O	not
O	induce
O	CYP1A2
O	activity
O	,
O	and
O	it
O	is
O	unlikely
O	to
O	have
O	a
O	clinically
O	significant
O	effect
O	on
O	the
O	metabolism
O	of
O	CYP1A2
O	substrates
O	.

O	In
O	a
O	comparison
O	of
B-group	digitalis
O	tolerance
O	in
O	dogs
O	anesthetized
O	with
B-drug	ketamine
O	,
B-brand	Innovar
I-brand	Vet
O	,
O	or
B-drug	pentobarbital
O	,
O	the
O	dosage
O	of
B-drug	ouabain
O	needed
O	to
O	cause
O	ventricular
O	tachycardia
O	was
O	significantly
O	higher
O	,
O	as
O	was
O	the
O	LD50
O	of
B-drug	ouabain
O	,
O	with
B-drug	ketamine
O	or
B-brand	Innovar
O	than
O	with
B-drug	pentobarbital
O	.

O	Should
O	it
O	be
O	decided
O	to
O	discontinue
O	therapy
O	in
O	patients
O	receiving
B-group	beta-blockers
O	and
B-drug	clonidine
O	concurrently
O	,
O	the
B-group	beta-blocker
O	should
O	be
O	discontinued
O	slowly
O	over
O	several
O	days
O	before
O	the
O	gradual
O	withdrawal
O	of
B-drug	clonidine
O	.

O	Therefore
O	,
O	prothrombin
O	time
O	should
O	be
O	carefully
O	monitored
O	in
O	patients
O	receiving
B-drug	Itraconazole
O	and
B-group	coumarin-like
O	drugs
O	simultaneously
O	.

O	Few
O	data
O	exist
O	on
O	drug
O	interactions
O	with
B-drug	caffeine
O	in
O	preterm
O	neonates
O	.

B-drug	Ethosuximide
O	:
B-group	Amphetamines
O	may
O	delay
O	intestinal
O	absorption
O	of
B-drug	ethosuximide
O	.

O	Selective
O	survival
O	in
B-drug	pentazocine
O	and
B-drug	tripelennamine
O	of
O	Pseudomonas
O	aeruginosa
O	serotype
O	O11
O	from
O	drug
O	addicts
O	.

O	A
O	reduced
B-drug	Clozapine
O	dose
O	should
O	be
O	considered
O	.

O	Nevertheless
O	,
O	caution
O	is
O	indicated
O	in
O	the
O	coadministration
O	of
B-group	TCAs
O	with
O	any
O	of
O	the
B-group	SSRIs
O	and
O	also
O	in
O	switching
O	from
O	one
O	class
O	to
O	the
O	other
O	.

B-group	Ergot-Containing
I-group	Drugs
O	:
O	These
O	drugs
O	have
O	been
O	reported
O	to
O	cause
O	prolonged
O	vasospastic
O	reactions
O	.

O	Observations
O	from
O	drug
O	interaction
O	studies
O	with
B-brand	FORTOVASE
O	may
O	not
O	be
O	predictive
O	for
B-brand	INVIRASE
O	.

B-drug	Antihistamines
O	:
B-drug	astemizole*
O	,
B-drug	terfenadine*
O	CONTRAINDICATED
O	due
O	to
O	potential
O	for
O	serious
O	and/or
O	life-threatening
O	cardiac
O	arrhythmias
O	.

I-drug	indinavir
O	concentration
B-drug	ritonavir
O	concentration

O	No
O	data
O	on
O	the
O	level
O	of
O	circulating
O	catecholamines
O	after
B-drug	apraclonidine
O	withdrawal
O	are
O	available
O	.

B-drug	Amiodarone
O	inhibits
B-drug	CYP2D6
O	.

O	No
O	CNS
O	lesions
O	have
O	been
O	observed
O	in
O	mice
O	after
O	chronic
O	treatment
O	for
O	up
O	to
O	2
O	years
O	at
O	doses
O	up
O	to
O	400
O	mg/kg/day
O	or
O	in
O	rats
O	at
O	doses
O	up
O	to
O	100
O	mg/kg/day
O	.

O	Coadministration
O	of
B-drug	efavirenz
O	with
O	drugs
O	primarily
O	metabolized
O	by
O	these
O	isozymes
O	may
O	result
O	in
O	altered
O	plasma
O	concentrations
O	of
O	the
O	coadministered
O	drug
O	.

O	.

O	Coadministration
O	of
B-brand	VIRACEPT
O	and
O	drugs
O	that
O	inhibit
O	CYP3A
O	may
O	increase
B-drug	nelfinavir
O	plasma
O	concentrations
O	.

O	Changes
O	in
O	hepatic
O	function
O	induced
O	by
O	concomitant
O	therapies
O	may
O	affect
B-drug	epirubicin
O	metabolism
O	,
O	pharmacokinetics
O	,
O	therapeutic
O	efficacy
O	,
O	and/or
O	toxicity
O	.

O	Twitch
O	gradually
O	returned
O	to
B-drug	pre-gentamycin
O	strength
O	over
O	the
O	course
O	of
O	the
O	next
O	hour
O	.

